The Psychedelic Future of Post-Traumatic Stress Disorder Treatment


Citar

Texto integral

Resumo

Post-traumatic stress disorder (PTSD) is a mental health condition that can occur following exposure to a traumatic experience. An estimated 12 million U.S. adults are presently affected by this disorder. Current treatments include psychological therapies (e.g., exposure-based interventions) and pharmacological treatments (e.g., selective serotonin reuptake inhibitors (SSRIs)). However, a significant proportion of patients receiving standard-of-care therapies for PTSD remain symptomatic, and new approaches for this and other trauma-related mental health conditions are greatly needed. Psychedelic compounds that alter cognition, perception, and mood are currently being examined for their efficacy in treating PTSD despite their current status as Drug Enforcement Administration (DEA)- scheduled substances. Initial clinical trials have demonstrated the potential value of psychedelicassisted therapy to treat PTSD and other psychiatric disorders. In this comprehensive review, we summarize the state of the science of PTSD clinical care, including current treatments and their shortcomings. We review clinical studies of psychedelic interventions to treat PTSD, trauma-related disorders, and common comorbidities. The classic psychedelics psilocybin, lysergic acid diethylamide (LSD), and N,N-dimethyltryptamine (DMT) and DMT-containing ayahuasca, as well as the entactogen 3,4-methylenedioxymethamphetamine (MDMA) and the dissociative anesthetic ketamine, are reviewed. For each drug, we present the history of use, psychological and somatic effects, pharmacology, and safety profile. The rationale and proposed mechanisms for use in treating PTSD and traumarelated disorders are discussed. This review concludes with an in-depth consideration of future directions for the psychiatric applications of psychedelics to maximize therapeutic benefit and minimize risk in individuals and communities impacted by trauma-related conditions.

Sobre autores

Tamar Zaretsky

, James J. Peters Veterans Affairs Medical Center

Email: info@benthamscience.net

Kathleen Jagodnik

The Center for Psychedelic Psychotherapy and Trauma Research, Icahn School of Medicine at Mount Sina

Email: info@benthamscience.net

Robert Barsic

, James J. Peters Veterans Affairs Medical Center

Email: info@benthamscience.net

Josimar Antonio

The Center for Psychedelic Psychotherapy and Trauma Research, Icahn School of Medicine at Mount Sinai

Email: info@benthamscience.net

Philip Bonanno

The Center for Psychedelic Psychotherapy and Trauma Research, Icahn School of Medicine at Mount Sinai

Email: info@benthamscience.net

Carolyn MacLeod

, James J. Peters Veterans Affairs Medical Center

Email: info@benthamscience.net

Charlotte Pierce

The Center for Psychedelic Psychotherapy and Trauma Research, Icahn School of Medicine at Mount Sinai

Email: info@benthamscience.net

Hunter Carney

The Center for Psychedelic Psychotherapy and Trauma Research, Icahn School of Medicine at Mount Sinai

Email: info@benthamscience.net

Morgan Morrison

, James J. Peters Veterans Affairs Medical Center

Email: info@benthamscience.net

Charles Saylor

The Center for Psychedelic Psychotherapy and Trauma Research, Icahn School of Medicine at Mount Sinai

Email: info@benthamscience.net

George Danias

The Center for Psychedelic Psychotherapy and Trauma Research, Icahn School of Medicine at Mount Sinai

Email: info@benthamscience.net

Lauren Lepow

The Center for Psychedelic Psychotherapy and Trauma Research, Icahn School of Medicine at Mount Sinai

Email: info@benthamscience.net

Rachel Yehuda

, James J. Peters Veterans Affairs Medical Center

Autor responsável pela correspondência
Email: info@benthamscience.net

Bibliografia

  1. Kilpatrick, D.G.; Resnick, H.S.; Milanak, M.E.; Miller, M.W.; Keyes, K.M.; Friedman, M.J. National estimates of exposure to traumatic events and PTSD prevalence using DSM-IV and DSM-5 Criteria. J. Trauma. Stress, 2013, 26(5), 537-547. doi: 10.1002/jts.21848
  2. Yehuda, R. Post-traumatic stress disorder. N. Engl. J. Med., 2002, 346(2), 108-114. doi: 10.1056/NEJMra012941
  3. Kessler, R.C.; Sonnega, A.; Bromet, E.; Hughes, M.; Nelson, C.B. Posttraumatic stress disorder in the national comorbidity survey. Arch. Gen. Psychiatry, 1995, 52(12), 1048-1060. doi: 10.1001/archpsyc.1995.03950240066012
  4. De Jongh, A.; Resick, P.A.; Zoellner, L.A.; van Minnen, A.; Lee, C.W.; Monson, C.M.; Foa, E.B.; Wheeler, K.; Broeke, E.; Feeny, N.; Rauch, S.A.M.; Chard, K.M.; Mueser, K.T.; Sloan, D.M.; van der Gaag, M.; Rothbaum, B.O.; Neuner, F.; de Roos, C.; Hehenkamp, L.M.J.; Rosner, R.; Bicanic, I.A.E. Critical analysis of the current treatment guidelines for complex PTSD in adults. Depress. Anxiety, 2016, 33(5), 359-369. doi: 10.1002/da.22469
  5. Affairs DoV. VA/DOD clinical practice guideline for the management of posttraumatic stress disorder and acute stress disorder. 2017. Available at: https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal012418.pdf/
  6. Schnurr, P.P.; Chard, K.M.; Ruzek, J.I.; Chow, B.K.; Resick, P.A.; Foa, E.B.; Marx, B.P.; Friedman, M.J.; Bovin, M.J.; Caudle, K.L.; Castillo, D.; Curry, K.T.; Hollifield, M.; Huang, G.D.; Chee, C.L.; Astin, M.C.; Dickstein, B.; Renner, K.; Clancy, C.P.; Collie, C.; Maieritsch, K.; Bailey, S.; Thompson, K.; Messina, M.; Franklin, L.; Lindley, S.; Kattar, K.; Luedtke, B.; Romesser, J.; McQuaid, J.; Sylvers, P.; Varkovitzky, R.; Davis, L.; MacVicar, D.; Shih, M-C. Comparison of prolonged exposure vs cognitive processing therapy for treatment of posttraumatic stress disorder among us veterans. JAMA Netw. Open, 2022, 5(1), e2136921. doi: 10.1001/jamanetworkopen.2021.36921
  7. Lewis, C.; Roberts, N.P.; Gibson, S.; Bisson, J.I. Dropout from psychological therapies for posttraumatic stress disorder (PTSD) in adults: Systematic review and metaanalysis. Eur. J. Psychotraumatol., 2020, 11(1), 1709709. doi: 10.1080/20008198.2019.1709709
  8. Schottenbauer, M.A.; Glass, C.R.; Arnkoff, D.B.; Tendick, V.; Gray, S.H. Nonresponse and dropout rates in outcome studies on PTSD: Review and methodological considerations. Psychiatry, 2008, 71(2), 134-168. doi: 10.1521/psyc.2008.71.2.134
  9. Ogden, P.; Minton, K.; Pain, C. Trauma and the body: A sensorimotor approach to psychotherapy (norton series on interpersonal neurobiology); WW Norton & Company, 2006.
  10. Bradley, R.; Greene, J.; Russ, E.; Dutra, L.; Westen, D. A multidimensional metaanalysis of psychotherapy for PTSD. Am. J. Psychiatry, 2005, 162(2), 214-227. doi: 10.1176/appi.ajp.162.2.214
  11. Bell, V.; Robinson, B.; Katona, C.; Fett, A.K.; Shergill, S. When trust is lost: The impact of interpersonal trauma on social interactions. Psychol. Med., 2019, 49(6), 1041-1046. doi: 10.1017/S0033291718001800
  12. Zepinic, V. Trauma focused dynamic therapy model in treating complex psychological trauma. Psychology, 2017, 8(13), 2059-2101. doi: 10.4236/psych.2017.813132
  13. Armour, C.; Elklit, A.; Lauterbach, D.; Elhai, J.D. The DSM-5 dissociative-PTSD subtype: Can levels of depression, anxiety, hostility, and sleeping difficulties differentiate between dissociative-PTSD and PTSD in rape and sexual assault victims? J. Anxiety Disord., 2014, 28(4), 418-426. doi: 10.1016/j.janxdis.2013.12.008
  14. Williams, W.; Graham, D.P.; McCurry, K.; Sanders, A.; Eiseman, J.; Chiu, P.H.; King-Casas, B. Group psychotherapy’s impact on trust in veterans with PTSD: A pilot study. Bull. Menninger Clin., 2014, 78(4), 335-348. doi: 10.1521/bumc.2014.78.4.335
  15. Milad, M.R.; Quirk, G.J. Fear extinction as a model for translational neuroscience: Ten years of progress. Annu. Rev. Psychol., 2012, 63(1), 129-151. doi: 10.1146/annurev.psych.121208.131631
  16. Shin, L.M.; Wright, C.I.; Cannistraro, P.A.; Wedig, M.M.; McMullin, K.; Martis, B.; Macklin, M.L.; Lasko, N.B.; Cavanagh, S.R.; Krangel, T.S.; Orr, S.P.; Pitman, R.K.; Whalen, P.J.; Rauch, S.L. A functional magnetic resonance imaging study of amygdala and medial prefrontal cortex responses to overtly presented fearful faces in posttraumatic stress disorder. Arch. Gen. Psychiatry, 2005, 62(3), 273-281. doi: 10.1001/archpsyc.62.3.273
  17. Yan, X.; Brown, A.D.; Lazar, M.; Cressman, V.L.; Henn-Haase, C.; Neylan, T.C.; Shalev, A.; Wolkowitz, O.M.; Hamilton, S.P.; Yehuda, R.; Sodickson, D.K.; Weiner, M.W.; Marmar, C.R. Spontaneous brain activity in combat related PTSD. Neurosci. Lett., 2013, 547, 1-5. doi: 10.1016/j.neulet.2013.04.032
  18. Yehuda, R.; Antelman, S.M. Criteria for rationally evaluating animal models of postraumatic stress disorder. Biol. Psychiatry, 1993, 33(7), 479-486. doi: 10.1016/0006-3223(93)90001-T
  19. Jamieson, N.; Maple, M.; Ratnarajah, D.; Usher, K. Military moral injury: A concept analysis. Int. J. Ment. Health Nurs., 2020, 29(6), 1049-1066. doi: 10.1111/inm.12792
  20. Salter, M.; Hall, H. Reducing shame, promoting dignity: A model for the primary prevention of complex post-traumatic stress disorder. Trauma Violence Abuse, 2022, 23(3), 906-919. doi: 10.1177/1524838020979667
  21. Fine, N.B.; Ben-Zion, Z.; Biran, I.; Hendler, T. Neuroscientific account of guilt and shame driven PTSD phenotypes. Eur. J. Psychotraumatol., 2023, 14(2), 2202060. doi: 10.1080/20008066.2023.2202060
  22. Fenster, R.J.; Lebois, L.A.M.; Ressler, K.J.; Suh, J. Brain circuit dysfunction in posttraumatic stress disorder: From mouse to man. Nat. Rev. Neurosci., 2018, 19(9), 535-551. doi: 10.1038/s41583-018-0039-7
  23. DePierro, J.; Lepow, L.; Feder, A.; Yehuda, R. Translating molecular and neuroendocrine findings in posttraumatic stress disorder and resilience to novel therapies. Biol. Psychiatry, 2019, 86(6), 454-463. doi: 10.1016/j.biopsych.2019.07.009
  24. Yehuda, R.; Teicher, M.H.; Trestman, R.L.; Levengood, R.A.; Siever, L.J. Cortisol regulation in posttraumatic stress disorder and major depression: A chronobiological analysis. Biol. Psychiatry, 1996, 40(2), 79-88. doi: 10.1016/0006-3223(95)00451-3
  25. Cipriani, A.; Williams, T.; Nikolakopoulou, A.; Salanti, G.; Chaimani, A.; Ipser, J.; Cowen, P.J.; Geddes, J.R.; Stein, D.J. Comparative efficacy and acceptability of pharmacological treatments for posttraumatic stress disorder in adults: A network meta-analysis. Psychol. Med., 2018, 48(12), 1975-1984. doi: 10.1017/S003329171700349X
  26. Hoskins, M.; Pearce, J.; Bethell, A.; Dankova, L.; Barbui, C.; Tol, W.A.; van Ommeren, M.; de Jong, J.; Seedat, S.; Chen, H.; Bisson, J.I. Pharmacotherapy for post-traumatic stress disorder: Systematic review and meta-analysis. Br. J. Psychiatry, 2015, 206(2), 93-100. doi: 10.1192/bjp.bp.114.148551
  27. Abdallah, C.G.; Roache, J.D.; Averill, L.A.; Young-McCaughan, S.; Martini, B.; Gueorguieva, R.; Amoroso, T.; Southwick, S.M.; Guthmiller, K.; López-Roca, A.L.; Lautenschlager, K.; Mintz, J.; Litz, B.T.; Williamson, D.E.; Keane, T.M.; Peterson, A.L.; Krystal, J.H. Repeated ketamine infusions for antidepressant-resistant PTSD: Methods of a multicenter, randomized, placebo-controlled clinical trial. Contemp. Clin. Trials, 2019, 81, 11-18. doi: 10.1016/j.cct.2019.04.009
  28. De Gregorio, D.; Aguilar-Valles, A.; Preller, K.H.; Heifets, B.D.; Hibicke, M.; Mitchell, J.; Gobbi, G. Hallucinogens in mental health: Pre-clinical and clinical studies on LSD, Psilocybin, MDMA, and Ketamine. J. Neurosci., 2021, 41(5), 891-900. doi: 10.1523/JNEUROSCI.1659-20.2020
  29. Nichols, D.E. Psychedelics. Pharmacol. Rev., 2016, 68(2), 264-355. doi: 10.1124/pr.115.011478
  30. Preller, K.H.; Pokorny, T.; Hock, A. Effects of serotonin 2A/1A receptor stimulation on social exclusion processing. Proc. Nat. Acad. Sci.: PNAS., 2016, 113(18), 5119-5124.
  31. Pokorny, T.; Preller, K.H.; Kraehenmann, R.; Vollenweider, F.X. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. Eur. Neuropsychopharmacol., 2016, 26(4), 756-766. doi: 10.1016/j.euroneuro.2016.01.005
  32. Holze, F.; Caluori, T.V.; Vizeli, P.; Liechti, M.E. Safety pharmacology of acute LSD administration in healthy subjects. Psychopharmacology, 2022, 239(6), 1893-1905. doi: 10.1007/s00213-021-05978-6
  33. Holze, F.; Vizeli, P.; Ley, L.; Müller, F.; Dolder, P.; Stocker, M.; Duthaler, U.; Varghese, N.; Eckert, A.; Borgwardt, S.; Liechti, M.E. Acute dose-dependent effects of lysergic acid diethylamide in a doubleblind placebo-controlled study in healthy subjects. Neuropsychopharmacology, 2021, 46(3), 537-544. doi: 10.1038/s41386-020-00883-6
  34. Majić, T.; Schmidt, T.T.; Gallinat, J. Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences? J. Psychopharmacol., 2015, 29(3), 241-253. doi: 10.1177/0269881114568040
  35. Schmid, Y.; Enzler, F.; Gasser, P.; Grouzmann, E.; Preller, K.H.; Vollenweider, F.X.; Brenneisen, R.; Müller, F.; Borgwardt, S.; Liechti, M.E. Acute effects of lysergic acid diethylamide in healthy subjects. Biol. Psychiatry, 2015, 78(8), 544-553. doi: 10.1016/j.biopsych.2014.11.015
  36. Griffiths, R.R.; Johnson, M.W.; Richards, W.A.; Richards, B.D.; McCann, U.; Jesse, R. Psilocybin occasioned mystical-type experiences: Immediate and persisting doserelated effects. Psychopharmacology, 2011, 218(4), 649-665. doi: 10.1007/s00213-011-2358-5
  37. MacLean, K.A.; Johnson, M.W.; Griffiths, R.R. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J. Psychopharmacol., 2011, 25(11), 1453-1461. doi: 10.1177/0269881111420188
  38. Greenway, K.T.; Garel, N.; Jerome, L.; Feduccia, A.A. Integrating psychotherapy and psychopharmacology: Psychedelic-assisted psychotherapy and other combined treatments. Expert Rev. Clin. Pharmacol., 2020, 13(6), 655-670. doi: 10.1080/17512433.2020.1772054
  39. Jerome, L.; Feduccia, A.A.; Wang, J.B.; Hamilton, S.; Yazar-Klosinski, B.; Emerson, A.; Mithoefer, M.C.; Doblin, R. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: A longitudinal pooled analysis of six phase 2 trials. Psychopharmacology, 2020, 237(8), 2485-2497. doi: 10.1007/s00213-020-05548-2
  40. Mitchell, J.M.; Bogenschutz, M.; Lilienstein, A.; Harrison, C.; Kleiman, S.; Parker-Guilbert, K.; Ot’alora, G, M.; Garas, W.; Paleos, C.; Gorman, I.; Nicholas, C.; Mithoefer, M.; Carlin, S.; Poulter, B.; Mithoefer, A.; Quevedo, S.; Wells, G.; Klaire, S.S.; van der Kolk, B.; Tzarfaty, K.; Amiaz, R.; Worthy, R.; Shannon, S.; Woolley, J.D.; Marta, C.; Gelfand, Y.; Hapke, E.; Amar, S.; Wallach, Y.; Brown, R.; Hamilton, S.; Wang, J.B.; Coker, A.; Matthews, R.; de Boer, A.; Yazar-Klosinski, B.; Emerson, A.; Doblin, R. MDMA-assisted therapy for severe PTSD : A randomized, double-blind, placebo-controlled phase 3 study. Nat. Med., 2021, 27(6), 1025-1033. doi: 10.1038/s41591-021-01336-3
  41. Barone, W.; Beck, J.; Mitsunaga-Whitten, M.; Perl, P. Perceived benefits of MDMA-assisted psychotherapy beyond symptom reduction: Qualitative Follow-Up study of a clinical trial for individuals with treatmentresistant PTSD. J. Psychoactive Drugs, 2019, 51(2), 199-208. doi: 10.1080/02791072.2019.1580805
  42. Gorman, I.; Belser, A.B.; Jerome, L.; Hennigan, C.; Shechet, B.; Hamilton, S.; Yazar-Klosinski, B.; Emerson, A.; Feduccia, A.A. Posttraumatic growth after MDMA-Assisted psychotherapy for posttraumatic stress disorder. J. Trauma. Stress, 2020, 33(2), 161-170. doi: 10.1002/jts.22479
  43. Schlag, A.K.; Aday, J.; Salam, I.; Neill, J.C.; Nutt, D.J. Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. J. Psychopharmacol., 2022, 36(3), 258-272. doi: 10.1177/02698811211069100
  44. Lepow, L.; Jagodnik, K.M.; Glatman Zaretsky, T.; Hernandez Antonio, J.; Bonanno, P.A.; Yehuda, R. Psychedelic drugs as treatment agents.Charney & Nestler’s Neurobiology of Mental Illness, 6th; Charney, DS NE., Ed.; Oxford University Press, 2023.
  45. Association, A.P. Posttraumatic Stress Disorder; American Psychiatric Association, 2013.
  46. Burgess, A.W.; Holmstrom, L.L. Rape trauma syndrome. Am. J. Psychiatry, 1974, 131(9), 981-986. doi: 10.1176/ajp.131.9.981
  47. Lancaster, C.; Teeters, J.; Gros, D.; Back, S. Posttraumatic stress disorder: Overview of evidence-based assessment and treatment. J. Clin. Med., 2016, 5(11), 105. doi: 10.3390/jcm5110105
  48. Rothbaum, B.O.; Foa, E.B.; Riggs, D.S.; Murdock, T.; Walsh, W. A prospective examination of post traumatic stress disorder in rape victims. J. Trauma. Stress, 1992, 5(3), 455-475. doi: 10.1002/jts.2490050309
  49. Santiago, P.N.; Ursano, R.J.; Gray, C.L.; Pynoos, R.S.; Spiegel, D.; Lewis-Fernandez, R.; Friedman, M.J.; Fullerton, C.S. A systematic review of PTSD prevalence and trajectories in DSM-5 defined trauma exposed populations: Intentional and nonintentional traumatic events. PLoS One, 2013, 8(4), e59236. doi: 10.1371/journal.pone.0059236
  50. Friedman, M.J.; Resick, P.A.; Bryant, R.A.; Brewin, C.R. Considering PTSD for DSM-V. Depression and. Anxiety, 2011, 28(9), 750-769.
  51. Smid, G.E.; Mooren, T.T.M.; van der Mast, R.C.; Gersons, B.P.R.; Kleber, R.J. Delayed posttraumatic stress disorder: Systematic review, meta-analysis, and metaregression analysis of prospective studies. J. Clin. Psychiatry, 2009, 70(11), 1572-1582. doi: 10.4088/JCP.08r04484
  52. Utzon-Frank, N.; Breinegaard, N.; Bertelsen, M.; Borritz, M.; Eller, N.H.; Nordentoft, M.; Olesen, K.; Rod, N.H.; Rugulies, R.; Bonde, J.P. Occurrence of delayed-onset posttraumatic stress disorder: A systematic review and meta-analysis of prospective studies. Scand. J. Work Environ. Health, 2014, 40(3), 215-229. doi: 10.5271/sjweh.3420
  53. Andrews, B.; Brewin, C.R.; Philpott, R.; Stewart, L. Delayed-onset posttraumatic stress disorder: A systematic review of the evidence. Am. J. Psychiatry, 2007, 164(9), 1319-1326. doi: 10.1176/appi.ajp.2007.06091491
  54. Bonde, J.P.E.; Jensen, J.H.; Smid, G.E.; Flachs, E.M.; Elklit, A.; Mors, O.; Videbech, P. Time course of symptoms in posttraumatic stress disorder with delayed expression: A systematic review. Acta Psychiatr. Scand., 2022, 145(2), 116-131. doi: 10.1111/acps.13372
  55. American Psychiatric Association D. Association AP. Diagnostic and statistical manual of mental disorders: DSM-5: American psychiatric association Washington, DC, 2013.
  56. Organization, W.H. International statistical classification of diseases and related health problems, 11th; who; , 2019. Available at: https://icd.who.int/
  57. Kessler, RC; Aguilar-Gaxiola, S; Alonso, J Trauma and PTSD in the WHO world mental health surveys. Eurp. J. Psychotraumatol., 2017, (sup5), 1353383. doi: 10.1080/20008198.2017.1353383
  58. Koenen, K.C.; Ratanatharathorn, A.; Ng, L.; McLaughlin, K.A.; Bromet, E.J.; Stein, D.J.; Karam, E.G.; Meron Ruscio, A.; Benjet, C.; Scott, K.; Atwoli, L.; Petukhova, M.; Lim, C.C.W.; Aguilar-Gaxiola, S.; Al-Hamzawi, A.; Alonso, J.; Bunting, B.; Ciutan, M.; de Girolamo, G.; Degenhardt, L.; Gureje, O.; Haro, J.M.; Huang, Y.; Kawakami, N.; Lee, S.; Navarro-Mateu, F.; Pennell, B-E.; Piazza, M.; Sampson, N.; ten Have, M.; Torres, Y.; Viana, M.C.; Williams, D.; Xavier, M.; Kessler, R.C. Posttraumatic stress disorder in the world mental health surveys. Psychol. Med., 2017, 47(13), 2260-2274. doi: 10.1017/S0033291717000708
  59. Yehuda, R.; Hoge, C.W.; McFarlane, A.C.; Vermetten, E.; Lanius, R.A.; Nievergelt, C.M.; Hobfoll, S.E.; Koenen, K.C.; Neylan, T.C.; Hyman, S.E. Post-traumatic stress disorder. Nat. Rev. Dis. Primers, 2015, 1(1), 15057. doi: 10.1038/nrdp.2015.57
  60. Ressler, K.J.; Berretta, S.; Bolshakov, V.Y.; Rosso, I.M.; Meloni, E.G.; Rauch, S.L.; Carlezon, W.A., Jr Posttraumatic stress disorder: Clinical and translational neuroscience from cells to circuits. Nat. Rev. Neurol., 2022, 18(5), 273-288. doi: 10.1038/s41582-022-00635-8
  61. PTSD. National Center for PTSD; , 2023. Available at: https://www.ptsd.va.gov/understand/common/common_adults.asp
  62. Dekel, S.; Mamon, D.; Solomon, Z.; Lanman, O.; Dishy, G. Can guilt lead to psychological growth following trauma exposure? Psychiatry Res., 2016, 236, 196-198. doi: 10.1016/j.psychres.2016.01.011
  63. Terhakopian, A.; Sinaii, N.; Engel, C.C.; Schnurr, P.P.; Hoge, C.W. Estimating population prevalence of posttraumatic stress disorder : An example using the PTSD checklist. J. Trauma. Stress, 2008, 21(3), 290-300. doi: 10.1002/jts.20341
  64. Karam, E.G.; Friedman, M.J.; Hill, E.D.; Kessler, R.C.; McLaughlin, K.A.; Petukhova, M.; Sampson, L.; Shahly, V.; Angermeyer, M.C.; Bromet, E.J.; de Girolamo, G.; de Graaf, R.; Demyttenaere, K.; Ferry, F.; Florescu, S.E.; Haro, J.M.; He, Y.; Karam, A.N.; Kawakami, N.; Kovess-Masfety, V.; Medina-Mora, M.E.; Browne, M.A.O.; Posada-Villa, J.A.; Shalev, A.Y.; Stein, D.J.; Viana, M.C.; Zarkov, Z.; Koenen, K.C. Cumulative traumas and risk thresholds : 12-month PTSD in the world mental health (WMH) surveys. Depress. Anxiety, 2014, 31(2), 130-142. doi: 10.1002/da.22169
  65. DeRight, J. Posttraumatic stress disorder.Essential Neuropsychology: A Concise Handbook for Adult Practitioners; DeRight, J., Ed.; Springer International Publishing: Cham, 2022, pp. 269-277. doi: 10.1007/978-3-030-85372-3_38
  66. Marshall, R.D.; Yehuda, R.; Bone, S. Trauma-focused psychodynamic psychotherapy for individuals with posttraumatic stress symptoms. In: Inter. handbook of human response to trauma; , 2000; pp. 347-361. doi: 10.1007/978-1-4615-4177-6_25
  67. Friedman, M.J.; Schnurr, P.P.; Keane, T.M. Handbook of PTSD : Science and practice; , 2021.
  68. Atwoli, L.; Stein, D.J.; Koenen, K.C.; McLaughlin, K.A. Epidemiology of posttraumatic stress disorder. Curr. Opin. Psychiatry, 2015, 28(4), 307-311. doi: 10.1097/YCO.0000000000000167
  69. Galea, S.; Ahern, J.; Tracy, M.; Hubbard, A.; Cerda, M.; Goldmann, E.; Vlahov, D. Longitudinal determinants of posttraumatic stress in a population-based cohort study. Epidemiology, 2008, 19(1), 47-54. doi: 10.1097/EDE.0b013e31815c1dbf
  70. Kessler, R.C.; Rose, S.; Koenen, K.C.; Karam, E.G.; Stang, P.E.; Stein, D.J.; Heeringa, S.G.; Hill, E.D.; Liberzon, I.; McLaughlin, K.A.; McLean, S.A.; Pennell, B.E.; Petukhova, M.; Rosellini, A.J.; Ruscio, A.M.; Shahly, V.; Shalev, A.Y.; Silove, D.; Zaslavsky, A.M.; Angermeyer, M.C.; Bromet, E.J.; de Almeida, J.M.C.; de Girolamo, G.; de Jonge, P.; Demyttenaere, K.; Florescu, S.E.; Gureje, O.; Haro, J.M.; Hinkov, H.; Kawakami, N.; Kovess-Masfety, V.; Lee, S.; Medina-Mora, M.E.; Murphy, S.D.; Navarro-Mateu, F.; Piazza, M.; Posada-Villa, J.; Scott, K.; Torres, Y.; Carmen Viana, M. How well can post-traumatic stress disorder be predicted from pre-trauma risk factors? An exploratory study in the WHO World Mental Health Surveys. World Psychiatry, 2014, 13(3), 265-274. doi: 10.1002/wps.20150
  71. Koenen, K.C.; Harley, R.; Lyons, M.J.; Wolfe, J.; Simpson, J.C.; Goldberg, J.; Eisen, S.A.; Tsuang, M. A twin registry study of familial and individual risk factors for trauma exposure and posttraumatic stress disorder. J. Nerv. Ment. Dis., 2002, 190(4), 209-218. doi: 10.1097/00005053-200204000-00001
  72. True, W.R.; Rice, J.; Eisen, S.A. A twin study of genetic and environmental contributions to liability for posttraumatic stress symptoms. Arch. Gen. Psychiatry, 1993, 50(4), 257-264. doi: 10.1001/archpsyc.1993.01820160019002
  73. Yehuda, R. Biology of posttraumatic stress disorder. J. Clin. Psychiatry, 2001, 62(17), 41-46.
  74. Sack, W.H.; Clarke, G.N.; Seeley, J. Posttraumatic stress disorder across two generations of cambodian refugees. J. Am. Acad. Child Adolesc. Psychiatry, 1995, 34(9), 1160-1166. doi: 10.1097/00004583-199509000-00013
  75. Nievergelt, C.M.; Maihofer, A.X.; Klengel, T.; Atkinson, E.G.; Chen, C-Y.; Choi, K.W.; Coleman, J.R.I.; Dalvie, S.; Duncan, L.E.; Gelernter, J.; Levey, D.F.; Logue, M.W.; Polimanti, R.; Provost, A.C.; Ratanatharathorn, A.; Stein, M.B.; Torres, K.; Aiello, A.E.; Almli, L.M.; Amstadter, A.B.; Andersen, S.B.; Andreassen, O.A.; Arbisi, P.A.; Ashley-Koch, A.E.; Austin, S.B.; Avdibegovic, E.; Babić, D.; Bækvad-Hansen, M.; Baker, D.G.; Beckham, J.C.; Bierut, L.J.; Bisson, J.I.; Boks, M.P.; Bolger, E.A.; Børglum, A.D.; Bradley, B.; Brashear, M.; Breen, G.; Bryant, R.A.; Bustamante, A.C.; Bybjerg-Grauholm, J.; Calabrese, J.R. Caldas- de- Almeida, J.M.; Dale, A.M.; Daly, M.J.; Daskalakis, N.P.; Deckert, J.; Delahanty, D.L.; Dennis, M.F.; Disner, S.G.; Domschke, K.; Dzubur-Kulenovic, A.; Erbes, C.R.; Evans, A.; Farrer, L.A.; Feeny, N.C.; Flory, J.D.; Forbes, D.; Franz, C.E.; Galea, S.; Garrett, M.E.; Gelaye, B.; Geuze, E.; Gillespie, C.; Uka, A.G.; Gordon, S.D.; Guffanti, G.; Hammamieh, R.; Harnal, S.; Hauser, M.A.; Heath, A.C.; Hemmings, S.M.J.; Hougaard, D.M.; Jakovljevic, M.; Jett, M.; Johnson, E.O.; Jones, I.; Jovanovic, T.; Qin, X-J.; Junglen, A.G.; Karstoft, K-I.; Kaufman, M.L.; Kessler, R.C.; Khan, A.; Kimbrel, N.A.; King, A.P.; Koen, N.; Kranzler, H.R.; Kremen, W.S.; Lawford, B.R.; Lebois, L.A.M.; Lewis, C.E.; Linnstaedt, S.D.; Lori, A.; Lugonja, B.; Luykx, J.J.; Lyons, M.J.; Maples-Keller, J.; Marmar, C.; Martin, A.R.; Martin, N.G.; Maurer, D.; Mavissakalian, M.R.; McFarlane, A.; McGlinchey, R.E.; McLaughlin, K.A.; McLean, S.A.; McLeay, S.; Mehta, D.; Milberg, W.P.; Miller, M.W.; Morey, R.A.; Morris, C.P.; Mors, O.; Mortensen, P.B.; Neale, B.M.; Nelson, E.C.; Nordentoft, M.; Norman, S.B.; O’Donnell, M.; Orcutt, H.K.; Panizzon, M.S.; Peters, E.S.; Peterson, A.L.; Peverill, M.; Pietrzak, R.H.; Polusny, M.A.; Rice, J.P.; Ripke, S.; Risbrough, V.B.; Roberts, A.L.; Rothbaum, A.O.; Rothbaum, B.O.; Roy-Byrne, P.; Ruggiero, K.; Rung, A.; Rutten, B.P.F.; Saccone, N.L.; Sanchez, S.E.; Schijven, D.; Seedat, S.; Seligowski, A.V.; Seng, J.S.; Sheerin, C.M.; Silove, D.; Smith, A.K.; Smoller, J.W.; Sponheim, S.R.; Stein, D.J.; Stevens, J.S.; Sumner, J.A.; Teicher, M.H.; Thompson, W.K.; Trapido, E.; Uddin, M.; Ursano, R.J.; van den Heuvel, L.L.; Van Hooff, M.; Vermetten, E.; Vinkers, C.H.; Voisey, J.; Wang, Y.; Wang, Z.; Werge, T.; Williams, M.A.; Williamson, D.E.; Winternitz, S.; Wolf, C.; Wolf, E.J.; Wolff, J.D.; Yehuda, R.; Young, R.M.D.; Young, K.A.; Zhao, H.; Zoellner, L.A.; Liberzon, I.; Ressler, K.J.; Haas, M.; Koenen, K.C. International meta-analysis of PTSD genome-wide association studies identifies sex- and ancestry-specific genetic risk loci. Nat. Commun., 2019, 10(1), 4558. doi: 10.1038/s41467-019-12576-w
  76. Stein, M.B.; Jang, K.L.; Taylor, S.; Vernon, P.A.; Livesley, W.J. Genetic and environmental influences on trauma exposure and posttraumatic stress disorder symptoms: A twin study. Am. J. Psychiatry, 2002, 159(10), 1675-1681. doi: 10.1176/appi.ajp.159.10.1675
  77. Lang, U.E.; Hellweg, R.; Kalus, P.; Bajbouj, M.; Lenzen, K.P.; Sander, T.; Kunz, D.; Gallinat, J. Association of a functional BDNF polymorphism and anxiety-related personality traits. Psychopharmacology, 2005, 180(1), 95-99. doi: 10.1007/s00213-004-2137-7
  78. Renaud, E.F. The attachment characteristics of combat veterans with PTSD. Traumatology, 2008, 14(3), 1-12. doi: 10.1177/1534765608319085
  79. Koenen, K.C.; Nugent, N.R.; Amstadter, A.B. Gene-environment interaction in posttraumatic stress disorder. Eur. Arch. Psychiatry Clin. Neurosci., 2008, 258(2), 82-96. doi: 10.1007/s00406-007-0787-2
  80. Asch, R.H.; Esterlis, I.; Wendt, F.R.; Kachadourian, L.; Southwick, S.M.; Gelernter, J.; Polimanti, R.; Pietrzak, R.H. Polygenic risk for traumatic loss-related PTSD in US military veterans: Protective effect of secure attachment style. World J. Biol. Psychiatry, 2021, 22(10), 792-799. doi: 10.1080/15622975.2021.1907721
  81. Horn, S.R.; Feder, A. Understanding resilience and preventing and treating PTSD. Harv. Rev. Psychiatry, 2018, 26(3), 158-174. doi: 10.1097/HRP.0000000000000194
  82. Lee, D.J.; Lee, L.O.; Bovin, M.J.; Moshier, S.J.; Dutra, S.J.; Kleiman, S.E.; Rosen, R.C.; Vasterling, J.J.; Keane, T.M.; Marx, B.P. The 20-year course of posttraumatic stress disorder symptoms among veterans. J. Abnorm. Psychol., 2020, 129(6), 658-669. doi: 10.1037/abn0000571
  83. Able, M.L.; Benedek, D.M. Severity and symptom trajectory in combat-related PTSD: A review of the literature. Curr. Psychiatry Rep., 2019, 21(7), 58. doi: 10.1007/s11920-019-1042-z
  84. Steinert, C.; Hofmann, M.; Leichsenring, F.; Kruse, J. The course of PTSD in naturalistic long-term studies: High variability of outcomes. A systematic review. Nord. J. Psychiatry, 2015, 69(7), 483-496. doi: 10.3109/08039488.2015.1005023
  85. Morina, N.; Wicherts, J.M.; Lobbrecht, J.; Priebe, S. Remission from post-traumatic stress disorder in adults: A systematic review and meta-analysis of long term outcome studies. Clin. Psychol. Rev., 2014, 34(3), 249-255. doi: 10.1016/j.cpr.2014.03.002
  86. Rosellini, A.J.; Liu, H.; Petukhova, M.V.; Sampson, N.A.; Aguilar-Gaxiola, S.; Alonso, J.; Borges, G.; Bruffaerts, R.; Bromet, E.J.; de Girolamo, G.; de Jonge, P.; Fayyad, J.; Florescu, S.; Gureje, O.; Haro, J.M.; Hinkov, H.; Karam, E.G.; Kawakami, N.; Koenen, K.C.; Lee, S.; Lépine, J.P.; Levinson, D.; Navarro-Mateu, F.; Oladeji, B.D.; O’Neill, S.; Pennell, B-E.; Piazza, M.; Posada-Villa, J.; Scott, K.M.; Stein, D.J.; Torres, Y.; Viana, M.C.; Zaslavsky, A.M.; Kessler, R.C. Recovery from DSM-IV post-traumatic stress disorder in the WHO World Mental Health surveys. Psychol. Med., 2018, 48(3), 437-450. doi: 10.1017/S0033291717001817
  87. Tripp, J.C.; Norman, S.B.; Kim, H.M.; Venners, M.R.; Martis, B.; Simon, N.M.; Stein, M.B.; Allard, C.B.; Rauch, S.A.M. Residual symptoms of PTSD following Sertraline plus enhanced medication management, Sertraline plus PE, and PE plus placebo. Psychiatry Res., 2020, 291, 113279. doi: 10.1016/j.psychres.2020.113279
  88. Larsen, S.E.; Fleming, C.J.E.; Resick, P.A. Residual symptoms following empirically supported treatment for PTSD. Psychol. Trauma, 2019, 11(2), 207-215. doi: 10.1037/tra0000384
  89. Schnurr, P.P.; Lunney, C.A. Residual symptoms following prolonged exposure and present-centered therapy for PTSD in female veterans and soldiers. Depress. Anxiety, 2019, 36(2), 162-169. doi: 10.1002/da.22871
  90. Usman, M.; Rehman, A.; Bakhtawar, N.; Bhatti, A. Prognosis of ptsd in treated vs. non-treated groups. J. Pak. Psychiatr. Soc., 2015, 12(1), 39-42.
  91. Doctor, J.N.; Zoellner, L.A.; Feeny, N.C. Predictors of health-related quality-of-life utilities among persons with posttraumatic stress disorder. Psychiatr. Serv., 2011, 62(3), 272-277. doi: 10.1176/ps.62.3.pss6203_0272
  92. Pagotto, L.F.; Mendlowicz, M.V.; Coutinho, E.S.F.; Figueira, I.; Luz, M.P.; Araujo, A.X.; Berger, W. The impact of posttraumatic symptoms and comorbid mental disorders on the health-related quality of life in treatment-seeking PTSD patients. Compr. Psychiatry, 2015, 58, 68-73. doi: 10.1016/j.comppsych.2015.01.002
  93. Kartha, A.; Brower, V.; Saitz, R.; Samet, J.H.; Keane, T.M.; Liebschutz, J. The impact of trauma exposure and post-traumatic stress disorder on healthcare utilization among primary care patients. Med. Care, 2008, 46(4), 388-393. doi: 10.1097/MLR.0b013e31815dc5d2
  94. Alonso, J.; Petukhova, M.; Vilagut, G.; Chatterji, S.; Heeringa, S.; Üstün, T.B.; Alhamzawi, A.O.; Viana, M.C.; Angermeyer, M.; Bromet, E.; Bruffaerts, R.; de Girolamo, G.; Florescu, S.; Gureje, O.; Haro, J.M.; Hinkov, H.; Hu, C.; Karam, E.G.; Kovess, V.; Levinson, D. Medina-Mora, M.E.; Nakamura, Y.; Ormel, J.; Posada-Villa, J.; Sagar, R.; Scott, K.M.; Tsang, A.; Williams, D.R.; Kessler, R.C. Days out of role due to common physical and mental conditions: results from the WHO World Mental Health surveys. Mol. Psychiatry, 2011, 16(12), 1234-1246. doi: 10.1038/mp.2010.101
  95. Campbell, S.B.; Renshaw, K.D. Posttraumatic stress disorder and relationship functioning: A comprehensive review and organizational framework. Clin. Psychol. Rev., 2018, 65, 152-162. doi: 10.1016/j.cpr.2018.08.003
  96. Bernal, M.; Haro, J.M.; Bernert, S.; Brugha, T.; de Graaf, R.; Bruffaerts, R.; Lépine, J.P.; de Girolamo, G.; Vilagut, G.; Gasquet, I.; Torres, J.V.; Kovess, V.; Heider, D.; Neeleman, J.; Kessler, R.; Alonso, J. Risk factors for suicidality in Europe: Results from the ESEMED study. J. Affect. Disord., 2007, 101(1-3), 27-34. doi: 10.1016/j.jad.2006.09.018
  97. Pietrzak, R.H.; Goldstein, R.B.; Southwick, S.M.; Grant, B.F. Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: Results from wave 2 of the national epidemiologic survey on alcohol and related conditions. J. Anxiety Disord., 2011, 25(3), 456-465. doi: 10.1016/j.janxdis.2010.11.010
  98. Wilcox, H.C.; Storr, C.L.; Breslau, N. Posttraumatic stress disorder and suicide attempts in a community sample of urban american young adults. Arch. Gen. Psychiatry, 2009, 66(3), 305-311. doi: 10.1001/archgenpsychiatry.2008.557
  99. Stevens, D.; Wilcox, H.C.; MacKinnon, DF Posttraumatic stress disorder increases risk for suicide attempt in adults with recurrent major depression. Depress Anxiety, 2013, 30(10), 940-946. doi: 10.1002/da.22160 PMID: 23893768
  100. Pausch, M.J.; Matten, S.J. Trauma and Trauma Consequence Disorder: In Media, Management and Public; Springer Nature; , 2022, p. 121.
  101. Kraepelin, E. Der psychologische Versuch in der Psychiatrie. Psychologische Arbeiten., 1896, 1, 1-91.
  102. Freud, S.; Breuer, J. Studies in hysteria; Penguin, 2004.
  103. Gasquoine, P.G. Railway spine: The advent of compensation for concussive symptoms. J. Hist. Neurosci., 2020, 29(2), 234-245. doi: 10.1080/0964704X.2019.1711350
  104. Dutil, A. Hysteria and associated neurasthenia (railway-spine and traumatic neurosis), by A. Dutil: O. Doin; P; BLAKISTON, SON & CO: Philadelphia, 1889.
  105. Erichsen, J.E. Clinical Lecture, 1866.
  106. Steckel, H.A. The traumatic neuroses of war. Am. J. Psychiatry, 1942, 98(4), 624-625. doi: 10.1176/ajp.98.4.624
  107. GrinkerRRSpiegelJPMen under stress. Blakiston, 1945. doi: 10.1037/10784-000
  108. Grinker, R.R.; Spiegel, J.P. Reactions to combat, based on previous emotional disorders. In: Men under stress; Blakiston, 1945; pp. 53-81. doi: 10.1037/10784-004
  109. Vance, M.C.; Howell, J.D. Shell shock and PTSD: A tale of two diagnoses. Mayo Clin. Proc., 2020, 95(9), 1827-1830. doi: 10.1016/j.mayocp.2020.06.002
  110. Miller, L. History of the PTSD Concept and Its Relation to the Law.PTSD and Forensic Psychology: Applications to Civil and Criminal Law. SpringerBriefs in Psychology; Miller, L., Ed.; Springer International Publishing: Cham, 2015, pp. 1-7. doi: 10.1007/978-3-319-09081-8_1
  111. Jones, E. Historical approaches to post-combat disorders. Philos. Trans. R. Soc. Lond. B Biol. Sci., 2006, 361(1468), 533-542. doi: 10.1098/rstb.2006.1814
  112. Jablonski, R.K.; Leszek, J.; Rosińczuk, J.; Uchmanowicz, I.; Panaszek, B. Impact of incarceration in Nazi concentration camps on multi-morbidity of former prisoners. Neuropsychiatr. Dis. Treat., 2015, 11, 669-674.
  113. Trautman, E.C. Concentration Camp Survivors in Norway and Israel; Am Psychiatric Assoc, 1967.
  114. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders, 1952.
  115. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental. Disorders; Second Edition; Washington, D. C, 1968.
  116. American Psychiatric Association (APA). The Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM-III); American Psychiatric Association, 1980.
  117. Bryant, R.A.; Galatzer-Levy, I.; Hadzi-Pavlovic, D. The heterogeneity of posttraumatic stress disorder in DSM-5. JAMA Psychiat., 2023, 80(2), 189-191. doi: 10.1001/jamapsychiatry.2022.4092
  118. Lehrner, A.; Yehuda, R. Biomarkers of PTSD: Military applications and considerations. Eur. J. Psychotraumatol., 2014, 5, ecollection 2014. doi: 10.3402/ejpt.v5.23797
  119. Psychobiology of Posttraumatic Stress Disorder.Psychobiology of Posttraumatic Stress Disorder: A Decade of Progress, 1st; Mass: Wiley-Blackwell: Boston, 2006, 1071, p. 352.
  120. Zoellner, L.A.; Pruitt, L.D.; Farach, F.J.; Jun, J.J. Understanding heterogeneity in PTSD: Fear, dysphoria, and distress. Depress. Anxiety, 2014, 31(2), 97-106. doi: 10.1002/da.22133
  121. Flory, J.D.; Yehuda, R. Comorbidity between post-traumatic stress disorder and major depressive disorder: Alternative explanations and treatment considerations. Dialogues Clin. Neurosci., 2015, 17(2), 141-150. doi: 10.31887/DCNS.2015.17.2/jflory
  122. Sareen, J. Posttraumatic stress disorder in adults: Impact, comorbidity, risk factors, and treatment. Can. J. Psychiatry, 2014, 59(9), 460-467. doi: 10.1177/070674371405900902
  123. Van der Kolk, B.A.; McFarlane, A.C.; Weisaeth, L. Traumatic stress: The effects of overwhelming experience on mind, body, and society; Guilford Press, 2012.
  124. Bernal, G.; Jiménez-Chafey, M.I.; Domenech, R.M.M. Cultural adaptation of treatments: A resource for considering culture in evidence-based practice. Prof. Psychol. Res. Pr., 2009, 40(4), 361-368. doi: 10.1037/a0016401
  125. Yehuda, R. Treating trauma survivors with PTSD: American Psychiatric Pub, 2008.
  126. Monson, E.; Lonergan, M.; Caron, J.; Brunet, A. Assessing trauma and posttraumatic stress disorder: Single, open-ended question versus list-based inventory. Psychol. Assess., 2016, 28(8), 1001-1008. doi: 10.1037/pas0000223
  127. Livingston, N.A.; Brief, D.; Miller, M.; Keane, T. Assessment of PTSD and its comorbidities in adults; Handbook of PTSD; Science and practice, 2021, p. 283.
  128. Weathers, F.W.; Blake, D.D.; Schnurr, P.P.; Kaloupek, D.G.; Marx, B.P.; Keane, T.M. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). Assessment, 2013. Available from www.ptsd.va.gov
  129. First, M.B. Structured Clinical Interview for the DSM (SCID). The Encyclopedia of Clinical Psychology; Cautin, R.L.; Lilienfeld, S.O., Eds.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2015, pp. 1-6. doi: 10.1002/9781118625392.wbecp351
  130. Shalev, A.Y.; Peri, T.; Orr, S.P.; Bonne, O.; Pitman, R.K. Auditory startle responses in help-seeking trauma survivors. Psychiatry Res., 1997, 69(1), 1-7. doi: 10.1016/S0165-1781(96)03001-6
  131. Orr, S.P.; Lasko, N.B.; Shalev, A.Y.; Pitman, R.K. Physiologic responses to loud tones in Vietnam veterans with posttraumatic stress disorder. J. Abnorm. Psychol., 1995, 104(1), 75-82. doi: 10.1037/0021-843X.104.1.75
  132. Yehuda, R.; LeDoux, J. Response variation following trauma: A translational neuroscience approach to understanding PTSD. Neuron, 2007, 56(1), 19-32. doi: 10.1016/j.neuron.2007.09.006
  133. Bremner, J.D. Does stress damage the brain? Biol. Psychiatry, 1999, 45(7), 797-805. doi: 10.1016/S0006-3223(99)00009-8
  134. Bremner, J.D.; Randall, P.; Vermetten, E.; Staib, L.; Bronen, R.A.; Mazure, C.; Capelli, S.; McCarthy, G.; Innis, R.B.; Charney, D.S. Magnetic resonance imaging-based measurement of hippocampal volume in posttraumatic stress disorder related to childhood physical and sexual abuse—a preliminary report. Biol. Psychiatry, 1997, 41(1), 23-32. doi: 10.1016/S0006-3223(96)00162-X
  135. Geuze, E.; Vermetten, E.; de Kloet, C.S.; Westenberg, H.G.M. Precuneal activity during encoding in veterans with posttraumatic stress disorder. Prog. Brain Res., 2007, 167, 293-297. doi: 10.1016/S0079-6123(07)67026-5
  136. Cavanna, A.E.; Trimble, M.R. The precuneus: A review of its functional anatomy and behavioural correlates. Brain, 2006, 129(3), 564-583. doi: 10.1093/brain/awl004
  137. Bird, C.I.V.; Modlin, N.L.; Rucker, J.J.H. Psilocybin and MDMA for the treatment of trauma-related psychopathology. Int. Rev. Psychiatry, 2021, 33(3), 229-249. doi: 10.1080/09540261.2021.1919062
  138. Jatzko, A.; Schmitt, A.; Demirakca, T.; Weimer, E.; Braus, D.F. Disturbance in the neural circuitry underlying positive emotional processing in post-traumatic stress disorder (PTSD). Eur. Arch. Psychiatry Clin. Neurosci., 2006, 256(2), 112-114. doi: 10.1007/s00406-005-0617-3
  139. Sakamoto, H.; Fukuda, R.; Okuaki, T.; Rogers, M.; Kasai, K.; Machida, T.; Shirouzu, I.; Yamasue, H.; Akiyama, T.; Kato, N. Parahippo-campal activation evoked by masked traumatic images in posttraumatic stress disorder: A functional MRI study. Neuroimage, 2005, 26(3), 813-821. doi: 10.1016/j.neuroimage.2005.02.032
  140. St. Jacques, P.L.; Botzung, A.; Miles, A.; Rubin, D.C. Functional neuroimaging of emotionally intense autobiographical memories in post-traumatic stress disorder. J. Psychiatr. Res., 2011, 45(5), 630-637. doi: 10.1016/j.jpsychires.2010.10.011
  141. Brohawn, K.H.; Offringa, R.; Pfaff, D.L.; Hughes, K.C.; Shin, L.M. The neural correlates of emotional memory in posttraumatic stress disorder. Biol. Psychiatry, 2010, 68(11), 1023-1030. doi: 10.1016/j.biopsych.2010.07.018
  142. Sripada, R.K.; King, A.P.; Garfinkel, S.N.; Wang, X.; Sripada, C.S.; Welsh, R.C.; Liberzon, I. Altered resting-state amygdala functional connectivity in men with posttraumatic stress disorder. J. Psychiatry Neurosci., 2012, 37(4), 241-249. doi: 10.1503/jpn.110069
  143. Fitzgerald, J.M.; DiGangi, J.A.; Phan, K.L. Functional neuroanatomy of emotion and its regulation in PTSD. Harv. Rev. Psychiatry, 2018, 26(3), 116-128. doi: 10.1097/HRP.0000000000000185
  144. Bremner, J.D. Traumatic stress: Effects on the brain. Dialogues Clin. Neurosci., 2006, 8(4), 445-461. doi: 10.31887/DCNS.2006.8.4/jbremner
  145. Shin, L.M.; Rauch, S.L.; Pitman, R.K. Amygdala, medial prefrontal cortex, and hippocampal function in PTSD. Ann. N. Y. Acad. Sci., 2006, 1071(1), 67-79. doi: 10.1196/annals.1364.007
  146. Kunimatsu, A.; Yasaka, K.; Akai, H.; Kunimatsu, N.; Abe, O. MRI findings in posttraumatic stress disorder. J. Magn. Reson. Imaging, 2020, 52(2), 380-396. doi: 10.1002/jmri.26929
  147. Lanius, R.A.; Williamson, P.C.; Hopper, J.; Densmore, M.; Boksman, K.; Gupta, M.A.; Neufeld, R.W.J.; Gati, J.S.; Menon, R.S. Recall of emotional states in posttraumatic stress disorder: An fMRI investigation. Biol. Psychiatry, 2003, 53(3), 204-210. doi: 10.1016/S0006-3223(02)01466-X
  148. Lanius, R.A.; Brand, B.; Vermetten, E.; Frewen, P.A.; Spiegel, D. The dissociative subtype of posttraumatic stress disorder: Rationale, clinical and neurobiological evidence, and implications. Depress. Anxiety, 2012, 29(8), 701-708. doi: 10.1002/da.21889
  149. Dunlop, B.W.; Wong, A. The hypothalamicpituitaryadrenal axis in PTSD: Pathophysiology and treatment interventions. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2019, 89, 361-379. doi: 10.1016/j.pnpbp.2018.10.010
  150. Klaassens, E.R.; Giltay, E.J.; Cuijpers, P.; van Veen, T.; Zitman, F.G. Adulthood trauma and HPA-axis functioning in healthy subjects and PTSD patients: A meta-analysis. Psychoneuroendocrinology, 2012, 37(3), 317-331. doi: 10.1016/j.psyneuen.2011.07.003
  151. Yehuda, R.; Halligan, S.L.; Golier, J.A.; Grossman, R.; Bierer, L.M. Effects of trauma exposure on the cortisol response to dexamethasone administration in PTSD and major depressive disorder. Psychoneuroendocrinology, 2004, 29(3), 389-404. doi: 10.1016/S0306-4530(03)00052-0
  152. Shi, C.; Ren, Z.; Zhao, C.; Zhang, T.; Chan, S.H. Shame, guilt, and posttraumatic stress symptoms: A three-level meta-analysis. J. Anxiety Disord., 2021, 82, 102443. Epub 2021 Jul 2 doi: 10.1016/j.janxdis.2021.102443 PMID: 34265540
  153. Bastin, C.; Harrison, B.J.; Davey, C.G.; Moll, J.; Whittle, S. Feelings of shame, embarrassment and guilt and their neural correlates: A systematic review. Neurosci. Biobehav. Rev., 2016, 71, 455-471. doi: 10.1016/j.neubiorev.2016.09.019
  154. Lloyd, C.S.; Nicholson, A.A.; Densmore, M.; Théberge, J.; Neufeld, R.W.J.; Jetly, R.; McKinnon, M.C.; Lanius, R.A. Shame on the brain: Neural correlates of moral injury event recall in posttraumatic stress disorder. Depress. Anxiety, 2021, 38(6), 596-605. doi: 10.1002/da.23128
  155. Cohen, H.; Zohar, J.; Matar, M. The relevance of differential response to trauma in an animal model of posttraumatic stress disorder. Biol. Psychiatry, 2003, 53(6), 463-473. doi: 10.1016/S0006-3223(02)01909-1
  156. Sanacora, G.; Yan, Z.; Popoli, M. The stressed synapse 2.0: Pathophysiological mechanisms in stress-related neuropsychiatric disorders. Nat. Rev. Neurosci., 2022, 23(2), 86-103. doi: 10.1038/s41583-021-00540-x
  157. Duman, R.S.; Aghajanian, G.K.; Sanacora, G.; Krystal, J.H. Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants. Nat. Med., 2016, 22(3), 238-249. doi: 10.1038/nm.4050
  158. van Zuiden, M.; Kavelaars, A.; Geuze, E.; Olff, M.; Heijnen, C.J. Predicting PTSD: Pre-existing vulnerabilities in glucocorticoid-signaling and implications for preventive interventions. Brain Behav. Immun., 2013, 30, 12-21. doi: 10.1016/j.bbi.2012.08.015
  159. Sriram, K.; Rodriguez-Fernandez, M.; Doyle, F.J. Modeling cortisol dynamics in the neuro-endocrine axis distinguishes normal, depression, and post-traumatic stress disorder (PTSD) in humans. PLOS Comput. Biol., 2012, 8(2), e1002379. doi: 10.1371/journal.pcbi.1002379
  160. Yehuda, R. Clinical relevance of biologic findings in PTSD. Psychiatr. Q., 2002, 73(2), 123-133. doi: 10.1023/A:1015055711424
  161. Yehuda, R.; Southwick, S.M.; Krystal, J.H. Enhanced suppression of cortisol following dexamethasone administration in posttraumatic stress disorder. Am. J. Psychiatry, 1993, 150(1), 83-86. doi: 10.1176/ajp.150.1.83
  162. Jovanovic, T.; Phifer, J.E.; Sicking, K.; Weiss, T.; Norrholm, S.D.; Bradley, B.; Ressler, K.J. Cortisol suppression by dexamethasone reduces exaggerated fear responses in posttraumatic stress disorder. Psychoneuroendocrinology, 2011, 36(10), 1540-1552. doi: 10.1016/j.psyneuen.2011.04.008
  163. Inslicht, S.S.; Rao, M.N.; Richards, A.; O’Donovan, A.; Gibson, C.J.; Baum, T.; Metzler, T.J.; Neylan, T.C. Sleep and hypothalamic pituitary adrenal axis responses to metyrapone in posttraumatic stress disorder. Psychoneuroendocrinology, 2018, 88, 136-143. doi: 10.1016/j.psyneuen.2017.12.002
  164. Neylan, T.C.; Lenoci, M.; Maglione, M.L.; Rosenlicht, N.Z.; Metzler, T.J.; Otte, C.; Schoenfeld, F.B.; Yehuda, R.; Marmar, C.R. Delta sleep response to metyrapone in post-traumatic stress disorder. Neuropsychopharmacology, 2003, 28(9), 1666-1676. doi: 10.1038/sj.npp.1300215
  165. Breen, M.S.; Bierer, L.M.; Daskalakis, N.P.; Bader, H.N.; Makotkine, I.; Chattopadhyay, M.; Xu, C.; Buxbaum Grice, A.; Tocheva, A.S.; Flory, J.D.; Buxbaum, J.D.; Meaney, M.J.; Brennand, K.; Yehuda, R. Differential transcriptional response following glucocorticoid activation in cultured blood immune cells: A novel approach to PTSD biomarker development. Transl. Psychiatry, 2019, 9(1), 201. doi: 10.1038/s41398-019-0539-x
  166. Seah, C.; Breen, M.S.; Rusielewicz, T.; Bader, H.N.; Xu, C.; Hunter, C.J.; McCarthy, B.; Deans, P.J.M.; Chattopadhyay, M.; Goldberg, J.; Desarnaud, F.; Makotkine, I.; Flory, J.D.; Bierer, L.M.; Staniskyte, M.; Bauer, L.; Brenner, K.; Buckley-Herd, G.; DesMarteau, S.; Fenton, P.; Ferrarotto, P.; Hall, J.; Jacob, S.; Kroeker, T.; Lallos, G.; Martinez, H.; McCoy, P.; Monsma, F.J.; Moroziewicz, D.; Otto, R.; Reggio, K.; Sun, B.; Tibbets, R.; Shin, D.W.; Zhou, H.; Zimmer, M.; Noggle, S.A.; Huckins, L.M.; Paull, D.; Brennand, K.J.; Yehuda, R. Modeling gene × environment interactions in PTSD using human neurons reveals diagnosis-specific glucocorticoid-induced gene expression. Nat. Neurosci., 2022, 25(11), 1434-1445. doi: 10.1038/s41593-022-01161-y
  167. Garrett, M.E.; Qin, X.J.; Mehta, D.; Dennis, M.F.; Marx, C.E.; Grant, G.A.; Stein, M.B.; Kimbrel, N.A.; Beckham, J.C.; Hauser, M.A.; Ashley-Koch, A.E. Gene expression analysis in three posttraumatic stress disorder cohorts implicates inflammation and innate immunity pathways and uncovers shared genetic risk with major depressive disorder. Front. Neurosci., 2021, 15, 678548. doi: 10.3389/fnins.2021.678548
  168. Passos, I.C.; Vasconcelos-Moreno, M.P.; Costa, L.G.; Kunz, M.; Brietzke, E.; Quevedo, J.; Salum, G.; Magalhães, P.V.; Kapczinski, F.; Kauer-Sant’Anna, M. Inflammatory markers in post-traumatic stress disorder: A systematic review, meta-analysis, and meta-regression. Lancet Psychiatry, 2015, 2(11), 1002-1012. doi: 10.1016/S2215-0366(15)00309-0
  169. O’Donovan, A.; Ahmadian, A.J.; Neylan, T.C.; Pacult, M.A.; Edmondson, D.; Cohen, B.E. Current posttraumatic stress disorder and exaggerated threat sensitivity associated with elevated inflammation in the Mind Your Heart Study. Brain Behav. Immun., 2017, 60, 198-205. doi: 10.1016/j.bbi.2016.10.014
  170. Kim, T.D.; Lee, S.; Yoon, S. Inflammation in post-traumatic stress disorder (PTSD): A review of potential correlates of PTSD with a neurological perspective. Antioxidants, 2020, 9(2), 107. doi: 10.3390/antiox9020107
  171. Yehuda, R.; Daskalakis, N.P.; Desarnaud, F.; Makotkine, I.; Lehrner, A.L.; Koch, E.; Flory, J.D.; Buxbaum, J.D.; Meaney, M.J.; Bierer, L.M. Epigenetic biomarkers as predictors and correlates of symptom improvement following psychotherapy in combat veterans with PTSD. Front. Psychiatry, 2013, 4, 118. doi: 10.3389/fpsyt.2013.00118
  172. Yehuda, R.; Flory, J.D.; Bierer, L.M.; Henn-Haase, C.; Lehrner, A.; Desarnaud, F.; Makotkine, I.; Daskalakis, N.P.; Marmar, C.R.; Meaney, M.J. Lower methylation of glucocorticoid receptor gene promoter 1F in peripheral blood of veterans with posttraumatic stress disorder. Biol. Psychiatry, 2015, 77(4), 356-364. doi: 10.1016/j.biopsych.2014.02.006
  173. Carvalho, V.S.; Gomes, W.R.; Calado, R.T. Recent advances in understanding telomere diseases. Fac. Rev., 2022, 11, 31.
  174. Kim, T.Y.; Kim, S.J.; Choi, J.R.; Lee, S-T.; Kim, J.; Hwang, I.S.; Chung, H.G.; Choi, J.H.; Kim, H.W.; Kim, S.H.; Kang, J.I. The effect of trauma and PTSD on telomere length: An exploratory study in people exposed to combat trauma. Sci. Rep., 2017, 7(1), 4375. doi: 10.1038/s41598-017-04682-w
  175. Mellon, S.H.; Gautam, A.; Hammamieh, R.; Jett, M.; Wolkowitz, O.M. Metabolism, metabolomics, and inflammation in posttraumatic stress disorder. Biol. Psychiatry, 2018, 83(10), 866-875. doi: 10.1016/j.biopsych.2018.02.007
  176. Dean, K.R.; Hammamieh, R.; Mellon, S.H.; Abu-Amara, D.; Flory, J.D.; Guffanti, G.; Wang, K.; Daigle, B.J., Jr; Gautam, A.; Lee, I.; Yang, R.; Almli, L.M.; Bersani, F.S.; Chakraborty, N.; Donohue, D.; Kerley, K.; Kim, T-K.; Laska, E.; Young Lee, M.; Lindqvist, D.; Lori, A.; Lu, L.; Misganaw, B.; Muhie, S.; Newman, J.; Price, N.D.; Qin, S.; Reus, V.I.; Siegel, C.; Somvanshi, P.R.; Thakur, G.S.; Zhou, Y.; Hood, L.; Ressler, K.J.; Wolkowitz, O.M.; Yehuda, R.; Jett, M.; Doyle, F.J., III; Marmar, C. Multi-omic biomarker identification and validation for diagnosing warzone-related post-traumatic stress disorder. Mol. Psychiatry, 2020, 25(12), 3337-3349. doi: 10.1038/s41380-019-0496-z
  177. Malan-Muller, S.; Valles-Colomer, M.; Foxx, C.L.; Vieira-Silva, S.; van den Heuvel, L.L.; Raes, J.; Seedat, S.; Lowry, C.A.; Hemmings, S.M.J. Exploring the relationship between the gut microbiome and mental health outcomes in a posttraumatic stress disorder cohort relative to trauma-exposed controls. Eur. Neuropsychopharmacol., 2022, 56, 24-38. doi: 10.1016/j.euroneuro.2021.11.009
  178. Yang, R.; Gautam, A.; Getnet, D.; Daigle, B.J.; Miller, S.; Misganaw, B.; Dean, K.R.; Kumar, R.; Muhie, S.; Wang, K.; Lee, I.; Abu-Amara, D.; Flory, J.D.; Hoke, A.; Chakraborty, N.; Petzold, L.; Wu, G.; Guffanti, G.; Kim, T-K.; Lee, M.Y.; Bierer, L.; Hood, L.; Wolkowitz, O.M.; Mellon, S.H.; Doyle, F.J., III; Yehuda, R.; Marmar, C.R.; Ressler, K.J.; Hammamieh, R.; Jett, M. Epigenetic biotypes of post-traumatic stress disorder in war-zone exposed veteran and active duty males. Mol. Psychiatry, 2021, 26(8), 4300-4314. doi: 10.1038/s41380-020-00966-2
  179. Friedman, M.J.; Yehuda, R. Post-traumatic stress disorder and comorbidity: Psychobiological approaches to differential diagnosis. Neurobiological and clinical consequences of stress: From normal adaptation to post-traumatic stress disorder; Lippincott Williams & Wilkins Publishers: Philadelphia, PA, US, 1995, pp. 429-445.
  180. Lewis, C.; Roberts, N.P.; Andrew, M.; Starling, E.; Bisson, J.I. Psychological therapies for post-traumatic stress disorder in adults: Systematic review and meta-analysis. Eur. J. Psychotraumatol., 2020, 11(1), 1729633. doi: 10.1080/20008198.2020.1729633
  181. Bryant, R.A.; O’Donnell, M.L.; Creamer, M.; McFarlane, A.C.; Clark, C.R.; Silove, D. The psychiatric sequelae of traumatic injury. Am. J. Psychiatry, 2010, 167(3), 312-320. doi: 10.1176/appi.ajp.2009.09050617
  182. Nijdam, M.J.; Gersons, B.P.R.; Olff, M. The role of major depression in neurocognitive functioning in patients with posttraumatic stress disorder. Eur. J. Psychotraumatol., 2013, 4(1), 19979. doi: 10.3402/ejpt.v4i0.19979
  183. Green, B.L.; Krupnick, J.L.; Chung, J.; Siddique, J.; Krause, E.D.; Revicki, D.; Frank, L.; Miranda, J. Impact of PTSD comorbidity on one-year outcomes in a depression trial. J. Clin. Psychol., 2006, 62(7), 815-835. doi: 10.1002/jclp.20279
  184. Ramsawh, H.J.; Fullerton, C.S.; Mash, H.B.H.; Ng, T.H.H.; Kessler, R.C.; Stein, M.B.; Ursano, R.J. Risk for suicidal behaviors associated with PTSD, depression, and their comorbidity in the U.S. Army. J. Affect. Disord., 2014, 161, 116-122. doi: 10.1016/j.jad.2014.03.016
  185. Roberts, N.P.; Roberts, P.A.; Jones, N.; Bisson, J.I. Psychological interventions for post-traumatic stress disorder and comorbid substance use disorder: A systematic review and meta-analysis. Clin. Psychol. Rev., 2015, 38, 25-38. doi: 10.1016/j.cpr.2015.02.007
  186. Goldberg, S.B.; Livingston, W.S.; Blais, R.K.; Brignone, E.; Suo, Y.; Lehavot, K.; Simpson, T.L.; Fargo, J.; Gundlapalli, A.V. A positive screen for military sexual trauma is associated with greater risk for substance use disorders in women veterans. Psychol. Addict. Behav., 2019, 33(5), 477-483. doi: 10.1037/adb0000486
  187. Simpson, T.L.; Rise, P.; Browne, K.C.; Lehavot, K.; Kaysen, D. Clinical presentations, social functioning, and treatment receipt among individuals with comorbid life-time PTSD and alcohol use disorders versus drug use disorders: Findings from NESARC-III. Addiction, 2019, 114(6), 983-993. doi: 10.1111/add.14565
  188. McDevitt-Murphy, M.E.; Williams, J.L.; Bracken, K.L. PTSD symptoms, hazardous drinking, and health functioning among U.S. OEF and OIF veterans presenting to primary care. J. Traumat. Stress, 2010, 23(1), 108-111.
  189. Ginzburg, K.; Ein-Dor, T.; Solomon, Z. Comorbidity of posttraumatic stress disorder, anxiety and depression: A 20-year longitudinal study of war veterans. J. Affect. Disord., 2010, 123(1-3), 249-257. doi: 10.1016/j.jad.2009.08.006
  190. Wolfson, P.E.; Andries, J.; Feduccia, A.A.; Jerome, L.; Wang, J.B.; Williams, E.; Carlin, S.C.; Sola, E.; Hamilton, S.; Yazar-Klosinski, B.; Emerson, A.; Mithoefer, M.C.; Doblin, R. MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: A randomized pilot study. Sci. Rep., 2020, 10(1), 20442. doi: 10.1038/s41598-020-75706-1
  191. Asmundson, G.J.G.; Coons, M.J.; Taylor, S.; Katz, J. PTSD and the experience of pain: Research and clinical implications of shared vulnerability and mutual maintenance models. Can. J. Psychiatry, 2002, 47(10), 930-937. doi: 10.1177/070674370204701004
  192. Fishbain, D.A.; Pulikal, A.; Lewis, J.E.; Gao, J. Chronic pain types differ in their reported prevalence of post -traumatic stress disorder (PTSD) and there is consistent evidence that chronic pain is associated with PTSD: An evidence-based structured systematic review. Pain Med., 2017, 18(4), 711-735.
  193. Kind, S.; Otis, J.D. The interaction between chronic pain and PTSD. Curr. Pain Headache Rep., 2019, 23(12), 91. doi: 10.1007/s11916-019-0828-3
  194. El-Solh, A.A.; Riaz, U.; Roberts, J. Sleep disorders in patients with posttraumatic stress disorder. Chest, 2018, 154(2), 427-439. doi: 10.1016/j.chest.2018.04.007
  195. Ohayon, M.M.; Shapiro, C.M. Sleep disturbances and psychiatric disorders associated with posttraumatic stress disorder in the general population. Compr. Psychiatry, 2000, 41(6), 469-478. doi: 10.1053/comp.2000.16568
  196. Britvić, D.; Antičević, V.; Kaliterna, M.; Lušić, L.; Beg, A.; Brajević-Gizdić, I.; Kudrić, M.; Stupalo, Ž.; Krolo, V.; Pivac, N. Comorbidities with posttraumatic stress disorder (PTSD) among combat veterans: 15 years postwar analysis. Int. J. Clin. Health Psychol., 2015, 15(2), 81-92. doi: 10.1016/j.ijchp.2014.11.002
  197. Pacella, M.L.; Hruska, B.; Delahanty, D.L. The physical health consequences of PTSD and PTSD symptoms: A meta-analytic review. J. Anxiety Disord., 2013, 27(1), 33-46. doi: 10.1016/j.janxdis.2012.08.004
  198. Ryder, A.L.; Azcarate, P.M.; Cohen, B.E. PTSD and physical health. Curr. Psychiatry Rep., 2018, 20(12), 116. doi: 10.1007/s11920-018-0977-9
  199. Foa, E.B.; Keane, T.M.; Friedman, M.J.; Cohen, J.A. Effective treatments for PTSD: practice guidelines from the International Society for Traumatic Stress Studies; Guilford Press, 2010.
  200. Krause-Utz, A.; Frost, R.; Winter, D.; Elzinga, B.M. Dissociation and alterations in brain function and structure: implications for borderline personality disorder. Curr. Psychiatry Rep., 2017, 19(1), 6. doi: 10.1007/s11920-017-0757-y
  201. Choi, K.R.; Seng, J.S.; Briggs, E.C.; Munro-Kramer, M.L.; Graham-Bermann, S.A.; Lee, R.C.; Ford, J.D. The dissociative subtype of post-traumatic stress disorder (PTSD) among adolescents: Co-occurring PTSD, depersonalization/derealization, and other dissociation symptoms. J. Am. Acad. Child Adolesc. Psychiatry, 2017, 56(12), 1062-1072. doi: 10.1016/j.jaac.2017.09.425
  202. Cloitre, M.; Petkova, E.; Wang, J.; Lu, L.F. An examination of the influence of a sequential treatment on the course and impact of dissociation among women with PTSD related to childhood abuse. Depress. Anxiety, 2012, 29(8), 709-717. doi: 10.1002/da.21920
  203. Lanius, R.A.; Vermetten, E.; Loewenstein, R.J.; Brand, B.; Schmahl, C.; Bremner, J.D.; Spiegel, D. Emotion modulation in PTSD: Clinical and neurobiological evidence for a dissociative subtype. Am. J. Psychiatry, 2010, 167(6), 640-647. doi: 10.1176/appi.ajp.2009.09081168
  204. Berman, R.M.; Cappiello, A.; Anand, A.; Oren, D.A.; Heninger, G.R.; Charney, D.S.; Krystal, J.H. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry, 2000, 47(4), 351-354. doi: 10.1016/S0006-3223(99)00230-9
  205. Niciu, M.J.; Shovestul, B.J.; Jaso, B.A.; Farmer, C.; Luckenbaugh, D.A.; Brutsche, N.E.; Park, L.T.; Ballard, E.D.; Zarate, C.A., Jr Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. J. Affect. Disord., 2018, 232, 310-315. doi: 10.1016/j.jad.2018.02.049
  206. Burback, L.; Brémault-Phillips, S.; Nijdam, M.J.; McFarlane, A.; Vermetten, E. Treatment of posttraumatic stress disorder: A state-of-the-art review. Curr. Neuropharmacol., 2023, 22, 627-705. doi: 10.2174/1570159X21666230428091433
  207. Kearns, M.C.; Ressler, K.J.; Zatzick, D.; Rothbaum, B.O. Early interventions for PTSD: A review. Depress. Anxiety, 2012, 29(10), 833-842. doi: 10.1002/da.21997
  208. Grinage, B.D. Diagnosis and management of post-traumatic stress disorder. Am. Fam. Physician, 2003, 68(12), 2401-2408.
  209. Aliev, G.; Beeraka, N.M.; Nikolenko, V.N.; Svistunov, A.A.; Rozhnova, T.; Kostyuk, S.; Cherkesov, I.; Gavryushova, L.V.; Chekhonatsky, A.A.; Mikhaleva, L.M.; Somasundaram, S.G.; Avila-Rodriguez, M.F.; Kirkland, C.E. Neurophysiology and psychopathology underlying PTSD and recent insights into the PTSD therapies: A comprehensive review. J. Clin. Med., 2020, 9(9), 2951. doi: 10.3390/jcm9092951
  210. Le, Q.A.; Doctor, J.N.; Zoellner, L.A.; Feeny, N.C. Effects of treatment, choice, and preference on health-related quality-of-life outcomes in patients with posttraumatic stress disorder (PTSD). Qual. Life Res., 2018, 27(6), 1555-1562. doi: 10.1007/s11136-018-1833-4
  211. Bryant, R.A. Post-traumatic stress disorder: A state-of-the-art review of evidence and challenges. World Psychiatry, 2019, 18(3), 259-269. doi: 10.1002/wps.20656
  212. Raabe, S.; Ehring, T.; Marquenie, L.; Arntz, A.; Kindt, M. Imagery rescripting as a stand-alone treatment for posttraumatic stress disorder related to childhood abuse: A randomized controlled trial. J. Behav. Ther. Exp. Psychiatry, 2022, 77, 101769. doi: 10.1016/j.jbtep.2022.101769
  213. Najavits, L.M.; Anderson, M.L. Psychosocial treatments for posttraumatic stress disorder; Oxford University Press, 2015. doi: 10.1093/med:psych/9780199342211.003.0018
  214. Galovski, T.E.; Blain, L.M.; Mott, J.M.; Elwood, L.; Houle, T. Manualized therapy for PTSD: Flexing the structure of cognitive processing therapy. J. Consult. Clin. Psychol., 2012, 80(6), 968-981. doi: 10.1037/a0030600
  215. Powers, M.B.; Halpern, J.M.; Ferenschak, M.P.; Gillihan, S.J.; Foa, E.B. A meta-analytic review of prolonged exposure for posttraumatic stress disorder. Clin. Psychol. Rev., 2010, 30(6), 635-641. doi: 10.1016/j.cpr.2010.04.007
  216. Jeffries, F.W.; Davis, P. What is the role of eye movements in eye movement desensitization and reprocessing (EMDR) for post-traumatic stress disorder (PTSD)? A review. Behav. Cogn. Psychother., 2013, 41(3), 290-300. doi: 10.1017/S1352465812000793
  217. Siehl, S.; Robjant, K.; Crombach, A. Systematic review and meta-analyses of the long-term efficacy of narrative exposure therapy for adults, children and perpetrators. Psychother. Res., 2021, 31(6), 695-710. doi: 10.1080/10503307.2020.1847345
  218. Lely, J.C.; Smid, G.E.; Jongedijk, R.A.W.; Knipscheer, J.; Kleber, R.J. The effectiveness of narrative exposure therapy: A review, meta-analysis and meta-regression analysis. Eur. J. Psychotraumatol., 2019, 10(1), 1550344. doi: 10.1080/20008198.2018.1550344
  219. Nijdam, M.J.; Meewisse, M-L.; Smid, G.E.; Gersons, B.P. Brief Eclectic Psychotherapy for PTSD. Evidence based treatments for trauma-related psychological disorders: A practical guide for clinicians; Springer, 2022, pp. 281-306.
  220. Bufka, L.F.; Wright, C.V.E.; Halfond, R.W. Casebook to the APA Clinical Practice Guideline for the treatment of PTSD; American Psychological Association, 2020. doi: 10.1037/0000196-000
  221. de la Rie, S.M.; van Sint Fiet, A.; Bos, J.B.A.; Mooren, N.; Smid, G.; Gersons, B.P.R. Brief Eclectic Psychotherapy for Moral Trauma (BEP-MT): treatment protocol description and a case study. Eur. J. Psychotraumatol., 2021, 12(1), 1929026. doi: 10.1080/20008198.2021.1929026
  222. Jericho, B.; Luo, A.; Berle, D. Trauma-focused psychotherapies for post-traumatic stress disorder: A systematic review and network meta-analysis. Acta Psychiatr. Scand., 2022, 145(2), 132-155. doi: 10.1111/acps.13366
  223. Weber, M.; Schumacher, S.; Hannig, W. Long-term outcomes of psychological treatment for posttraumatic stress disorder: A systematic review and meta-analysis; Corrigendum, 2021.
  224. Navarro, P.N.; Landin-Romero, R.; Guardiola-Wanden-Berghe, R. 25 years of Eye Movement Desensitization and Reprocessing (EMDR): The EMDR therapy protocol, hypotheses of its mechanism of action and a systematic review of its efficacy in the treatment of post-traumatic stress disorder. Rev. Psiquiatr. Salud Ment., 2018, 11(2), 101-114.
  225. Pary, R.; Micchelli, A.N.; Lippmann, S. How we treat posttraumatic stress disorder. Prim. Care Companion CNS Disord., 2021, 23(1), 25982. doi: 10.4088/PCC.19nr02572
  226. Belsher, B.E.; Beech, E.; Evatt, D. Present-centered therapy (PCT) for post-traumatic stress disorder (PTSD) in adults. Cochrane Database Syst. Rev., 2019, 11.
  227. Althobaiti, S.; Kazantzis, N.; Ofori-Asenso, R.; Romero, L.; Fisher, J.; Mills, K.E.; Liew, D. Efficacy of interpersonal psychotherapy for post-traumatic stress disorder: A systematic review and meta-analysis. J. Affect. Disord., 2020, 264, 286-294. doi: 10.1016/j.jad.2019.12.021
  228. Bleiberg, K.L.; Markowitz, J.C. Interpersonal psychotherapy for PTSD: Treating trauma without exposure. J. Psychother. Integration, 2019, 29(1), 15-22. doi: 10.1037/int0000113
  229. Jackson, S.; Baity, M.R.; Bobb, K.; Swick, D.; Giorgio, J. Stress inoculation training outcomes among veterans with PTSD and TBI. Psychol. Trauma, 2019, 11(8), 842-850. doi: 10.1037/tra0000432
  230. Steenkamp, M.M.; Litz, B.T.; Hoge, C.W.; Marmar, C.R. Psychotherapy for Military-Related PTSD. JAMA, 2015, 314(5), 489-500. doi: 10.1001/jama.2015.8370
  231. Kelmendi, B.; Adams, T.G.; Yarnell, S.; Southwick, S.; Abdallah, C.G.; Krystal, J.H. PTSD: from neurobiology to pharmacological treatments. Eur. J. Psychotraumatol., 2016, 7(1), 31858. doi: 10.3402/ejpt.v7.31858
  232. Berger, W.; Mendlowicz, M.V.; Marques-Portella, C.; Kinrys, G.; Fontenelle, L.F.; Marmar, C.R.; Figueira, I. Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: A systematic review. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2009, 33(2), 169-180. doi: 10.1016/j.pnpbp.2008.12.004
  233. Lee, D.J.; Schnitzlein, C.W.; Wolf, J.P.; Vythilingam, M.; Rasmusson, A.M.; Hoge, C.W. Psychotherapy versus pharmacotherapy for post-traumatic stress disorder: Systemic review and meta-analyses to determine first-line treatments. Depress. Anxiety, 2016, 33(9), 792-806. doi: 10.1002/da.22511
  234. Williams, T.; Phillips, N.J.; Stein, D.J.; Ipser, J.C. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst. Rev., 2022, 3, CD002795.
  235. Friedman, M.J.; Keane, T.M.; Resick, P.A. Handbook of PTSD, 1st; Science and Practice: Guilford Press, 2007, p. 609.
  236. Davidson, J.R.T.; Tharwani, H.M.; Connor, K.M. Davidson Trauma Scale (DTS): Normative scores in the general population and effect sizes in placebo-controlled SSRI trials. Depress. Anxiety, 2002, 15(2), 75-78. doi: 10.1002/da.10021
  237. Marshall, R.D.; Beebe, K.L.; Oldham, M.; Zaninelli, R. Efficacy and safety of paroxetine treatment for chronic PTSD: A fixed-dose, placebo-controlled study. Am. J. Psychiatry, 2001, 158(12), 1982-1988. doi: 10.1176/appi.ajp.158.12.1982
  238. Tucker, P.; Zaninelli, R.; Yehuda, R.; Ruggiero, L.; Dillingham, K.; Pitts, C.D. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J. Clin. Psychiatry, 2001, 62(11), 860-868. doi: 10.4088/JCP.v62n1105
  239. McRae, A.L.; Brady, K.T. Review of sertraline and its clinical applications in psychiatric disorders. Expert Opin. Pharmacother., 2001, 2(5), 883-892. doi: 10.1517/14656566.2.5.883
  240. Duek, O.; Li, Y.; Kelmendi, B. Modulating amygdala activation to traumatic memories with a single ketamine infusion. Medrxiv, 2021. doi: 10.1101/2021.07.07.21260166
  241. Warner, M.D.; Dorn, M.R.; Peabody, C.A. Survey on the usefulness of trazodone in patients with PTSD with insomnia or nightmares. Pharmacopsychiatry, 2001, 34(4), 128-131. doi: 10.1055/s-2001-15871
  242. Akiki, T.J.; Abdallah, C.G. Are there effective psychopharmacologic treatments for PTSD? J. Clin. Psychiatry, 2019, 80(3), 1309.
  243. Hamblen, J.L.; Norman, S.B.; Sonis, J.H.; Phelps, A.J.; Bisson, J.I.; Nunes, V.D.; Megnin-Viggars, O.; Forbes, D.; Riggs, D.S.; Schnurr, P.P. A guide to guidelines for the treatment of posttraumatic stress disorder in adults: An update. Psychotherapy, 2019, 56(3), 359-373. doi: 10.1037/pst0000231
  244. Bajor, L.A.; Balsara, C.; Osser, D.N. An evidence-based approach to psychopharmacology for posttraumatic stress disorder (PTSD): 2022 update. Psychiatry Res., 2022, 317, 114840. doi: 10.1016/j.psychres.2022.114840
  245. Singh, B.; Hughes, A.J.; Mehta, G.; Erwin, P.J.; Parsaik, A.K. Efficacy of prazosin in posttraumatic stress disorder: A systematic review and meta-analysis. Prim. Care Companion CNS Disord., 2016, 18(4), 26306. doi: 10.4088/PCC.16r01943
  246. Raskind, M.A.; Peterson, K.; Williams, T.; Hoff, D.J.; Hart, K.; Holmes, H.; Homas, D.; Hill, J.; Daniels, C.; Calohan, J.; Millard, S.P.; Rohde, K.; O’Connell, J.; Pritzl, D.; Feiszli, K.; Petrie, E.C.; Gross, C.; Mayer, C.L.; Freed, M.C.; Engel, C.; Peskind, E.R. A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. Am. J. Psychiatry, 2013, 170(9), 1003-1010. doi: 10.1176/appi.ajp.2013.12081133
  247. Zhang, Y.; Ren, R.; Sanford, L.D.; Tang, X. Commentary on Yücel DE et al. Downgrading recommendation level of prazosin for treating trauma-related nightmares: Should decision be based on a single study? Sleep Med. Rev., 2020, 51, 101285. doi: 10.1016/j.smrv.2020.101285
  248. Hoskins, M.D.; Sinnerton, R.; Nakamura, A.; Underwood, J.F.G.; Slater, A.; Lewis, C.; Roberts, N.P.; Bisson, J.I.; Lee, M.; Clarke, L. Pharmacological-assisted psychotherapy for post traumatic stress disorder: A systematic review and meta-analysis. Eur. J. Psychotraumatol., 2021, 12(1), 1853379. doi: 10.1080/20008198.2020.1853379
  249. Hetrick, S.E.; Purcell, R.; Garner, B.; Parslow, R. Combined pharmacotherapy and psychological therapies for post traumatic stress disorder (PTSD). Cochrane Database Syst. Rev., 2010, 7, CD007316.
  250. Rauch, S.A.M.; Kim, H.M.; Powell, C.; Tuerk, P.W.; Simon, N.M.; Acierno, R.; Allard, C.B.; Norman, S.B.; Venners, M.R.; Rothbaum, B.O.; Stein, M.B.; Porter, K.; Martis, B.; King, A.P.; Liberzon, I.; Phan, K.L.; Hoge, C.W. Efficacy of prolonged exposure therapy, sertraline hydrochloride, and their combination among combat veterans with posttraumatic stress disorder: A randomized clinical trial. JAMA Psychiatry, 2019, 76(2), 117-126. doi: 10.1001/jamapsychiatry.2018.3412
  251. Averill, L.A.; Abdallah, C.G. Investigational drugs for assisting psychotherapy for posttraumatic stress disorder (PTSD): Emerging approaches and shifting paradigms in the era of psychedelic medicine. Expert Opin. Investig. Drugs, 2022, 31(2), 133-137. doi: 10.1080/13543784.2022.2035358
  252. Niles, B.L.; Mori, D.L.; Polizzi, C.; Pless Kaiser, A.; Weinstein, E.S.; Gershkovich, M.; Wang, C. A systematic review of randomized trials of mind-body interventions for PTSD. J. Clin. Psychol., 2018, 74(9), 1485-1508. doi: 10.1002/jclp.22634
  253. Bisson, J.I.; van Gelderen, M.; Roberts, N.P.; Lewis, C. Non-pharmacological and non-psychological approaches to the treatment of PTSD: Results of a systematic review and meta-analyses. Eur. J. Psychotraumatol., 2020, 11(1), 1795361. doi: 10.1080/20008198.2020.1795361
  254. Sripada, R.K.; Blow, F.C.; Rauch, S.A.M.; Ganoczy, D.; Hoff, R.; Harpaz-Rotem, I.; Bohnert, K.M. Examining the nonresponse phenomenon: Factors associated with treatment response in a national sample of veterans undergoing residential PTSD treatment. J. Anxiety Disord., 2019, 63, 18-25. doi: 10.1016/j.janxdis.2019.02.001
  255. Edwards-Stewart, A.; Smolenski, D.J.; Bush, N.E.; Cyr, B-A.; Beech, E.H.; Skopp, N.A.; Belsher, B.E. Posttraumatic stress disorder treatment dropout among military and veteran populations: A systematic review and meta-analysis. J. Trauma. Stress, 2021, 34(4), 808-818. doi: 10.1002/jts.22653
  256. Varker, T.; Jones, K.A.; Arjmand, H.A.; Hinton, M.; Hiles, S.A.; Freijah, I.; Forbes, D.; Kartal, D.; Phelps, A.; Bryant, R.A.; McFarlane, A.; Hopwood, M.; O’Donnell, M. Dropout from guideline-recommended psychological treatments for posttraumatic stress disorder: A systematic review and meta-analysis. J. Affect. Disord. Rep., 2021, 4, 100093. doi: 10.1016/j.jadr.2021.100093
  257. Barawi, K.S.; Lewis, C.; Simon, N.; Bisson, J.I. A systematic review of factors associated with outcome of psychological treatments for post-traumatic stress disorder. Eur. J. Psychotraumatol., 2020, 11(1), 1774240. doi: 10.1080/20008198.2020.1774240
  258. Fleming, C.J.E.; Kholodkov, T.; Dillon, K.H.; Belvet, B.; Crawford, E.F. Actuarial prediction of psychotherapy retention among Iraq-Afghanistan veterans with posttraumatic stress disorder. Psychol. Serv., 2018, 15(2), 172-180. doi: 10.1037/ser0000139
  259. Jakupcak, M.; Hoerster, K.D.; Blais, R.K.; Malte, C.A.; Hunt, S.; Seal, K. Readiness for change predicts VA mental healthcare utilization among Iraq and Afghanistan war veterans. J. Trauma. Stress, 2013, 26(1), 165-168. doi: 10.1002/jts.21768
  260. Lepow, L.; Morishita, H.; Yehuda, R. Critical period plasticity as a framework for psychedelic-assisted psychotherapy. Front. Neurosci., 2021, 15, 710004. doi: 10.3389/fnins.2021.710004
  261. Schenberg, E.E. Psychedelic-assisted psychotherapy: A paradigm shift in psychiatric research and development. Front. Pharmacol., 2018, 9, 733. doi: 10.3389/fphar.2018.00733
  262. Chi, T.; Gold, J.A. A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses. J. Neurol. Sci., 2020, 411, 116715. doi: 10.1016/j.jns.2020.116715
  263. Krediet, E.; Bostoen, T.; Breeksema, J.; van Schagen, A.; Passie, T.; Vermetten, E. Reviewing the potential of psychedelics for the treatment of PTSD. Int. J. Neuropsychopharmacol., 2020, 23(6), 385-400. doi: 10.1093/ijnp/pyaa018
  264. Bourguignon, E. Religion, altered states of consciousness, and social change; The Ohio State University Press, 1973.
  265. Hofmann, A. LSD, my problem child; McGraw-Hill: New York, 1980.
  266. Swanson, L.R. Unifying theories of psychedelic drug effects. Front. Pharmacol., 2018, 9, 172. doi: 10.3389/fphar.2018.00172
  267. Passie, T. Psycholytic and psychedelic therapy research 1931- 1995: A complete international bibliography; Laurentius Publishers: Hannover, 1997.
  268. Hofmann, A.; Heim, R.; Brack, A.; Kobel, H. Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen RauschpilzPsilocybe mexicana Heim. Experientia, 1958, 14(3), 107-109. doi: 10.1007/BF02159243
  269. Nichols, D.E.; Walter, H. The history of psychedelics in psychiatry. Pharmacopsychiatry, 2021, 54(4), 151-166. doi: 10.1055/a-1310-3990
  270. Moreno, F. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J. Clin. Psychiatry, 2006, 67(11), 1735-1740. doi: 10.4088/JCP.v67n1110
  271. Siegel, J.S.; Daily, J.E.; Perry, D.A.; Nicol, G.E. Psychedelic drug legislative reform and legalization in the US. JAMA Psychiatry, 2023, 80(1), 77-83. doi: 10.1001/jamapsychiatry.2022.4101
  272. Nutt, D.; Carhart-Harris, R. The current status of psychedelics in psychiatry. JAMA Psychiatry, 2021, 78(2), 121-122. doi: 10.1001/jamapsychiatry.2020.2171
  273. Kočárová, R.; Horáček, J.; Carhart-Harris, R. Does psychedelic therapy have a transdiagnostic action and prophylactic potential? Front. Psychiatry, 2021, 12, 661233.
  274. MAPS Psychotherapy Manual; Santa Cruz, CA: U.S, , 2017.
  275. Mithoefer, M.C.; Wagner, M.T.; Mithoefer, A.T.; Jerome, L.; Martin, S.F.; Yazar-Klosinski, B.; Michel, Y.; Brewerton, T.D.; Doblin, R. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: A prospective long-term follow-up study. J. Psychopharmacol., 2013, 27(1), 28-39. doi: 10.1177/0269881112456611
  276. Grinspoon, L.; Doblin, R. Psychedelics as catalysts of insight-oriented psychotherapy. Soc. Res., 2001, 677-695.
  277. Richards, W.A. Psychedelic psychotherapy: Insights from 25 years of research. J. Humanist. Psychol., 2017, 57(4), 323-337. doi: 10.1177/0022167816670996
  278. Horton, D.M.; Morrison, B.; Schmidt, J. Systematized review of psychotherapeutic components of psilocybin-assisted psychotherapy. Am. J. Psychother., 2021, 74(4), 140-149. doi: 10.1176/appi.psychotherapy.20200055
  279. Thal, S.B.; Lommen, M.J.J. Current perspective on MDMA-assisted psychotherapy for posttraumatic stress disorder. J. Contemp. Psychother., 2018, 48(2), 99-108. doi: 10.1007/s10879-017-9379-2
  280. Vollenweider, F.X.; Smallridge, J.W. Classic psychedelic drugs: Update on biological mechanisms. Pharmacopsychiatry, 2022, 55(3), 121-138. doi: 10.1055/a-1721-2914
  281. de Wit, H.; Bershad, A.K.; Grob, C. Challenges in translational research: MDMA in the laboratory versus therapeutic settings. J. Psychopharmacol., 2022, 36(3), 252-257. doi: 10.1177/02698811211015221
  282. Mithoefer, M.C.; Feduccia, A.A.; Jerome, L.; Mithoefer, A.; Wagner, M.; Walsh, Z.; Hamilton, S.; Yazar-Klosinski, B.; Emerson, A.; Doblin, R. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology, 2019, 236(9), 2735-2745. doi: 10.1007/s00213-019-05249-5
  283. Freudenmann, R.W.; Öxler, F.; Bernschneider-Reif, S. The origin of MDMA (ecstasy) revisited: The true story reconstructed from the original documents. Addiction, 2006, 101(9), 1241-1245. doi: 10.1111/j.1360-0443.2006.01511.x
  284. Shulgin, A.T.; Shulgin, A. PIHKAL: A chemical love story; Transform Press: Berkeley, CA, 1991.
  285. Holland, J. Ecstasy: The complete guide: A comprehensive look at the risks and benefits of MDMA; Inner Traditions/Bear & Co, 2001.
  286. Adamson, S.; Metzner, R. The nature of the MDMA experience and its role in healing, psychotherapy and spiritual practice. ReVision., 1988, 10(4), 59-72.
  287. Nichols, D.E. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. identification of a new therapeutic class. Entactogens. J. Psychoactive Drugs, 1986, 18(4), 305-313. doi: 10.1080/02791072.1986.10472362
  288. Nichols, D.E. Entactogens: How the name for a novel class of psychoactive agents originated. Front. Psychiatry, 2022, 13, 863088. doi: 10.3389/fpsyt.2022.863088
  289. Climko, R.P.; Roehrich, H.; Sweeney, D.R.; Al-Razi, J. ECSTACY: A review of MDMA and MDA. Int. J. Psychiatry Med., 1987, 16(4), 359-372. doi: 10.2190/DCRP-U22M-AUMD-D84H
  290. Liamis, G.; Milionis, H.; Elisaf, M. A review of drug-induced hyponatremia. Am. J. Kidney Dis., 2008, 52(1), 144-153. doi: 10.1053/j.ajkd.2008.03.004
  291. Parrott, A.C. Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol. Biochem. Behav., 2002, 71(4), 837-844. doi: 10.1016/S0091-3057(01)00711-0
  292. Vollenweider, F.X.; Gamma, A.; Liechti, M.; Huber, T. Psychological and cardiovascular effects and short-term sequelae of MDMA ("Ecstasy") in MDMA-naïve healthy volunteers. Neuropsychopharmacology, 1998, 19(4), 241-251. doi: 10.1038/sj.npp.1395197
  293. Gowing, L.R.; Henry-Edwards, S.M.; Irvine, R.J.; Ali, R.L. The health effects of ecstasy: A literature review. Drug Alcohol Rev., 2002, 21(1), 53-63. doi: 10.1080/09595230220119363
  294. Bonny, H.L.; Pahnke, W.N. The use of music in psychedelic (LSD) psychotherapy. J. Music Ther., 1972, 9(2), 64-87. doi: 10.1093/jmt/9.2.64
  295. Kaelen, M.; Giribaldi, B.; Raine, J.; Evans, L.; Timmerman, C.; Rodriguez, N.; Roseman, L.; Feilding, A.; Nutt, D.; Carhart-Harris, R. The hidden therapist: Evidence for a central role of music in psychedelic therapy. Psychopharmacology, 2018, 235(2), 505-519. doi: 10.1007/s00213-017-4820-5
  296. Feduccia, A.A.; Holland, J.; Mithoefer, M.C. Progress and promise for the MDMA drug development program. Psychopharmacology, 2018, 235(2), 561-571. doi: 10.1007/s00213-017-4779-2
  297. Carhart-Harris, R.; Leech, R.; Tagliazucchi, E. How do hallucinogens work on the brain. J. Psychophysiol., 2014, 71(1), 2-8.
  298. Wardle, M.C.; de Wit, H. MDMA alters emotional processing and facilitates positive social interaction. Psychopharmacology, 2014, 231(21), 4219-4229. doi: 10.1007/s00213-014-3570-x
  299. Wardle, M.C.; Kirkpatrick, M.G.; de Wit, H. ‘Ecstasy’ as a social drug: MDMA preferentially affects responses to emotional stimuli with social content. Soc. Cogn. Affect. Neurosci., 2014, 9(8), 1076-1081. doi: 10.1093/scan/nsu035
  300. Bershad, A.K.; Miller, M.A.; Baggott, M.J.; de Wit, H. The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants? J. Psychopharmacol., 2016, 30(12), 1248-1258. doi: 10.1177/0269881116663120
  301. Kamilar-Britt, P.; Bedi, G. The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals. Neurosci. Biobehav. Rev., 2015, 57, 433-446. doi: 10.1016/j.neubiorev.2015.08.016
  302. Baylen, C.A.; Rosenberg, H. A review of the acute subjective effects of MDMA/ecstasy. Addiction, 2006, 101(7), 933-947. doi: 10.1111/j.1360-0443.2006.01423.x
  303. Camí, J.; Farré, M.; Mas, M.; Roset, P.N.; Poudevida, S.; Mas, A.; San, L.; de la Torre, R. Human pharmacology of 3,4-methylenedioxymeth-amphetamine ("Ecstasy"): Psychomotor performance and subjective effects. J. Clin. Psychopharmacol., 2000, 20(4), 455-466. doi: 10.1097/00004714-200008000-00010
  304. Studerus, E.; Vizeli, P.; Harder, S.; Ley, L.; Liechti, M.E. Prediction of MDMA response in healthy humans: A pooled analysis of placebo-controlled studies. J. Psychopharmacol., 2021, 35(5), 556-565. doi: 10.1177/0269881121998322
  305. Verheyden, S.L.; Henry, J.A.; Curran, H.V. Acute, sub-acute and long-term subjective consequences of ecstasy? (MDMA) consumption in 430 regular users. Hum. Psychopharmacol., 2003, 18(7), 507-517. doi: 10.1002/hup.529
  306. Montoya, A.G.; Sorrentino, R.; Lukas, S.E.; Price, B.H. Long-term neuropsychiatric consequences of "Ecstasy" (MDMA): A review. Harv. Rev. Psychiatry, 2002, 10(4), 212-220. doi: 10.1080/10673220216223
  307. Amoroso, T. The spurious relationship between ecstasy use and neurocognitive deficits: A bradford hill review. Int. J. Drug Policy, 2019, 64, 47-53. doi: 10.1016/j.drugpo.2018.11.002
  308. Rogers, G; Elston, J; Garside, R The harmful health effects of recreational ecstasy: A systematic review of observational evidence. Heal.Technol.Assess., 2009, 136, iii-iv-ix-xii, 1-315. doi: 10.3310/hta13060
  309. Zakzanis, K.K.; Campbell, Z.; Jovanovski, D. The neuropsychology of ecstasy (MDMA) use: A quantitative review. Hum. Psychopharmacol., 2007, 22(7), 427-435. doi: 10.1002/hup.873
  310. Morgan, M.J. Ecstasy (MDMA): A review of its possible persistent psychological effects. Psychopharmacology, 2000, 152(3), 230-248. doi: 10.1007/s002130000545
  311. Morgan, M.J. Memory deficits associated with recreational use of "ecstasy" (MDMA). Psychopharmacology, 1999, 141(1), 30-36. doi: 10.1007/s002130050803
  312. Saleemi, S.; Pennybaker, S.J.; Wooldridge, M.; Johnson, M.W. Who is ‘Molly’? MDMA adulterants by product name and the impact of harm-reduction services at raves. J. Psychopharmacol., 2017, 31(8), 1056-1060. doi: 10.1177/0269881117715596
  313. Morefield, K.M.; Keane, M.; Felgate, P.; White, J.M.; Irvine, R.J. Pill content, dose and resulting plasma concentrations of 3,4-methylendioxymethamphetamine (MDMA) in recreational ‘ecstasy’ users. Addiction, 2011, 106(7), 1293-1300. doi: 10.1111/j.1360-0443.2011.03399.x
  314. Gouzoulis-Mayfrank, E.; Daumann, J. The confounding problem of polydrug use in recreational ecstasy/MDMA users: A brief overview. J. Psychopharmacol., 2006, 20(2), 188-193. doi: 10.1177/0269881106059939
  315. Randolph, C.; Tierney, M.C.; Mohr, E.; Chase, T.N. The repeatable battery for the assessment of neuropsychological status (RBANS): Preliminary clinical validity. J. Clin. Exp. Neuropsychol., 1998, 20(3), 310-319. doi: 10.1076/jcen.20.3.310.823
  316. Gronwall, D.M.A. Paced auditory serial-addition task: A measure of recovery from concussion. Percept. Mot. Skills, 1977, 44(2), 367-373. doi: 10.2466/pms.1977.44.2.367
  317. Roman, D.D.; Edwall, G.E.; Buchanan, R.J.; Patton, J.H. Extended norms for the paced auditory serial addition task. Clin. Neuropsychol., 1991, 5(1), 33-40. doi: 10.1080/13854049108401840
  318. Kirkpatrick, M.G.; Gunderson, E.W.; Perez, A.Y.; Haney, M.; Foltin, R.W.; Hart, C.L. A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology, 2012, 219(1), 109-122. doi: 10.1007/s00213-011-2383-4
  319. Kolbrich, E.A.; Goodwin, R.S.; Gorelick, D.A.; Hayes, R.J.; Stein, E.A.; Huestis, M.A. Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J. Clin. Psychopharmacol., 2008, 28(4), 432-440. doi: 10.1097/JCP.0b013e31817ef470
  320. Lester, S.J.; Baggott, M.; Welm, S. Cardiovascular effects of 3, 4-methylenedioxymethamphetamine: A double-blind, placebo-controlled trial. Ann. Intern. Med., 2000, 133(12), 969-973. doi: 10.7326/0003-4819-133-12-200012190-00012
  321. Mas, M.; Farré, M.; de la Torre, R. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxy-methamphetamine in humans. J. Pharmacol. Exp. Ther., 1999, 290(1), 136-145.
  322. Vizeli, P.; Liechti, M.E. Safety pharmacology of acute MDMA administration in healthy subjects. J. Psychopharmacol., 2017, 31(5), 576-588. doi: 10.1177/0269881117691569
  323. Mithoefer, M.C.; Mithoefer, A.T.; Feduccia, A.A.; Jerome, L.; Wagner, M.; Wymer, J.; Holland, J.; Hamilton, S.; Yazar-Klosinski, B.; Emerson, A.; Doblin, R. 3,4-methylenedioxy-methamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: A randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry, 2018, 5(6), 486-497. doi: 10.1016/S2215-0366(18)30135-4
  324. De La Torre, R.; Farré, M.; Roset, P.N.; López, C.H.; Mas, M.; Ortuño, J.; Menoyo, E.; Pizarro, N.; Segura, J.; Camí, J. Pharmacology of MDMA in Humans. Ann. N. Y. Acad. Sci., 2000, 914(1), 225-237. doi: 10.1111/j.1749-6632.2000.tb05199.x
  325. Feduccia, A.A.; Jerome, L.; Mithoefer, M.C.; Holland, J. Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy. Psychopharmacology, 2021, 238(2), 581-588. doi: 10.1007/s00213-020-05710-w
  326. Oeri, H.E. Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy. J. Psychopharmacol., 2021, 35(5), 512-536. doi: 10.1177/0269881120920420
  327. Papaseit, E.; Pérez-Mañá, C.; Torrens, M.; Farré, A.; Poyatos, L.; Hladun, O.; Sanvisens, A.; Muga, R.; Farré, M. MDMA interactions with pharmaceuticals and drugs of abuse. Expert Opin. Drug Metab. Toxicol., 2020, 16(5), 357-369. doi: 10.1080/17425255.2020.1749262
  328. Simmler, L.D.; Buser, T.A.; Donzelli, M.; Schramm, Y.; Dieu, L-H.; Huwyler, J.; Chaboz, S.; Hoener, M.C.; Liechti, M.E. Pharmacological characterization of designer cathinones in vitro. Br. J. Pharmacol., 2013, 168(2), 458-470. doi: 10.1111/j.1476-5381.2012.02145.x
  329. Nardou, R.; Lewis, E.M.; Rothhaas, R.; Xu, R.; Yang, A.; Boyden, E.; Dölen, G. Oxytocin-dependent reopening of a social reward learning critical period with MDMA. Nature, 2019, 569(7754), 116-120. doi: 10.1038/s41586-019-1075-9
  330. Dölen, G. Oxytocin: Parallel processing in the social brain? J. Neuroendocrinol., 2015, 27(6), 516-535. doi: 10.1111/jne.12284
  331. Thompson, M.R.; Callaghan, P.D.; Hunt, G.E.; Cornish, J.L.; McGregor, I.S. A role for oxytocin and 5-HT1A receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy"). Neuroscience, 2007, 146(2), 509-514. doi: 10.1016/j.neuroscience.2007.02.032
  332. Florea, T.; Palimariciuc, M.; Cristofor, A.C.; Dobrin, I.; Chiriță, R.; Bîrsan, M.; Dobrin, R.P.; Pădurariu, M. Oxytocin: Narrative expert review of current perspectives on the relationship with other neurotransmitters and the impact on the main psychiatric disorders. Medicina, 2022, 58(7), 923. doi: 10.3390/medicina58070923
  333. MAPS Investigators Brochure, 14th; U.S., 2022, pp. 13-253.
  334. Dumont, G.J.H.; Sweep, F.C.G.J.; van der Steen, R.; Hermsen, R.; Donders, A.R.T.; Touw, D.J.; van Gerven, J.M.A.; Buitelaar, J.K.; Verkes, R.J. Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Soc. Neurosci., 2009, 4(4), 359-366. doi: 10.1080/17470910802649470
  335. Tancer, M.; Johanson, C.E. The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology, 2006, 189(4), 565-573. doi: 10.1007/s00213-006-0576-z
  336. Farré, M.; Abanades, S.; Roset, P.N.; Peiró, A.M.; Torrens, M.; O’Mathúna, B.; Segura, M.; de la Torre, R. Pharmacological interaction between 3,4-methylenedioxymethamphetamine (Ecstasy) and paroxetine: Pharmacological effects and pharmacokinetics. J. Pharmacol. Exp. Ther., 2007, 323(3), 954-962. doi: 10.1124/jpet.107.129056
  337. Liechti, M.E.; Gamma, A.; Vollenweider, F.X. Gender differences in the subjective effects of MDMA. Psychopharmacology, 2001, 154(2), 161-168. doi: 10.1007/s002130000648
  338. Kuypers, K.P.C.; de la Torre, R.; Farre, M.; Pizarro, N.; Xicota, L.; Ramaekers, J.G. MDMA-induced indifference to negative sounds is mediated by the 5-HT2A receptor. Psychopharmacology, 2018, 235(2), 481-490. doi: 10.1007/s00213-017-4699-1
  339. Kuypers, K.P.C.; de la Torre, R.; Farre, M.; Yubero-Lahoz, S.; Dziobek, I.; Van den Bos, W.; Ramaekers, J.G. No Evidence that MDMA-induced enhancement of emotional empathy is related to peripheral oxytocin levels or 5-HT1a receptor activation. PLoS One, 2014, 9(6), e100719. doi: 10.1371/journal.pone.0100719
  340. Liechti, M.E.; Vollenweider, F.X. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum. Psychopharmacol., 2001, 16(8), 589-598. doi: 10.1002/hup.348
  341. Casey, A.B.; Cui, M.; Booth, R.G.; Canal, C.E. "Selective" serotonin 5-HT2A receptor antagonists. Biochem. Pharmacol., 2022, 200, 115028. doi: 10.1016/j.bcp.2022.115028
  342. Price, C.M.; Feduccia, A.F.; DeBonis, K. Effects of selective serotonin reuptake inhibitor use on 3,4-methylenedioxy-methamphetamine-assisted therapy for posttraumatic stress disorder a review of the evidence, neurobiological plausibility, and clinical significance. J. Clin. Psychopharmacol., 2022, 42(5), 464-469.
  343. Hysek, C.M.; Domes, G.; Liechti, M.E. MDMA enhances "mind reading" of positive emotions and impairs "mind reading" of negative emotions. Psychopharmacology, 2012, 222(2), 293-302. doi: 10.1007/s00213-012-2645-9
  344. Hysek, C.M.; Simmler, L.D.; Ineichen, M.; Grouzmann, E.; Hoener, M.C.; Brenneisen, R.; Huwyler, J.; Liechti, M.E. The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA ("Ecstasy") in humans. Clin. Pharmacol. Ther., 2011, 90(2), 246-255. doi: 10.1038/clpt.2011.78
  345. Hysek, C.M.; Simmler, L.D.; Nicola, V.G.; Vischer, N.; Donzelli, M.; Krähenbühl, S.; Grouzmann, E.; Huwyler, J.; Hoener, M.C.; Liechti, M.E. Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS One, 2012, 7(5), e36476. doi: 10.1371/journal.pone.0036476
  346. Schenk, S.; Highgate, Q. Methylenedioxymethamphetamine (MDMA): Serotonergic and dopaminergic mechanisms related to its use and misuse. J. Neurochem., 2021, 157(5), 1714-1724. doi: 10.1111/jnc.15348
  347. Ramos, L.; Hicks, C.; Caminer, A.; Couto, K.; Narlawar, R.; Kassiou, M.; McGregor, I.S. MDMA (‘Ecstasy’), oxytocin and vasopressin modulate social preference in rats: A role for handling and oxytocin receptors. Pharmacol. Biochem. Behav., 2016, 150-151, 115-123. doi: 10.1016/j.pbb.2016.10.002
  348. Vizeli, P.; Liechti, M.E. Oxytocin receptor gene variations and socio-emotional effects of MDMA: A pooled analysis of controlled studies in healthy subjects. PLoS One, 2018, 13(6), e0199384. doi: 10.1371/journal.pone.0199384
  349. Schmid, Y.; Hysek, C.M.; Simmler, L.D.; Crockett, M.J.; Quednow, B.B.; Liechti, M.E. Differential effects of MDMA and methylphenidate on social cognition. J. Psychopharmacol., 2014, 28(9), 847-856. doi: 10.1177/0269881114542454
  350. Kuypers, K.P.C.; Dolder, P.C.; Ramaekers, J.G.; Liechti, M.E. Multifaceted empathy of healthy volunteers after single doses of MDMA: A pooled sample of placebo-controlled studies. J. Psychopharmacol., 2017, 31(5), 589-598. doi: 10.1177/0269881117699617
  351. Hysek, C.M.; Schmid, Y.; Simmler, L.D.; Domes, G.; Heinrichs, M.; Eisenegger, C.; Preller, K.H.; Quednow, B.B.; Liechti, M.E. MDMA enhances emotional empathy and prosocial behavior. Soc. Cogn. Affect. Neurosci., 2014, 9(11), 1645-1652. doi: 10.1093/scan/nst161
  352. Kirkpatrick, M.G.; Francis, S.M.; Lee, R.; de Wit, H.; Jacob, S. Plasma oxytocin concentrations following MDMA or intranasal oxytocin in humans. Psychoneuroendocrinology, 2014, 46, 23-31. doi: 10.1016/j.psyneuen.2014.04.006
  353. Bershad, A.K.; Weafer, J.J.; Kirkpatrick, M.G.; Wardle, M.C.; Miller, M.A.; de Wit, H. Oxytocin receptor gene variation predicts subjective responses to MDMA. Soc. Neurosci., 2016, 11(6), 592-599. doi: 10.1080/17470919.2016.1143026
  354. Boxler, M.I.; Streun, G.L.; Liechti, M.E.; Schmid, Y.; Kraemer, T.; Steuer, A.E. Human metabolome changes after a single dose of 3,4-methylenedioxymethamphetamine (MDMA) with special focus on steroid metabolism and inflammation processes. J. Proteome Res., 2018, 17(8), 2900-2907. doi: 10.1021/acs.jproteome.8b00438
  355. Seibert, J.; Hysek, C.M.; Penno, C.A.; Schmid, Y.; Kratschmar, D.V.; Liechti, M.E.; Odermatt, A. Acute effects of 3,4-methylenedioxymethamphetamine and methylphenidate on circulating steroid levels in healthy subjects. Neuroendocrinology, 2014, 100(1), 17-25. doi: 10.1159/000364879
  356. Farré, M.; de la Torre, R.; Ó Mathúna, B.; Roset, P.N.; Peiró, A.M.; Torrens, M.; Ortuño, J.; Pujadas, M.; Camí, J. Repeated doses administration of MDMA in humans: Pharmacological effects and pharmacokinetics. Psychopharmacology, 2004, 173(3-4), 364-375. doi: 10.1007/s00213-004-1789-7
  357. Harris, D.S.; Baggott, M.; Mendelson, J.H.; Mendelson, J.E.; Jones, R.T. Subjective and hormonal effects of 3,4-methylenedioxy-methamphetamine (MDMA) in humans. Psychopharmacology, 2002, 162(4), 396-405. doi: 10.1007/s00213-002-1131-1
  358. Forsling, M.; Fallon, J.K.; Kicman, A.T.; Hutt, A.J.; Cowan, D.A.; Henry, J.A. Arginine vasopressin release in response to the administration of 3,4-methylenedioxymethamphetamine ("ecstasy"): Is metabolism a contributory factor? J. Pharm. Pharmacol., 2010, 53(10), 1357-1363. doi: 10.1211/0022357011777855
  359. Breeksema, J.J.; Kuin, B.W.; Kamphuis, J. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. J. Psychopharm, 2022, 026988112211169.
  360. McNamee, S.; Devenot, N.; Buisson, M. Studying harms is key to improving psychedelic-assisted therapy—participants call for changes to research landscape. JAMA Psychiatry, 2023, 80(5), 411. doi: 10.1001/jamapsychiatry.2023.0099
  361. Regan, A.; Margolis, S.; de Wit, H.; Lyubomirsky, S. Does ±3,4-methylenedioxymethamphetamine (ecstasy) induce subjective feelings of social connection in humans? A multilevel meta-analysis. PLoS One, 2021, 16(10), e0258849. doi: 10.1371/journal.pone.0258849
  362. Kirkpatrick, M.G.; Lee, R.; Wardle, M.C.; Jacob, S.; de Wit, H. Effects of MDMA and intranasal oxytocin on social and emotional processing. Neuropsychopharmacology, 2014, 39(7), 1654-1663. doi: 10.1038/npp.2014.12
  363. Bedi, G.; Hyman, D.; de Wit, H. Is Ecstasy an "Empathogen"? effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol. Psychiatry, 2010, 68(12), 1134-1140. doi: 10.1016/j.biopsych.2010.08.003
  364. Hysek, C.M.; Simmler, L.D.; Schillinger, N.; Meyer, N.; Schmid, Y.; Donzelli, M.; Grouzmann, E.; Liechti, M.E. Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination. Int. J. Neuropsychopharmacol., 2014, 17(3), 371-381. doi: 10.1017/S1461145713001132
  365. Bedi, G.; Phan, K.L.; Angstadt, M.; de Wit, H. Effects of MDMA on sociability and neural response to social threat and social reward. Psychopharmacology, 2009, 207(1), 73-83. doi: 10.1007/s00213-009-1635-z
  366. Mithoefer, M.C.; Wagner, M.T.; Mithoefer, A.T.; Jerome, L.; Doblin, R. The safety and efficacy of ±3,4-methylenedioxy-methamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study. J. Psychopharmacol., 2011, 25(4), 439-452. doi: 10.1177/0269881110378371
  367. Bouso, J.C.; Doblin, R.; Farré, M.; Alcázar, M.Á.; Gómez-Jarabo, G. MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. J. Psychoactive Drugs, 2008, 40(3), 225-236. doi: 10.1080/02791072.2008.10400637
  368. Baggott, M.J.; Coyle, J.R.; Siegrist, J.D.; Garrison, K.J.; Galloway, G.P.; Mendelson, J.E. Effects of 3,4-methylenedioxy-methamphetamine on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting. J. Psychopharmacol., 2016, 30(4), 378-387. doi: 10.1177/0269881115626348
  369. Baggott, M.J.; Kirkpatrick, M.G.; Bedi, G.; de Wit, H. Intimate insight: MDMA changes how people talk about significant others. J. Psychopharmacol., 2015, 29(6), 669-677. doi: 10.1177/0269881115581962
  370. Frye, C.G.; Wardle, M.C.; Norman, G.J.; de Wit, H. MDMA decreases the effects of simulated social rejection. Pharmacol. Biochem. Behav., 2014, 117, 1-6. doi: 10.1016/j.pbb.2013.11.030
  371. Howard, R.; Berry, K.; Haddock, G. Therapeutic alliance in psychological therapy for posttraumatic stress disorder: A systematic review and meta-analysis. Clin. Psychol. Psychother., 2022, 29(2), 373-399. doi: 10.1002/cpp.2642
  372. Borissova, A.; Ferguson, B.; Wall, M.B.; Morgan, C.J.A.; Carhart-Harris, R.L.; Bolstridge, M.; Bloomfield, M.A.P.; Williams, T.M.; Feilding, A.; Murphy, K.; Tyacke, R.J.; Erritzoe, D.; Stewart, L.; Wolff, K.; Nutt, D.; Curran, H.V.; Lawn, W. Acute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment. J. Psychopharmacol., 2021, 35(5), 547-555. doi: 10.1177/0269881120926673
  373. Gabay, A.S.; Kempton, M.J.; Gilleen, J.; Mehta, M.A. MDMA increases cooperation and recruitment of social brain areas when playing trustworthy players in an iterated prisoner’s dilemma. J. Neurosci., 2019, 39(2), 307-320. doi: 10.1523/JNEUROSCI.1276-18.2018
  374. Gamma, A. 3,4-methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by H215O-PET in healthy humans. Neuropsychopharmacology, 2000, 23(4), 388-395. doi: 10.1016/S0893-133X(00)00130-5
  375. Lanius, R.A.; Bluhm, R.L.; Frewen, P.A. How understanding the neurobiology of complex post-traumatic stress disorder can inform clinical practice: A social cognitive and affective neuroscience approach. Acta Psychiatr. Scand., 2011, 124(5), 331-348. doi: 10.1111/j.1600-0447.2011.01755.x
  376. Carhart-Harris, R.L.; Murphy, K.; Leech, R.; Erritzoe, D.; Wall, M.B.; Ferguson, B.; Williams, L.T.J.; Roseman, L.; Brugger, S.; De Meer, I.; Tanner, M.; Tyacke, R.; Wolff, K.; Sethi, A.; Bloomfield, M.A.P.; Williams, T.M.; Bolstridge, M.; Stewart, L.; Morgan, C.; Newbould, R.D.; Feilding, A.; Curran, H.V.; Nutt, D.J. The effects of acutely administered 3,4-methylenedioxymethamphetamine on spontaneous brain function in healthy volunteers measured with arterial spin labeling and blood oxygen level-dependent resting state functional connectivity. Biol. Psychiatry, 2015, 78(8), 554-562. doi: 10.1016/j.biopsych.2013.12.015
  377. Carhart-Harris, R.L.; Wall, M.B.; Erritzoe, D.; Kaelen, M.; Ferguson, B.; De Meer, I.; Tanner, M.; Bloomfield, M.; Williams, T.M.; Bolstridge, M.; Stewart, L.; Morgan, C.J.; Newbould, R.D.; Feilding, A.; Curran, H.V.; Nutt, D.J. The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. Int. J. Neuropsychopharmacol., 2014, 17(4), 527-540. doi: 10.1017/S1461145713001405
  378. Carhart-Harris, R.L.; Erritzoe, D.; Williams, T.; Stone, J.M.; Reed, L.J.; Colasanti, A.; Tyacke, R.J.; Leech, R.; Malizia, A.L.; Murphy, K.; Hobden, P.; Evans, J.; Feilding, A.; Wise, R.G.; Nutt, D.J. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc. Natl. Acad. Sci., 2012, 109(6), 2138-2143. doi: 10.1073/pnas.1119598109
  379. Berman, M.G.; Peltier, S.; Nee, D.E.; Kross, E.; Deldin, P.J.; Jonides, J. Depression, rumination and the default network. Soc. Cogn. Affect. Neurosci., 2011, 6(5), 548-555. doi: 10.1093/scan/nsq080
  380. Walpola, I.C.; Nest, T.; Roseman, L.; Erritzoe, D.; Feilding, A.; Nutt, D.J.; Carhart-Harris, R.L. Altered insula connectivity under MDMA. Neuropsychopharmacology, 2017, 42(11), 2152-2162. doi: 10.1038/npp.2017.35
  381. Tsakiris, M; Critchley, H. Interoception beyond homeostasis: Affect, cognition and mental health. Biol. Sci., 2016, 371(1708), 20160002. doi: 10.1098/rstb.2016.0002
  382. Alvarez, R.P.; Kirlic, N.; Misaki, M. Increased anterior insula activity in anxious individuals is linked to diminished perceived control. Transl. Psychiat., 2015, 5, 591. doi: 10.1038/tp.2015.84
  383. Etkin, A.; Wager, T.D. Functional neuroimaging of anxiety: A meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. Am. J. Psychiatry, 2007, 164(10), 1476-1488. doi: 10.1176/appi.ajp.2007.07030504
  384. Seeley, W.W.; Menon, V.; Schatzberg, A.F.; Keller, J.; Glover, G.H.; Kenna, H.; Reiss, A.L.; Greicius, M.D. Dissociable intrinsic connectivity networks for salience processing and executive control. J. Neurosci., 2007, 27(9), 2349-2356. doi: 10.1523/JNEUROSCI.5587-06.2007
  385. Peterson, A.; Thome, J.; Frewen, P.; Lanius, R.A. Resting state neuroimaging studies: A new way of identifying differences and similarities among the anxiety disorders? Can. J. Psychiatry, 2014, 59(6), 294-300. doi: 10.1177/070674371405900602
  386. Lewis, C.R.; Tafur, J.; Spencer, S.; Green, J.M.; Harrison, C.; Kelmendi, B.; Rabin, D.M.; Yehuda, R.; Yazar-Klosinski, B.; Cahn, B.R. Pilot study suggests DNA methylation of the glucocorticoid receptor gene (NR3C1) is associated with MDMA-assisted therapy treatment response for severe PTSD. Front. Psychiatry, 2023, 14, 959590. doi: 10.3389/fpsyt.2023.959590
  387. Siegel, D.J. The developing mind: Toward a neurobiology of interpersonal experience; Guilford Press, 1999.
  388. Corrigan, F.M.; Fisher, J.J.; Nutt, D.J. Autonomic dysregulation and the Window of Tolerance model of the effects of complex emotional trauma. J. Psychopharmacol., 2011, 25(1), 17-25. doi: 10.1177/0269881109354930
  389. Wilbarger, PaJ.W. Sensory defensiveness and related social/ emotional and neurological problems; Wilbarger: Van Nuys, 1997.
  390. Vizeli, P.; Straumann, I.; Duthaler, U.; Varghese, N.; Eckert, A.; Paulus, M.P.; Risbrough, V.; Liechti, M.E. Effects of 3, 4-methylenedioxymethamphetamine on conditioned fear extinction and retention in a crossover study in healthy subjects. Front. Pharmacol., 2022, 13, 906639. doi: 10.3389/fphar.2022.906639
  391. Glavonic, E.; Mitic, M.; Adzic, M. Hallucinogenic drugs and their potential for treating fear-related disorders: Through the lens of fear extinction. J. Neurosci. Res., 2022, 100(4), 947-969. doi: 10.1002/jnr.25017
  392. Raut, S.B.; Marathe, P.A.; van Eijk, L.; Eri, R.; Ravindran, M.; Benedek, D.M.; Ursano, R.J.; Canales, J.J.; Johnson, L.R. Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation. Pharmacol. Ther., 2022, 239, 108195. doi: 10.1016/j.pharmthera.2022.108195
  393. Maples-Keller, J.L.; Norrholm, S.D.; Burton, M.; Reiff, C.; Coghlan, C.; Jovanovic, T.; Yasinski, C.; Jarboe, K.; Rakofsky, J.; Rauch, S.; Dunlop, B.W.; Rothbaum, B.O. A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults. J. Psychopharmacol., 2022, 36(3), 368-377. doi: 10.1177/02698811211069124
  394. Feduccia, A.A.; Mithoefer, M.C. MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? Prog. Neuropsychopharmacol. Biol. Psychiatry, 2018, 84, 221-228. doi: 10.1016/j.pnpbp.2018.03.003
  395. Young, M.B.; Andero, R.; Ressler, K.J.; Howell, L.L. 3,4- methylenedioxymethamphetamine facilitates fear extinction learning. Transl. Psychiatry., 2015, 5(9), e634-e.
  396. Young, M.B.; Norrholm, S.D.; Khoury, L.M.; Jovanovic, T.; Rauch, S.A.M.; Reiff, C.M.; Dunlop, B.W.; Rothbaum, B.O.; Howell, L.L. Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxy-methamphetamine (MDMA). Psychopharmacology, 2017, 234(19), 2883-2895. doi: 10.1007/s00213-017-4684-8
  397. Calhoun, Ta. The posttraumatic growth inventory: Measuring the positive legacy of trauma. J. Trauma. Stress, 1996, 9(3), 455-471.
  398. Feduccia, A.A.; Jerome, L.; Yazar-Klosinski, B.; Emerson, A.; Mithoefer, M.C.; Doblin, R. Breakthrough for trauma treatment: Safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. Front. Psychiatry, 2019, 10, 650. doi: 10.3389/fpsyt.2019.00650
  399. Monson, C.M.; Wagner, A.C.; Mithoefer, A.T.; Liebman, R.E.; Feduccia, A.A.; Jerome, L.; Yazar-Klosinski, B.; Emerson, A.; Doblin, R.; Mithoefer, M.C. MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: An uncontrolled trial. Eur. J. Psychotraumatol., 2020, 11(1), 1840123. doi: 10.1080/20008198.2020.1840123
  400. Johnson, M.W.; Hendricks, P.S.; Barrett, F.S.; Griffiths, R.R. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol. Ther., 2019, 197, 83-102. doi: 10.1016/j.pharmthera.2018.11.010
  401. Zamberlan, F.; Sanz, C.; Martínez, V.R.; Pallavicini, C.; Erowid, F.; Erowid, E.; Tagliazucchi, E. The varieties of the psychedelic experience: a preliminary study of the association between the reported subjective effects and the binding affinity profiles of substituted phenethylamines and tryptamines. Front. Integr. Nuerosci., 2018, 12, 54. doi: 10.3389/fnint.2018.00054
  402. Woolley, D.W.; Shaw, E. A biochemical and pharmacological suggestion about certain mental disorders. Proc. Natl. Acad. Sci., 1954, 40(4), 228-231. doi: 10.1073/pnas.40.4.228
  403. Carod-Artal, F.J. Hallucinogenic drugs in pre-Columbian Mesoamerican cultures. Neurologia, 2015, 30(1), 42-49. doi: 10.1016/j.nrl.2011.07.003
  404. Nichols, D.E. Psilocybin: From ancient magic to modern medicine. J. Antibiot., 2020, 73(10), 679-686. doi: 10.1038/s41429-020-0311-8
  405. Wasson, R.G. Life magazine: Seeking the magic mushroom. Time. Inc. Magaz. Comp., 1957, 100(2), 9-20.
  406. Busch, A.K.; Johnson, W.C.L.S.D. 25 as an aid in psychotherapy: Preliminary report of a new drug. Dis. Nerv. Syst., 1950, 11(8), 241-243.
  407. Bastiaans, J. Mental Liberation Facilitated by the Use of Hallucinogenic Drugs; Human Sciences: New York, 1984.
  408. Luna, L.E. The Ethnopharmacology of Ayahuasca: Indigenous and mestizo use of ayahuasca. An overview: In: Transworl.Res. Netw; 2011, pp. 1-21.
  409. McKenna, D.J.; Towers, G.H.N. Biochemistry and pharmacology of tryptamines and β-carbolines a minireview. J. Psychoactive Drugs, 1984, 16(4), 347-358. doi: 10.1080/02791072.1984.10472305
  410. Naranjo, P. Hallucinogenic plant use and related indigenous belief systems in the ecuadorian amazon. J. Ethnopharmacol., 1979, 1(2), 121-145. doi: 10.1016/0378-8741(79)90003-5
  411. Luna, L.E. The concept of plants as teachers among four mestizo shamans of iquitos. Northeastern Peru. J. Ethnopharmacol., 1984, 11(2), 135-156. doi: 10.1016/0378-8741(84)90036-9
  412. Villavicencio, M. Geography of the Republic of Ecuador; R; Craighead: New York, 1858.
  413. McKenna, D.J. Clinical investigations of the therapeutic potential of ayahuasca: Rationale and regulatory challenges. Pharmacol. Ther., 2004, 102(2), 111-129. doi: 10.1016/j.pharmthera.2004.03.002
  414. Veteran Psychedelic Group Therapy Fellowship. Available from: https://www.veteransofwar.org/how (updated 07-2019).
  415. Heroic Hearts Project ⋅ ayahuasca & psychedelic therapy for military veterans. Available from: https://heroicheartsproject.org/ (updated 03-2017).
  416. Bogenschutz, M.P.; Forcehimes, A.A. Development of a psychotherapeutic model for psilocybin-assisted treatment of alcoholism. J. Humanist. Psychol., 2017, 57(4), 389-414. doi: 10.1177/0022167816673493
  417. Johnson, M.W.; Richards, W.A.; Griffiths, R.R. Human hallucinogen research: Guidelines for safety. J. Psychopharmacol., 2008, 22(6), 603-620. doi: 10.1177/0269881108093587
  418. Strickland, J.C.; Garcia-Romeu, A.; Johnson, M.W. Set and setting: A randomized study of different musical genres in supporting psychedelic therapy. ACS Pharmacol. Transl. Sci., 2021, 4(2), 472-478. doi: 10.1021/acsptsci.0c00187
  419. Kaelen, M.; Barrett, F.S.; Roseman, L.; Lorenz, R.; Family, N.; Bolstridge, M.; Curran, H.V.; Feilding, A.; Nutt, D.J.; Carhart-Harris, R.L. LSD enhances the emotional response to music. Psychopharmacology, 2015, 232(19), 3607-3614. doi: 10.1007/s00213-015-4014-y
  420. Studerus, E.; Gamma, A.; Kometer, M.; Vollenweider, F.X. Prediction of psilocybin response in healthy volunteers. PLoS One, 2012, 7(2), e30800. doi: 10.1371/journal.pone.0030800
  421. Griffiths, R.R.; Richards, W.A.; McCann, U.; Jesse, R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 2006, 187(3), 268-283. doi: 10.1007/s00213-006-0457-5
  422. Mithoefer, M.C.; Grob, C.S.; Brewerton, T.D. Novel psychopharmacological therapies for psychiatric disorders: Psilocybin and MDMA. Lancet Psychiatry, 2016, 3(5), 481-488. doi: 10.1016/S2215-0366(15)00576-3
  423. Fuentes, J.; Fuentes, J.J.; Fonseca, F.; Ellices, M.; Farré, M.; Torrens, M. Therapeutic use of lsd in psychiatry: A systematic review of randomized controlled clinical trials. Front. Psychiatry, 2020, 21, 10-943. doi: 10.3389/fpsyt.2019.00943
  424. Pahnke, W.N.; Kurland, A.A.; Unger, S.; Savage, C.; Grof, S. The experimental use of psychedelic (LSD) psychotherapy. JAMA, 1970, 212(11), 1856-1863. doi: 10.1001/jama.1970.03170240060010
  425. Labate, B. The therapeutic use of ayahuasca; Springer-Verlag: Berlin, Heidelberg, 2014. doi: 10.1007/978-3-642-40426-9
  426. Bathje, G.J.; Fenton, J.; Pillersdorf, D.; Hill, L.C. A qualitative study of intention and impact of ayahuasca use by westerners. J. Humanist. Psychol., 2021. doi: 10.1177/00221678211008331
  427. Uthaug, M.V.; Mason, N.L.; Toennes, S.W.; Reckweg, J.T.; de Sousa, F.P.E.B.; Kuypers, K.P.C.; van Oorsouw, K.; Riba, J.; Ramaekers, J.G. A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats. Psychopharmacology, 2021, 238(7), 1899-1910. doi: 10.1007/s00213-021-05817-8
  428. Baker, J.R. Psychedelic sacraments. J. Psychoactive Drugs, 2005, 37(2), 179-187. doi: 10.1080/02791072.2005.10399799
  429. Callon, C.; Williams, M.; Lafrance, A. "Meeting the medicine halfway": Ayahuasca ceremony leaders’ perspectives on preparation and integration practices for participants. J. Humanist. Psychol., 2021. doi: 10.1177/00221678211043300
  430. Ludwig, A.M.; Levine, J. A controlled comparison of five brief treatment techniques employing LSD, hypnosis, and psychotherapy. Am. J. Psychother., 1965, 19(3), 417-435. doi: 10.1176/appi.psychotherapy.1965.19.3.417
  431. Preller, K.H.; Vollenweider, F.X. Phenomenology, structure, and dynamic of psychedelic states. Curr. Top. Behav. Neurosci., 2016, 36, 221-256. doi: 10.1007/7854_2016_459
  432. Díaz, J.L. Sacred plants and visionary consciousness. Phenomenol. Cogn. Sci., 2010, 9(2), 159-170. doi: 10.1007/s11097-010-9157-z
  433. Domínguez-Clavé, E.; Soler, J.; Elices, M.; Pascual, J.C.; Álvarez, E.; de la Fuente Revenga, M.; Friedlander, P.; Feilding, A.; Riba, J. Ayahuasca: Pharmacology, neuroscience and therapeutic potential. Brain Res. Bull., 2016, 126, 89-101. doi: 10.1016/j.brainresbull.2016.03.002
  434. de Araujo, D.B.; Ribeiro, S.; Cecchi, G.A.; Carvalho, F.M.; Sanchez, T.A.; Pinto, J.P.; de Martinis, B.S.; Crippa, J.A.; Hallak, J.E.C.; Santos, A.C. Seeing with the eyes shut: Neural basis of enhanced imagery following ayahuasca ingestion. Hum. Brain Mapp., 2012, 33(11), 2550-2560. doi: 10.1002/hbm.21381
  435. Kometer, M.; Cahn, B.R.; Andel, D.; Carter, O.L.; Vollenweider, F.X. The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations. Biol. Psychiatry, 2011, 69(5), 399-406. doi: 10.1016/j.biopsych.2010.10.002
  436. Studerus, E.; Kometer, M.; Hasler, F.; Vollenweider, F.X. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: A pooled analysis of experimental studies. J. Psychopharmacol., 2011, 25(11), 1434-1452. doi: 10.1177/0269881110382466
  437. Shanon, B. Ayahuasca visualizations: A structural typology. J. Conscious. Stud., 2002, 9, 3-30.
  438. Dittrich, A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry,, 1998, 31(S 2)(2), 80-84. doi: 10.1055/s-2007-979351
  439. Gallimore, A.R.; Strassman, R.J. A model for the application of target-controlled intravenous infusion for a prolonged immersive DMT psychedelic experience. Front. Pharmacol., 2016, 7, 211. doi: 10.3389/fphar.2016.00211
  440. Strassman, R.J.; Qualls, C.R.; Uhlenhuth, E.H.; Kellner, R. Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch. Gen. Psychiatry, 1994, 51(2), 98-108. doi: 10.1001/archpsyc.1994.03950020022002
  441. Barrett, F.S.; Robbins, H.; Smooke, D.; Brown, J.L.; Griffiths, R.R. Qualitative and quantitative features of music reported to support peak mystical experiences during psychedelic therapy sessions. Front. Psychol., 2017, 8, 1238. doi: 10.3389/fpsyg.2017.01238
  442. Leuner, H. Die experimentelle psychose: Ihre psychopharmakologie, phänomenologie und dynamik in beziehung zur person.In: Versuch Einer Konditonal-Genetischen und Funktionalen Psychopathologie der Psychose; Springer-Verlag, 2013, p. 286.
  443. Fischer, R.; Georgi, F.; Weber, R. Psychophysical correlations. VIII. Experimental tests in schizophrenia; lysergic acid diethylamide and mescaline. Schweiz. Med. Wochenschr., 1951, 81(35), 837-840.
  444. Fischer, R.; Griffin, F.; Archer, R.C.; Zinsmeister, S.C.; Jastram, P.S. Weber ratio in gustatory chemoreception; an indicator of systemic (Drug) reactivity. Nature, 1965, 207(5001), 1049-1053. doi: 10.1038/2071049a0
  445. Fischer, R.; Kaelbling, R. Increase in taste acuity with sympathetic stimulation: The relation of a justnoticeable taste difference to systemic psychotropic drug dose. Recent Adv. Biol. Psychiatry, 1966, 9, 183-195.
  446. Hirschfeld, T.; Schmidt, T.T. Doseresponse relationships of psilocybininduced subjective experiences in humans. J. Psychopharmacol., 2021, 35(4), 384-397. doi: 10.1177/0269881121992676
  447. Hasler, F.; Grimberg, U.; Benz, M.A.; Huber, T.; Vollenweider, F.X. Acute psychological and physiological effects of psilocybin in healthy humans: A doubleblind, placebocontrolled dose?effect study. Psychopharmacology, 2004, 172(2), 145-156. doi: 10.1007/s00213-003-1640-6
  448. Cohen, S. Lysergic acid diethylamide: Side effects and complications. J. Nerv. Ment. Dis., 1960, 130(1), 30-40. doi: 10.1097/00005053-196001000-00005
  449. Belouin, S.J.; Averill, L.A.; Henningfield, J.E.; Xenakis, S.N.; Donato, I.; Grob, C.S.; Berger, A.; Magar, V.; Danforth, A.L.; Anderson, B.T. Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines. Neuropharmacology, 2022, 219, 109214. doi: 10.1016/j.neuropharm.2022.109214
  450. Gashi, L.; Sandberg, S.; Pedersen, W. Making "bad trips" good: How users of psychedelics narratively transform challenging trips into valuable experiences. Int. J. Drug Policy, 2021, 87, 102997. doi: 10.1016/j.drugpo.2020.102997
  451. Perkins, D.; Ruffell, S.G.D.; Day, K.; Pinzon Rubiano, D.; Sarris, J. Psychotherapeutic and neurobiological processes associated with ayahuasca: A proposed model and implications for therapeutic use. Front. Neurosci., 2023, 16, 879221. doi: 10.3389/fnins.2022.879221
  452. Griffiths, R.R.; Richards, W.A.; Johnson, M.W.; McCann, U.D.; Jesse, R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J. Psychopharmacol., 2008, 22(6), 621-632. doi: 10.1177/0269881108094300
  453. Palhano-Fontes, F.; Barreto, D.; Onias, H.; Andrade, K.C.; Novaes, M.M.; Pessoa, J.A.; Mota-Rolim, S.A.; Osório, F.L.; Sanches, R.; dos Santos, R.G.; Tófoli, L.F.; de Oliveira Silveira, G.; Yonamine, M.; Riba, J.; Santos, F.R.; Silva-Junior, A.A.; Alchieri, J.C.; Galvão-Coelho, N.L.; Lobão-Soares, B.; Hallak, J.E.C.; Arcoverde, E.; Maia-de-Oliveira, J.P.; Araújo, D.B. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. Psychol. Med., 2019, 49(4), 655-663. doi: 10.1017/S0033291718001356
  454. Liechti, M.E.; Dolder, P.C.; Schmid, Y. Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacology, 2017, 234(9-10), 1499-1510. doi: 10.1007/s00213-016-4453-0
  455. Holze, F.; Ley, L.; Müller, F.; Becker, A.M.; Straumann, I.; Vizeli, P.; Kuehne, S.S.; Roder, M.A.; Duthaler, U.; Kolaczynska, K.E.; Varghese, N.; Eckert, A.; Liechti, M.E. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology, 2022, 47(6), 1180-1187. doi: 10.1038/s41386-022-01297-2
  456. Gandy, S. Predictors and potentiators of psychedelic-occasioned mystical experiences. J. Psychedelic Stud., 2022, 6(1), 31-47. doi: 10.1556/2054.2022.00198
  457. Roseman, L.; Nutt, D.J.; Carhart-Harris, R.L. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front. Pharmacol., 2018, 8, 974. doi: 10.3389/fphar.2017.00974
  458. Williams, M.T.; Davis, A.K.; Xin, Y.; Sepeda, N.D.; Grigas, P.C.; Sinnott, S.; Haeny, A.M. People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences. Drugs Educ. Prev. Policy, 2021, 28(3), 215-226. doi: 10.1080/09687637.2020.1854688
  459. Healy, C.J. The acute effects of classic psychedelics on memory in humans. Psychopharmacology, 2021, 238(3), 639-653. doi: 10.1007/s00213-020-05756-w
  460. Carter, O.L.; Burr, D.C.; Pettigrew, J.D.; Wallis, G.M.; Hasler, F.; Vollenweider, F.X. Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J. Cogn. Neurosci., 2005, 17(10), 1497-1508. doi: 10.1162/089892905774597191
  461. Wittmann, M.; Carter, O.; Hasler, F.; Cahn, B.R.; Grimberg, U.; Spring, P.; Hell, D.; Flohr, H.; Vollenweider, F.X. Effects of psilocybin on time perception and temporal control of behaviour in humans. J. Psychopharmacol., 2007, 21(1), 50-64. doi: 10.1177/0269881106065859
  462. Family, N.; Maillet, E.L.; Williams, L.T.J.; Krediet, E.; Carhart-Harris, R.L.; Williams, T.M.; Nichols, C.D.; Goble, D.J.; Raz, S. Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. Psychopharmacology, 2020, 237(3), 841-853. doi: 10.1007/s00213-019-05417-7
  463. Bershad, A.K.; Schepers, S.T.; Bremmer, M.P.; Lee, R.; de Wit, H. Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers. Biol. Psychiatry, 2019, 86(10), 792-800. doi: 10.1016/j.biopsych.2019.05.019
  464. Bouso, J.C.; Fábregas, J.M.; Antonijoan, R.M.; Rodríguez-Fornells, A.; Riba, J. Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users. Psychopharmacology, 2013, 230(3), 415-424. doi: 10.1007/s00213-013-3167-9
  465. Pokorny, T.; Preller, K.H.; Kometer, M.; Dziobek, I.; Vollenweider, F.X. Effect of psilocybin on empathy and moral decision-making. Int. J. Neuropsychopharmacol., 2017, 20(9), 747-757. doi: 10.1093/ijnp/pyx047
  466. Dolder, P.C.; Schmid, Y.; Müller, F.; Borgwardt, S.; Liechti, M.E. LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology, 2016, 41(11), 2638-2646. doi: 10.1038/npp.2016.82
  467. Kometer, M.; Schmidt, A.; Bachmann, R. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol. Psychiatry, 2012, 72(11), 898-906.
  468. Watts, R.; Day, C.; Krzanowski, J.; Nutt, D.; Carhart-Harris, R. Patients’ accounts of increased "connectedness" and "acceptance" after psilocybin for treatment-resistant depression. J. Humanist. Psychol., 2017, 57(5), 520-564. doi: 10.1177/0022167817709585
  469. Bernasconi, F.; Schmidt, A.; Pokorny, T. Spatiotemporal brain dynamics of emotional face processing modulations induced by the serotonin 1A/2A receptor agonist psilocybin. Cerebral cortex, 2014, 24(12), 3221-3231.
  470. Schmidt, A.; Kometer, M.; Bachmann, R.; Seifritz, E.; Vollenweider, F. The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions. Psychopharmacology, 2013, 225(1), 227-239. doi: 10.1007/s00213-012-2811-0
  471. Mueller, F.; Lenz, C.; Dolder, P.C. Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects. Translational Psychiatry, 2017, 7(4), e1084-e. doi: 10.1038/tp.2017.54
  472. Kiraga, M.K.; Mason, N.L.; Uthaug, M.V.; van Oorsouw, K.I.M.; Toennes, S.W.; Ramaekers, J.G.; Kuypers, K.P.C. Persisting effects of ayahuasca on empathy, creative thinking, decentering, personality, and well-being. Front. Pharmacol., 2021, 12, 721537. doi: 10.3389/fphar.2021.721537
  473. Rocha, J.M.; Rossi, G.N.; de Lima Osório, F.; Bouso, J.C.; de Oliveira Silveira, G.; Yonamine, M.; Campos, A.C.; Bertozi, G.; Cecílio Hallak, J.E.; dos Santos, R.G. Effects of ayahuasca on the recognition of facial expressions of emotions in naive healthy volunteers. J. Clin. Psychopharmacol., 2021, 41(3), 267-274. doi: 10.1097/JCP.0000000000001396
  474. Sampedro, F.; de la Fuente Revenga, M.; Valle, M.; Roberto, N.; Domínguez-Clavé, E.; Elices, M.; Luna, L.E.; Crippa, J.A.S.; Hallak, J.E.C.; de Araujo, D.B.; Friedlander, P.; Barker, S.A.; Álvarez, E.; Soler, J.; Pascual, J.C.; Feilding, A.; Riba, J. Assessing the psychedelic "after-glow" in ayahuasca users: Post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities. Int. J. Neuropsychopharmacol., 2017, 20(9), 698-711. doi: 10.1093/ijnp/pyx036
  475. Soler, J.; Elices, M.; Franquesa, A.; Barker, S.; Friedlander, P.; Feilding, A.; Pascual, J.C.; Riba, J. Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities. Psychopharmacology, 2016, 233(5), 823-829. doi: 10.1007/s00213-015-4162-0
  476. Kometer, M.; Pokorny, T.; Seifritz, E.; Volleinweider, F.X. Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations. Psychopharmacology, 2015, 232(19), 3663-3676. doi: 10.1007/s00213-015-4026-7
  477. Frecska, E.; Móré, C.E.; Vargha, A.; Luna, L.E. Enhancement of creative expression and entoptic phenomena as after-effects of repeated ayahuasca ceremonies. J. Psychoactive Drugs, 2012, 44(3), 191-199. doi: 10.1080/02791072.2012.703099
  478. Madsen, M.K.; Fisher, P.M.; Stenbæk, D.S.; Kristiansen, S.; Burmester, D.; Lehel, S.; Páleníček, T.; Kuchař, M.; Svarer, C.; Ozenne, B.; Knudsen, G.M. A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neo-cortical 5-HT2A receptor binding. Eur. Neuropsychopharmacol., 2020, 33, 71-80. doi: 10.1016/j.euroneuro.2020.02.001
  479. Smigielski, L.; Scheidegger, M.; Kometer, M.; Vollenweider, F.X. Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. Neuroimage, 2019, 196, 207-215. doi: 10.1016/j.neuroimage.2019.04.009
  480. Wießner, I.; Falchi, M.; Palhano-Fontes, F.; Feilding, A.; Ribeiro, S.; Tófoli, L.F. LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model. Psychol. Med., 2023, 53(4), 1151-1165. doi: 10.1017/S0033291721002531
  481. Uthaug, M.V.; Lancelotta, R.; van Oorsouw, K.; Kuypers, K.P.C.; Mason, N.; Rak, J.; Šuláková, A.; Jurok, R.; Maryška, M.; Kuchař, M.; Páleníček, T.; Riba, J.; Ramaekers, J.G. A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. Psychopharmacology, 2019, 236(9), 2653-2666. doi: 10.1007/s00213-019-05236-w
  482. Uthaug, M.V.; van Oorsouw, K.; Kuypers, K.P.C.; van Boxtel, M.; Broers, N.J.; Mason, N.L.; Toennes, S.W.; Riba, J.; Ramaekers, J.G. Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution. Psychopharmacology, 2018, 235(10), 2979-2989. doi: 10.1007/s00213-018-4988-3
  483. Uthaug, M.V.; Lancelotta, R.; Szabo, A.; Davis, A.K.; Riba, J.; Ramaekers, J.G. Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment. Psychopharmacology, 2020, 237(3), 773-785. doi: 10.1007/s00213-019-05414-w
  484. Domínguez-Clavé, E.; Soler, J.; Pascual, J.C.; Elices, M.; Franquesa, A.; Valle, M.; Alvarez, E.; Riba, J. Ayahuasca improves emotion dysregulation in a community sample and in individuals with borderline-like traits. Psychopharmacology, 2019, 236(2), 573-580. doi: 10.1007/s00213-018-5085-3
  485. Soler, J.; Elices, M.; Dominguez-Clavé, E.; Pascual, J.C.; Feilding, A.; Navarro-Gil, M.; García-Campayo, J.; Riba, J. Four weekly ayahuasca sessions lead to increases in "acceptance" capacities: A comparison study with a standard 8-week mindfulness training program. Front. Pharmacol., 2018, 9, 224. doi: 10.3389/fphar.2018.00224
  486. Franquesa, A.; Sainz-Cort, A.; Gandy, S.; Soler, J.; Alcázar-Córcoles, M.Á.; Bouso, J.C. Psychological variables implied in the therapeutic effect of ayahuasca: A contextual approach. Psychiatry Res., 2018, 264, 334-339. doi: 10.1016/j.psychres.2018.04.012
  487. Fresco, D.M.; Moore, M.T.; van Dulmen, M.H.M.; Segal, Z.V.; Ma, S.H.; Teasdale, J.D.; Williams, J.M.G. Initial psychometric properties of the experiences questionnaire: Validation of a self-report measure of decentering. Behav. Ther., 2007, 38(3), 234-246. doi: 10.1016/j.beth.2006.08.003
  488. González, D.; Cantillo, J.; Pérez, I.; Farré, M.; Feilding, A.; Obiols, J.E.; Bouso, J.C. Therapeutic potential of ayahuasca in grief: A prospective, observational study. Psychopharmacology, 2020, 237(4), 1171-1182. doi: 10.1007/s00213-019-05446-2
  489. Kuypers, K.P.C.; Riba, J.; de la Fuente Revenga, M.; Barker, S.; Theunissen, E.L.; Ramaekers, J.G. Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking. Psychopharmacology, 2016, 233(18), 3395-3403. doi: 10.1007/s00213-016-4377-8
  490. Loizaga-Velder, A.; Pazzi, A.L. Therapist and patient perspectives on ayahuasca-assisted treatment for substance dependence. The Therapeutic Use of Ayahuasca; Labate, B.C.; Cavnar, C., Eds.; Springer: Berlin, Heidelberg, 2014, pp. 133-152. doi: 10.1007/978-3-642-40426-9_8
  491. Carhart-Harris, R.L.; Kaelen, M.; Whalley, M.G.; Bolstridge, M.; Feilding, A.; Nutt, D.J. LSD enhances suggestibility in healthy volunteers. Psychopharmacology, 2015, 232(4), 785-794. doi: 10.1007/s00213-014-3714-z
  492. Forgeard, M.J.C.; Elstein, J.G. Advancing the clinical science of creativity. Front. Psychol., 2014, 5, 613. doi: 10.3389/fpsyg.2014.00613
  493. Mason, N.L.; Kuypers, K.P.C.; Reckweg, J.T.; Müller, F.; Tse, D.H.Y.; Da Rios, B.; Toennes, S.W.; Stiers, P.; Feilding, A.; Ramaekers, J.G. Spontaneous and deliberate creative cognition during and after psilocybin exposure. Transl. Psychiatry, 2021, 11(1), 209. doi: 10.1038/s41398-021-01335-5
  494. Wießner, I.; Falchi, M.; Maia, L.O.; Daldegan-Bueno, D.; Palhano-Fontes, F.; Mason, N.L.; Ramaekers, J.G.; Gross, M.E.; Schooler, J.W.; Feilding, A.; Ribeiro, S.; Araujo, D.B.; Tófoli, L.F. LSD and creativity: Increased novelty and symbolic thinking, decreased utility and convergent thinking. J. Psychopharmacol., 2022, 36(3), 348-359. doi: 10.1177/02698811211069113
  495. Mednick, S.A. The remote associates test. J. Creat. Behav., 1968, 2(3), 213-214. doi: 10.1002/j.2162-6057.1968.tb00104.x
  496. Kjellgren, A.; Eriksson, A.; Norlander, T. Experiences of encounters with ayahuasca—"the vine of the soul". J. Psychoactive Drugs, 2009, 41(4), 309-315. doi: 10.1080/02791072.2009.10399767
  497. Duerler, P.; Schilbach, L.; Stämpfli, P.; Vollenweider, F.X.; Preller, K.H. LSD-induced increases in social adaptation to opinions similar to one’s own are associated with stimulation of serotonin receptors. Sci. Rep., 2020, 10(1), 12181. doi: 10.1038/s41598-020-68899-y
  498. Bogenschutz, M.P.; Ross, S.; Bhatt, S.; Baron, T.; Forcehimes, A.A.; Laska, E.; Mennenga, S.E.; O’Donnell, K.; Owens, L.T.; Podrebarac, S.; Rotrosen, J.; Tonigan, J.S.; Worth, L. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder. JAMA Psychiatry, 2022, 79(10), 953. doi: 10.1001/jamapsychiatry.2022.2096
  499. Carhart-Harris, R.; Giribaldi, B.; Watts, R.; Baker-Jones, M.; Murphy-Beiner, A.; Murphy, R.; Martell, J.; Blemings, A.; Erritzoe, D.; Nutt, D.J. Trial of psilocybin versus escitalopram for depression. N. Engl. J. Med., 2021, 384(15), 1402-1411. doi: 10.1056/NEJMoa2032994
  500. Davis, A.K.; Barrett, F.S.; May, D.G.; Cosimano, M.P.; Sepeda, N.D.; Johnson, M.W.; Finan, P.H.; Griffiths, R.R. Effects of psilocybin-assisted therapy on major depressive disorder. JAMA Psychiatry, 2021, 78(5), 481-489. doi: 10.1001/jamapsychiatry.2020.3285
  501. Riba, J.; Valle, M.; Urbano, G.; Yritia, M.; Morte, A.; Barbanoj, M.J. Human pharmacology of ayahuasca: Subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J. Pharmacol. Exp. Ther., 2003, 306(1), 73-83. doi: 10.1124/jpet.103.049882
  502. Durante, Í.; dos Santos, R.G.; Bouso, J.C.; Hallak, J.E. Risk assessment of ayahuasca use in a religious context: self-reported risk factors and adverse effects. Br. J. Psychiatry, 2021, 43(4), 362-369. doi: 10.1590/1516-4446-2020-0913
  503. dos Santos, R.G.; Valle, M.; Bouso, J.C.; Nomdedéu, J.F.; Rodríguez-Espinosa, J.; McIlhenny, E.H.; Barker, S.A.; Barbanoj, M.J.; Riba, J. Autonomic, neuroendocrine, and immunological effects of ayahuasca. J. Clin. Psychopharmacol., 2011, 31(6), 717-726. doi: 10.1097/JCP.0b013e31823607f6
  504. Riba, J.; Barbanoj, M.J. Bringing ayahuasca to the clinical research laboratory. J. Psychoactive Drugs, 2005, 37(2), 219-230. doi: 10.1080/02791072.2005.10399804
  505. Strajhar, P.; Schmid, Y.; Liakoni, E.; Dolder, P.C.; Rentsch, K.M.; Kratschmar, D.V.; Odermatt, A.; Liechti, M.E. Acute effects of lysergic acid diethylamide on circulating steroid levels in healthy subjects. J. Neuroendocrinol., 2016, 28(3), 12374. doi: 10.1111/jne.12374
  506. House, R.V.; Thomas, P.T.; Bhargava, H.N. Immunological consequences of in vitro exposure to lysergic acid diethylamide (LSD). Immunopharmacol. Immunotoxicol., 1994, 16(1), 23-40. doi: 10.3109/08923979409029898
  507. Galvão, ACdM Cortisol modulation by ayahuasca in patients with treatment resistant depression and healthy controls. Front. Psychiatry, 2018, 9.
  508. Galvão-Coelho, N.L.; de Menezes Galvão, A.C.; de Almeida, R.N.; Palhano-Fontes, F.; Campos Braga, I.; Lobão Soares, B.; Maia-de-Oliveira, J.P.; Perkins, D.; Sarris, J.; de Araujo, D.B. Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca. J. Psychopharmacol., 2020, 34(10), 1125-1133. doi: 10.1177/0269881120936486
  509. Flanagan, T.W.; Nichols, C.D. Psychedelics as anti-inflammatory agents. Int. Rev. Psychiatry, 2018, 30(4), 363-375. doi: 10.1080/09540261.2018.1481827
  510. Passie, T.; Halpern, J.H.; Stichtenoth, D.O.; Emrich, H.M.; Hintzen, A. The pharmacology of lysergic acid diethylamide: A review. CNS Neurosci. Ther., 2008, 14(4), 295-314. doi: 10.1111/j.1755-5949.2008.00059.x
  511. Dinis-Oliveira, R.J. Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug Metab. Rev., 2017, 49(1), 84-91. doi: 10.1080/03602532.2016.1278228
  512. Inserra, A.; De Gregorio, D.; Gobbi, G. Psychedelics in psychiatry: Neuroplastic, immunomodulatory, and neurotransmitter mechanisms. Pharmacol. Rev., 2021, 73(1), 202-277. doi: 10.1124/pharmrev.120.000056
  513. Canal, C.E.; Murnane, K.S. The serotonin 5-HT 2C receptor and the non-addictive nature of classic hallucinogens. J. Psychopharmacol., 2017, 31(1), 127-143. doi: 10.1177/0269881116677104
  514. (NIH) NIoH. National Center for Biotechnology Information. 2023. Available from: https://ncbi.nlm.nih.gov/
  515. Barker, S.A. N,N-Dimethyltryptamine (DMT), an endogenous hallucinogen: Past, present, and future research to determine its role and function. Front. Neurosci., 2018, 12, 536. doi: 10.3389/fnins.2018.00536
  516. Frecska, E.; Bokor, P.; Winkelman, M. The therapeutic potentials of ayahuasca: Possible effects against various diseases of civilization. Front. Pharmacol., 2016, 7, 35. doi: 10.3389/fphar.2016.00035
  517. Brito-da-Costa, A.M.; Dias-da-Silva, D.; Gomes, N.G.M.; Dinis-Oliveira, R.J.; Madureira-Carvalho, Á. Toxicokinetics and toxicodynamics of ayahuasca alkaloids N,N-dimethyltryptamine (DMT), Harmine, harmaline and tetrahydroharmine: clinical and forensic impact. Pharmaceuticals (Basel), 2020, 13(11), 334. doi: 10.3390/ph13110334
  518. Gable, R.S. Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. Addiction, 2007, 102(1), 24-34. doi: 10.1111/j.1360-0443.2006.01652.x
  519. dos Santos, R.G.; Grasa, E.; Valle, M.; Ballester, M.R.; Bouso, J.C.; Nomdedéu, J.F.; Homs, R.; Barbanoj, M.J.; Riba, J. Pharmacology of ayahuasca administered in two repeated doses. Psychopharmacology, 2012, 219(4), 1039-1053. doi: 10.1007/s00213-011-2434-x
  520. Riba, J.; McIlhenny, E.H.; Valle, M.; Bouso, J.C.; Barker, S.A. Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca. Drug Test. Anal., 2012, 4(7-8), 610-616. doi: 10.1002/dta.1344
  521. Ruffell, S.; Netzband, N.; Bird, C.; Young, A.H.; Juruena, M.F. The pharmacological interaction of compounds in ayahuasca: A systematic review. Br. J. Psychiatry, 2020, 42(6), 646-656. doi: 10.1590/1516-4446-2020-0884
  522. Nichols, D.E. Hallucinogens. Pharmacol. Ther., 2004, 101(2), 131-181. doi: 10.1016/j.pharmthera.2003.11.002
  523. Rickli, A.; Moning, O.D.; Hoener, M.C.; Liechti, M.E. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur. Neuropsychopharmacol., 2016, 26(8), 1327-1337. doi: 10.1016/j.euroneuro.2016.05.001
  524. Luethi, D.; Hoener, M.C.; Krähenbühl, S.; Liechti, M.E.; Duthaler, U. Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use. Biochem. Pharmacol., 2019, 164, 129-138. doi: 10.1016/j.bcp.2019.04.013
  525. Vollenweider, F.X.; Preller, K.H. Psychedelic drugs: Neurobiology and potential for treatment of psychiatric disorders. Nat. Rev. Neurosci., 2020, 21(11), 611-624. doi: 10.1038/s41583-020-0367-2
  526. Glennon, R.A.; Titeler, M.; McKenney, J.D. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci., 1984, 35(25), 2505-2511. doi: 10.1016/0024-3205(84)90436-3
  527. Jaster, A.M.; de la Fuente Revenga, M.; González-Maeso, J. Molecular targets of psychedelic-induced plasticity. J. Neurochem., 2022, 162(1), 80-88. doi: 10.1111/jnc.15536
  528. Carbonaro, T.M.; Gatch, M.B. Neuropharmacology of N,N-dimethyltryptamine. Brain Res. Bull., 2016, 126, 74-88. doi: 10.1016/j.brainresbull.2016.04.016
  529. Mckenna, D.J.; Repke, D.B.; Lo, L.; Peroutka, S.J. Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. Neuropharmacology, 1990, 29(3), 193-198. doi: 10.1016/0028-3908(90)90001-8
  530. Kadriu, B.; Greenwald, M.; Henter, I.D.; Gilbert, J.R.; Kraus, C.; Park, L.T.; Zarate, C.A., Jr Ketamine and serotonergic psychedelics: Common mechanisms underlying the effects of rapid-acting antidepressants. Int. J. Neuropsychopharmacol., 2021, 24(1), 8-21. doi: 10.1093/ijnp/pyaa087
  531. Banks, M.I.; Zahid, Z.; Jones, N.T.; Sultan, Z.W.; Wenthur, C.J. Catalysts for change: The cellular neurobiology of psychedelics. Mol. Biol. Cell, 2021, 32(12), 1135-1144. doi: 10.1091/mbc.E20-05-0340
  532. Reiff, C.M.; Richman, E.E.; Nemeroff, C.B.; Carpenter, L.L.; Widge, A.S.; Rodriguez, C.I.; Kalin, N.H.; McDonald, W.M. Psychedelics and psychedelic-assisted psychotherapy. Am. J. Psychiatry, 2020, 177(5), 391-410. doi: 10.1176/appi.ajp.2019.19010035
  533. Ray, T.S. Psychedelics and the human receptorome. PLoS One, 2010, 5(2), e9019. doi: 10.1371/journal.pone.0009019
  534. Smith, R.; Canton, H.; Barrett, R.J.; Sanders-Bush, E. Agonist properties of N,N-dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors. Pharmacol. Biochem. Behav., 1998, 61(3), 323-330. doi: 10.1016/S0091-3057(98)00110-5
  535. Cameron, L.P.; Olson, D.E. Dark classics in chemical neuroscience: N, N -Dimethyltryptamine (DMT). ACS Chem. Neurosci., 2018, 9(10), 2344-2357. doi: 10.1021/acschemneuro.8b00101
  536. Callaway, J.C.; Airaksinen, M.M.; Mckenna, D.J.; Brito, G.S.; Grob, C.S. Platelet serotonin uptake sites increased in drinkers of ayahuasca. Psychopharmacology, 1994, 116(3), 385-387. doi: 10.1007/BF02245347
  537. Strassman, R.J. Human psychopharmacology of N,N-dimethyltryptamine. Behav. Brain Res., 1995, 73(1-2), 121-124. doi: 10.1016/0166-4328(96)00081-2
  538. Buckholtz, N.S.; Boggan, W.O. Monoamine oxidase inhibition in brain and liver produced by β-carbolines: structure-activity relationships and substrate specificity. Biochem. Pharmacol., 1977, 26(21), 1991-1996. doi: 10.1016/0006-2952(77)90007-7
  539. Glennon, R.A.; Dukat, M.; Grella, B.; Hong, S-S.; Costantino, L.; Teitler, M.; Smith, C.; Egan, C.; Davis, K.; Mattson, M.V. Binding of β-carbolines and related agents at serotonin (5-HT2 and 5-HT1A), dopamine (D2) and benzodiazepine receptors. Drug Alcohol Depend., 2000, 60(2), 121-132. doi: 10.1016/S0376-8716(99)00148-9
  540. Marona-Lewicka, D.; Thisted, R.A.; Nichols, D.E. Distinct temporal phases in the behavioral pharmacology of LSD: dopamine D2 receptor-mediated effects in the rat and implications for psychosis. Psychopharmacology, 2005, 180(3), 427-435. doi: 10.1007/s00213-005-2183-9
  541. Halberstadt, A.L.; Geyer, M.A. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 2011, 61(3), 364-381. doi: 10.1016/j.neuropharm.2011.01.017
  542. Bousquet, P.; Hudson, A.; García-Sevilla, J.A.; Li, J.X. Imidazoline receptor system: The past, the present, and the future. Pharmacol. Rev., 2020, 72(1), 50-79. doi: 10.1124/pr.118.016311
  543. Moreno, J.L.; Holloway, T.; Albizu, L.; Sealfon, S.C.; González-Maeso, J. Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Neurosci. Lett., 2011, 493(3), 76-79. doi: 10.1016/j.neulet.2011.01.046
  544. Fontanilla, D.; Johannessen, M.; Hajipour, A.R.; Cozzi, N.V.; Jackson, M.B.; Ruoho, A.E. The Hallucinogen N,N-dimethyl-tryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science, 2009, 323(5916), 934-937. doi: 10.1126/science.1166127
  545. Inserra, A. Hypothesis: The psychedelic ayahuasca heals traumatic memories via a sigma 1 receptor-mediated epigenetic-mnemonic process. Front. Pharmacol., 2018, 9, 330. doi: 10.3389/fphar.2018.00330
  546. Chaudhari, N.; Talwar, P.; Parimisetty, A.; Lefebvre d’Hellencourt, C.; Ravanan, P. A molecular web: endoplasmic reticulum stress, inflammation, and oxidative stress. Front. Cell. Neurosci., 2014, 8(1), 213. doi: 10.3389/fncel.2014.00213
  547. Pal, A.; Fontanilla, D.; Gopalakrishnan, A.; Chae, Y-K.; Markley, J.L.; Ruoho, A.E. The sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elements. Eur. J. Pharmacol., 2012, 682(1-3), 12-20. doi: 10.1016/j.ejphar.2012.01.030
  548. Andersen, K.A.A.; Carhart-Harris, R.; Nutt, D.J.; Erritzoe, D. Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. Acta Psychiatr. Scand., 2021, 143(2), 101-118. doi: 10.1111/acps.13249
  549. dos Santos, R.G.; Bouso, J.C.; Alcázar-Córcoles, M.Á.; Hallak, J.E.C. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: A systematic review of systematic reviews. Expert Rev. Clin. Pharmacol., 2018, 11(9), 889-902. doi: 10.1080/17512433.2018.1511424
  550. Brown, R.T.; Nicholas, C.R.; Cozzi, N.V.; Gassman, M.C.; Cooper, K.M.; Muller, D.; Thomas, C.D.; Hetzel, S.J.; Henriquez, K.M.; Ribaudo, A.S.; Hutson, P.R. Pharmacokinetics of escalating doses of oral psilocybin in healthy adults. Clin. Pharmacokinet., 2017, 56(12), 1543-1554. doi: 10.1007/s40262-017-0540-6
  551. Gukasyan, N.; Davis, A.K.; Barrett, F.S.; Cosimano, M.P.; Sepeda, N.D.; Johnson, M.W.; Griffiths, R.R. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J. Psychopharmacol., 2022, 36(2), 151-158. doi: 10.1177/02698811211073759
  552. Goodwin, G.M.; Aaronson, S.T.; Alvarez, O.; Arden, P.C.; Baker, A.; Bennett, J.C.; Bird, C.; Blom, R.E.; Brennan, C.; Brusch, D.; Burke, L.; Campbell-Coker, K.; Carhart-Harris, R.; Cattell, J.; Daniel, A.; DeBattista, C.; Dunlop, B.W.; Eisen, K.; Feifel, D.; Forbes, M.K.; Haumann, H.M.; Hellerstein, D.J.; Hoppe, A.I.; Husain, M.I.; Jelen, L.A.; Kamphuis, J.; Kawasaki, J.; Kelly, J.R.; Key, R.E.; Kishon, R.; Knatz Peck, S.; Knight, G.; Koolen, M.H.B.; Lean, M.; Licht, R.W.; Maples-Keller, J.L.; Mars, J.; Marwood, L.; McElhiney, M.C.; Miller, T.L.; Mirow, A.; Mistry, S.; Mletzko-Crowe, T.; Modlin, L.N.; Nielsen, R.E.; Nielson, E.M.; Offerhaus, S.R.; O’Keane, V.; Páleníček, T.; Printz, D.; Rademaker, M.C.; van Reemst, A.; Reinholdt, F.; Repantis, D.; Rucker, J.; Rudow, S.; Ruffell, S.; Rush, A.J.; Schoevers, R.A.; Seynaeve, M.; Shao, S.; Soares, J.C.; Somers, M.; Stansfield, S.C.; Sterling, D.; Strockis, A.; Tsai, J.; Visser, L.; Wahba, M.; Williams, S.; Young, A.H.; Ywema, P.; Zisook, S.; Malievskaia, E. Single-dose psilocybin for a treatment-resistant episode of major depression. N. Engl. J. Med., 2022, 387(18), 1637-1648. doi: 10.1056/NEJMoa2206443
  553. Chandler, A.L. Lysergic acid diethylamide (LSD-25) as a facilitating agent in psychotherapy. Arch. Gen. Psychiatry, 1960, 2(3), 286-299. doi: 10.1001/archpsyc.1960.03590090042008
  554. Malleson, N. Acute adverse reactions to LSD in clinical and experimental use in the United Kingdom. Br. J. Psychiatry, 1971, 118(543), 229-230. doi: 10.1192/bjp.118.543.229
  555. Sanches, R.F.; de Lima Osório, F.; dos Santos, R.G.; Macedo, L.R.H.; Maia-de-Oliveira, J.P.; Wichert-Ana, L.; de Araujo, D.B.; Riba, J.; Crippa, J.A.S.; Hallak, J.E.C. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression. J. Clin. Psychopharmacol., 2016, 36(1), 77-81. doi: 10.1097/JCP.0000000000000436
  556. dos Santos, R.G. A critical evaluation of reports associating ayahuasca with life-threatening adverse reactions. J. Psychoactive Drugs, 2013, 45(2), 179-188. doi: 10.1080/02791072.2013.785846
  557. Frecska, E. Therapeutic guidelines: Dangers and contra-indications in therapeutic applications of hallucinogens. Psychedelic medicine: new evidence for hallucinogenic substances as treatments., 2007, 69-95.
  558. dos Santos, R.G.; Bouso, J.C.; Hallak, J.E.C. Ayahuasca, dimethyltryptamine, and psychosis: A systematic review of human studies. Ther. Adv. Psychopharmacol., 2017, 7(4), 141-157. doi: 10.1177/2045125316689030
  559. Callaway, J.C.; Grob, C.S. Ayahuasca preparations and serotonin reuptake inhibitors: A potential combination for severe adverse interactions. J. Psychoactive Drugs, 1998, 30(4), 367-369. doi: 10.1080/02791072.1998.10399712
  560. Sklerov, J.; Levine, B.; Moore, K.A.; King, T.; Fowler, D. A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. J. Anal. Toxicol., 2005, 29(8), 838-841. doi: 10.1093/jat/29.8.838
  561. McEwen, B.S. Brain on stress: How the social environment gets under the skin. Proc. Natl. Acad. Sci., 2012, 109(2), 17180-17185. doi: 10.1073/pnas.1121254109
  562. D’Sa, C.; Duman, R.S. Antidepressants and neuroplasticity. Bipolar Disord., 2002, 4(3), 183-194. doi: 10.1034/j.1399-5618.2002.01203.x
  563. Olson, D.E. Psychoplastogens: A promising class of plasticity-promoting neurotherapeutics. J. Exp. Neurosci., 2018, 12, 1179069518800508. doi: 10.1177/1179069518800508
  564. Russo, S.J.; Dietz, D.M.; Dumitriu, D. The addicted synapse: mechanisms of synaptic and structural plasticity in nucleus accumbens. Trends Neurosci., 2010, 33(6), 267-276. doi: 10.1016/j.tins.2010.02.002
  565. Ly, C.; Greb, A.C.; Cameron, L.P.; Wong, J.M.; Barragan, E.V.; Wilson, P.C.; Burbach, K.F.; Soltanzadeh, Z.S.; Sood, A.; Paddy, M.R.; Duim, W.C.; Dennis, M.Y.; McAllister, A.K.; Ori-McKenney, K.M.; Gray, J.A.; Olson, D.E. Psychedelics promote structural and functional neural plasticity. Cell Rep., 2018, 23(11), 3170-3182. doi: 10.1016/j.celrep.2018.05.022
  566. Frankel, P.S.; Cunningham, K.A. The hallucinogen d-lysergic acid diethylamide (d-LSD) induces the immediate-early gene c-Fos in rat forebrain. Brain Res., 2002, 958(2), 251-260. doi: 10.1016/S0006-8993(02)03548-5
  567. González-Maeso, J.; Weisstaub, N.V.; Zhou, M.; Chan, P.; Ivic, L.; Ang, R.; Lira, A.; Bradley-Moore, M.; Ge, Y.; Zhou, Q.; Sealfon, S.C.; Gingrich, J.A. Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior. Neuron, 2007, 53(3), 439-452. doi: 10.1016/j.neuron.2007.01.008
  568. Gewirtz, J.C.; Chen, A.C.; Terwilliger, R.; Duman, R.C.; Marek, G.J. Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors. Pharmacol. Biochem. Behav., 2002, 73(2), 317-326. doi: 10.1016/S0091-3057(02)00844-4
  569. Jones, M.W.; Errington, M.L.; French, P.J.; Fine, A.; Bliss, T.V.P.; Garel, S.; Charnay, P.; Bozon, B.; Laroche, S.; Davis, S. A requirement for the immediate early gene Zif268 in the expression of late LTP and long-term memories. Nat. Neurosci., 2001, 4(3), 289-296. doi: 10.1038/85138
  570. DeSteno, D.A.; Schmauss, C. Induction of early growth response gene 2 expression in the forebrain of mice performing an attention-set-shifting task. Neuroscience, 2008, 152(2), 417-428. doi: 10.1016/j.neuroscience.2008.01.012
  571. Radiske, A.; Rossato, J.I.; Köhler, C.A.; Gonzalez, M.C.; Medina, J.H.; Cammarota, M. Requirement for BDNF in the reconsolidation of fear extinction. J. Neurosci., 2015, 35(16), 6570-6574. doi: 10.1523/JNEUROSCI.4093-14.2015
  572. Suárez-Pereira, I.; Carrión, Á.M. Updating stored memory requires adult hippocampal neurogenesis. Sci. Rep., 2015, 5(1), 13993. doi: 10.1038/srep13993
  573. Almeida, R.N.; Galvão, A.C.M.; da Silva, F.S.; Silva, E.A.S.; Palhano-Fontes, F.; Maia-de-Oliveira, J.P.; de Araújo, L-S.B.; Lobão-Soares, B.; Galvão-Coelho, N.L. Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: Observation from a randomized controlled trial. Front. Psychol., 2019, 10, 1234. doi: 10.3389/fpsyg.2019.01234
  574. Serra-Millàs, M. Are the changes in the peripheral brain-derived neurotrophic factor levels due to platelet activation? World J. Psychiatry, 2016, 6(1), 84-101. doi: 10.5498/wjp.v6.i1.84
  575. Kearney, D.J.; McManus, C.; Malte, C.A.; Martinez, M.E.; Felleman, B.; Simpson, T.L. Loving-kindness meditation and the broaden-and-build theory of positive emotions among veterans with posttraumatic stress disorder. Med. Care, 2014, 52(12)(5), S32-S38. doi: 10.1097/MLR.0000000000000221
  576. King, A.P.; Fresco, D.M. A neurobehavioral account for decentering as the salve for the distressed mind. Curr. Opin. Psychol., 2019, 28, 285-293. doi: 10.1016/j.copsyc.2019.02.009
  577. Bouso, J.C.; Palhano-Fontes, F.; Rodríguez-Fornells, A.; Ribeiro, S.; Sanches, R.; Crippa, J.A.S.; Hallak, J.E.C.; de Araujo, D.B.; Riba, J. Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. Eur. Neuropsychopharmacol., 2015, 25(4), 483-492. doi: 10.1016/j.euroneuro.2015.01.008
  578. Preller, K.H.; Burt, J.B.; Ji, J.L.; Schleifer, C.H.; Adkinson, B.D.; Stämpfli, P.; Seifritz, E.; Repovs, G.; Krystal, J.H.; Murray, J.D.; Vollen-weider, F.X.; Anticevic, A. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. eLife, 2018, 7, e35082. doi: 10.7554/eLife.35082
  579. Rousseau, P.F.; Malbos, E.; Verger, A.; Nicolas, F.; Lançon, C.; Khalfa, S.; Guedj, E. Increase of precuneus metabolism correlates with reduction of PTSD symptoms after EMDR therapy in military veterans: An 18F-FDG PET study during virtual reality exposure to war. Eur. J. Nucl. Med. Mol. Imaging, 2019, 46(9), 1817-1821. doi: 10.1007/s00259-019-04360-1
  580. Carhart-Harris, R.L.; Muthukumaraswamy, S.; Roseman, L.; Kaelen, M.; Droog, W.; Murphy, K.; Tagliazucchi, E.; Schenberg, E.E.; Nest, T.; Orban, C.; Leech, R.; Williams, L.T.; Williams, T.M.; Bolstridge, M.; Sessa, B.; McGonigle, J.; Sereno, M.I.; Nichols, D.; Hellyer, P.J.; Hobden, P.; Evans, J.; Singh, K.D.; Wise, R.G.; Curran, H.V.; Feilding, A.; Nutt, D.J. Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc. Natl. Acad. Sci., 2016, 113(17), 4853-4858. doi: 10.1073/pnas.1518377113
  581. Buckner, R.L.; Andrews-Hanna, J.R.; Schacter, D.L. The brain’s default network: Anatomy, function, and relevance to disease. Ann. N. Y. Acad. Sci., 2008, 1124(1), 1-38. doi: 10.1196/annals.1440.011
  582. Palhano-Fontes, F.; Andrade, K.C.; Tofoli, L.F.; Santos, A.C.; Crippa, J.A.S.; Hallak, J.E.C.; Ribeiro, S.; de Araujo, D.B. The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PLoS One, 2015, 10(2), e0118143. doi: 10.1371/journal.pone.0118143
  583. Gattuso, J.J.; Perkins, D.; Ruffell, S.; Lawrence, A.J.; Hoyer, D.; Jacobson, L.H.; Timmermann, C.; Castle, D.; Rossell, S.L.; Downey, L.A.; Pagni, B.A.; Galvão-Coelho, N.L.; Nutt, D.; Sarris, J. Default mode network modulation by psychedelics: A systematic review. Int. J. Neuropsychopharmacol., 2023, 26(3), 155-188. doi: 10.1093/ijnp/pyac074
  584. Harnett, N.G.; van Rooij, S.J.H.; Ely, T.D.; Lebois, L.A.M.; Murty, V.P.; Jovanovic, T.; Hill, S.B.; Dumornay, N.M.; Merker, J.B.; Bruce, S.E.; House, S.L.; Beaudoin, F.L.; An, X.; Zeng, D.; Neylan, T.C.; Clifford, G.D.; Linnstaedt, S.D.; Germine, L.T.; Bollen, K.A.; Rauch, S.L.; Lewandowski, C.; Hendry, P.L.; Sheikh, S.; Storrow, A.B.; Musey, P.I., Jr; Haran, J.P.; Jones, C.W.; Punches, B.E.; Swor, R.A.; McGrath, M.E.; Pascual, J.L.; Seamon, M.J.; Mohiuddin, K.; Chang, A.M.; Pearson, C.; Peak, D.A.; Domeier, R.M.; Rathlev, N.K.; Sanchez, L.D.; Pietrzak, R.H.; Joormann, J.; Barch, D.M.; Pizzagalli, D.A.; Sheridan, J.F.; Harte, S.E.; Elliott, J.M.; Kessler, R.C.; Koenen, K.C.; Mclean, S.; Ressler, K.J.; Stevens, J.S. Prognostic neuroimaging biomarkers of trauma-related psychopathology: resting-state fMRI shortly after trauma predicts future PTSD and depression symptoms in the AURORA study. Neuropsychopharmacology, 2021, 46(7), 1263-1271. doi: 10.1038/s41386-020-00946-8
  585. Miller, D.R.; Hayes, S.M.; Hayes, J.P.; Spielberg, J.M.; Lafleche, G.; Verfaellie, M. Default mode network subsystems are differentially disrupted in posttraumatic stress disorder. Biol. Psychiatry Cogn. Neurosci. Neuroimaging, 2017, 2(4), 363-371. doi: 10.1016/j.bpsc.2016.12.006
  586. Barrett, F.S.; Doss, M.K.; Sepeda, N.D.; Pekar, J.J.; Griffiths, R.R. Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci. Rep., 2020, 10(1), 2214. doi: 10.1038/s41598-020-59282-y
  587. Carhart-Harris, R.L.; Roseman, L.; Bolstridge, M.; Demetriou, L.; Pannekoek, J.N.; Wall, M.B.; Tanner, M.; Kaelen, M.; McGonigle, J.; Murphy, K.; Leech, R.; Curran, H.V.; Nutt, D.J. Psilocybin for treatment-resistant depression: FMRI-measured brain mechanisms. Sci. Rep., 2017, 7(1), 13187. doi: 10.1038/s41598-017-13282-7
  588. Akiki, T.J.; Averill, C.L.; Abdallah, C.G. A network-based neurobiological model of PTSD: Evidence from structural and functional neuroimaging studies. Curr. Psychiatry Rep., 2017, 19(11), 81. doi: 10.1007/s11920-017-0840-4
  589. Henner, R.L.; Keshavan, M.S.; Hill, K.P. Review of otential sychedelic reatments for PTSD. J. Neurol. Sci., 2022, 439, 120302. doi: 10.1016/j.jns.2022.120302
  590. Preller, K.H.; Razi, A.; Zeidman, P.; Stämpfli, P.; Friston, K.J.; Vollenweider, F.X. Effective connectivity changes in LSD-induced altered states of consciousness in humans. Proc. Natl. Acad. Sci., 2019, 116(7), 2743-2748. doi: 10.1073/pnas.1815129116
  591. Vollenweider, F.X.; Geyer, M.A. A systems model of altered consciousness: Integrating natural and drug-induced psychoses. Brain Res. Bull., 2001, 56(5), 495-507. doi: 10.1016/S0361-9230(01)00646-3
  592. Kraehenmann, R.; Preller, K.H.; Scheidegger, M.; Pokorny, T.; Bosch, O.G.; Seifritz, E.; Vollenweider, F.X. Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol. Psychiatry, 2015, 78(8), 572-581. doi: 10.1016/j.biopsych.2014.04.010
  593. Carhart-Harris, R.L.; Friston, K.J. REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics. Pharmacol. Rev., 2019, 71(3), 316-344. doi: 10.1124/pr.118.017160
  594. Duerler, P.; Brem, S.; Fraga-González, G. Psilocybin induces aberrant prediction error processing of tactile mismatch responses: A simultaneous EEG-FMRI study. Cereb. Cortex, 2021, 32(1), 186-196. doi: 10.1093/cercor/bhab202
  595. Alonso, J.F.; Romero, S.; Mañanas, M.À.; Riba, J. Serotonergic psychedelics temporarily modify information transfer in humans. Int. J. Neuropsychopharmacol., 2015, 18(8), 1-9. doi: 10.1093/ijnp/pyv039
  596. Kida, S. Reconsolidation/destabilization, extinction and forgetting of fear memory as therapeutic targets for PTSD. Psychopharmacology, 2019, 236(1), 49-57. doi: 10.1007/s00213-018-5086-2
  597. de Vos, C.M.H.; Mason, N.L.; Kuypers, K.P.C. Psychedelics and neuroplasticity: A systematic review unraveling the biological underpinnings of psychedelics. Front. Psychiatry, 2021, 12, 724606. doi: 10.3389/fpsyt.2021.724606
  598. Catlow, B.J.; Song, S.; Paredes, D.A.; Kirstein, C.L.; Sanchez-Ramos, J. Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp. Brain Res., 2013, 228(4), 481-491. doi: 10.1007/s00221-013-3579-0
  599. Kraehenmann, R.; Schmidt, A.; Friston, K.; Preller, K.H.; Seifritz, E.; Vollenweider, F.X. The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. Neuroimage Clin., 2016, 11, 53-60. doi: 10.1016/j.nicl.2015.08.009
  600. Grimm, O.; Kraehenmann, R.; Preller, K.H.; Seifritz, E.; Vollenweider, F.X. Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination. Eur. Neuropsychopharmacol., 2018, 28(6), 691-700. doi: 10.1016/j.euroneuro.2018.03.016
  601. Menon, V. Salience Network. Brain Mapping; Toga, A.W., Ed.; Academic Press: Waltham, 2015, pp. 597-611. doi: 10.1016/B978-0-12-397025-1.00052-X
  602. Nielson, J.L.; Megler, J.D. Ayahuasca as a candidate therapy for PTSD. The Therapeutic Use of Ayahuasca; Labate, B.C.; Cavnar, C., Eds.; Springer: Berlin, Heidelberg, 2014, pp. 41-58. doi: 10.1007/978-3-642-40426-9_3
  603. Castro-Neto, E.F.; Cunha, R.H.; Silveira, D.X.; Yonamine, M.; Gouveia, T.L.F.; Cavalheiro, E.A.; Amado, D.; Naffah-Mazzacoratti, M.G. Changes in aminoacidergic and monoaminergic neurotransmission in the hippocampus and amygdala of rats after ayahuasca ingestion. World J. Biol. Chem., 2013, 4(4), 141-147. doi: 10.4331/wjbc.v4.i4.141
  604. Abraham, A.D.; Neve, K.A.; Lattal, K.M. Dopamine and extinction: A convergence of theory with fear and reward circuitry. Neurobiol. Learn. Mem., 2014, 108, 65-77. doi: 10.1016/j.nlm.2013.11.007
  605. Rau, V.; Iyer, S.V.; Oh, I.; Chandra, D.; Harrison, N.; Eger, E.I.; Fanselow, M.S.; Homanics, G.E.; Sonner, J.M. Gamma-aminobutyric acid type A receptor alpha 4 subunit knockout mice are resistant to the amnestic effect of isoflurane. Anesth. Analg., 2009, 109(6), 1816-1822. doi: 10.1213/ANE.0b013e3181bf6ae6
  606. Roseman, L.; Haijen, E.; Idialu-Ikato, K.; Kaelen, M.; Watts, R.; Carhart-Harris, R. Emotional breakthrough and psychedelics: Validation of the emotional breakthrough inventory. J. Psychopharmacol., 2019, 33(9), 1076-1087. doi: 10.1177/0269881119855974
  607. Gorman, I.; Nielson, E.M.; Molinar, A.; Cassidy, K.; Sabbagh, J. Psychedelic harm reduction and integration: A transtheoretical model for clinical practice. Front. Psychol., 2021, 12, 645246. doi: 10.3389/fpsyg.2021.645246
  608. Fischman, L.G. Seeing without self: Discovering new meaning with psychedelic-assisted psychotherapy. Neuro-psychoanalysis, 2019, 21(2), 53-78. doi: 10.1080/15294145.2019.1689528
  609. Janssen, P.G.J.; Stoltz, S.; Cillessen, A.H.N.; van Ee, E. Deployment-related PTSD symptomatology and social functioning: Probing the mediating roles of emotion regulation and mentalization in an outpatient veteran sample. J. Psychiatr. Res., 2022, 156, 444-450. doi: 10.1016/j.jpsychires.2022.10.050
  610. Saraiya, T.; Lopez-Castro, T. Ashamed and afraid: A scoping review of the role of shame in post-traumatic stress disorder (PTSD). J. Clin. Med., 2016, 5(11), 94. doi: 10.3390/jcm5110094
  611. Pickover, A.; Lowell, A.; Lazarov, A.; Lopez-Yianilos, A.; Sanchez-Lacay, A.; Ryba, M.; Such, S.; Arnon, S.; Amsalem, D.; Neria, Y.; Markowitz, J.C. Interpersonal psychotherapy of posttraumatic stress disorder for veterans and family members: An open trial. Psychiatr. Serv., 2021, 72(8), 866-873. doi: 10.1176/appi.ps.202000355
  612. De Gregorio, D.; Popic, J.; Enns, J.P. Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission. Proc. Natl. Acad. Sci. USA, 2021, 118(5), e2020705118.
  613. Preller, K.H.; Vollenweider, F.X. Modulation of social cognition via hallucinogens and "entactogens". Front. Psychiatry, 2019, 10, 881. doi: 10.3389/fpsyt.2019.00881
  614. Carhart-Harris, R.L.; Goodwin, G.M. The therapeutic potential of psychedelic drugs: Past, present, and future. Neuropsychopharmacology, 2017, 42(11), 2105-2113. doi: 10.1038/npp.2017.84
  615. Noorani, T.; Garcia-Romeu, A.; Swift, T.C.; Griffiths, R.R.; Johnson, M.W. Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. J. Psychopharmacol., 2018, 32(7), 756-769. doi: 10.1177/0269881118780612
  616. Weiss, B.; Nygart, V.; Pommerencke, L.M.; Carhart-Harris, R.L.; Erritzoe, D. Examining psychedelic-induced changes in social functioning and connectedness in a naturalistic online sample using the five-factor model of personality. Front. Psychol., 2021, 12, 749788. doi: 10.3389/fpsyg.2021.749788
  617. Griffiths, R.R.; Johnson, M.W.; Richards, W.A.; Richards, B.D.; Jesse, R.; MacLean, K.A.; Barrett, F.S.; Cosimano, M.P.; Klinedinst, M.A. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J. Psychopharmacol., 2018, 32(1), 49-69. doi: 10.1177/0269881117731279
  618. Schmid, Y.; Liechti, M.E. Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology, 2018, 235(2), 535-545. doi: 10.1007/s00213-017-4733-3
  619. Zeifman, R.J.; Wagner, A.C.; Watts, R.; Kettner, H.; Mertens, L.J.; Carhart-Harris, R.L. Post-psychedelic reductions in experiential avoidance are associated with decreases in depression severity and suicidal ideation. Front. Psychiatry, 2020, 11, 782. doi: 10.3389/fpsyt.2020.00782
  620. Khan, A.J.; Bradley, E.; O’Donovan, A.; Woolley, J. Psilocybin for trauma-related disorders. Curr. Top. Behav. Neurosci., 2022, 56, 319-322. doi: 10.1007/7854_2022_366
  621. Anderson, B.T.; Danforth, A.; Daroff, P.R.; Stauffer, C.; Ekman, E.; Agin-Liebes, G.; Trope, A.; Boden, M.T.; Dilley, P.J.; Mitchell, J.; Woolley, J. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClin. Med., 2020, 27, 100538. doi: 10.1016/j.eclinm.2020.100538
  622. Malone, T.C.; Mennenga, S.E.; Guss, J.; Podrebarac, S.K.; Owens, L.T.; Bossis, A.P.; Belser, A.B.; Agin-Liebes, G.; Bogenschutz, M.P.; Ross, S. Individual experiences in four cancer patients following psilocybin-assisted psychotherapy. Front. Pharmacol., 2018, 9, 256. doi: 10.3389/fphar.2018.00256
  623. Oehen, P.; Gasser, P. Using a MDMA- and LSD-group therapy model in clinical practice in Switzerland and highlighting the treatment of trauma-related disorders. Front. Psychiatry, 2022, 13, 863552. doi: 10.3389/fpsyt.2022.863552
  624. Perkins, D.; Schubert, V.; Simonová, H.; Tófoli, L.F.; Bouso, J.C.; Horák, M.; Galvão-Coelho, N.L.; Sarris, J. Influence of context and setting on the mental health and wellbeing outcomes of ayahuasca drinkers: Results of a large international survey. Front. Pharmacol., 2021, 12, 623979. doi: 10.3389/fphar.2021.623979
  625. Jiménez-Garrido, D.F.; Gómez-Sousa, M.; Ona, G.; Dos Santos, R.G.; Hallak, J.E.C.; Alcázar-Córcoles, M.Á.; Bouso, J.C. Effects of ayahuasca on mental health and quality of life in naïve users: A longitudinal and cross-sectional study combination. Sci. Rep., 2020, 10(1), 4075. doi: 10.1038/s41598-020-61169-x
  626. Osório, F.L.; Sanches, R.F.; Macedo, L.R.; dos Santos, R.G.; Maia-de-Oliveira, J.P.; Wichert-Ana, L.; de Araujo, D.B.; Riba, J.; Crippa, J.A.; Hallak, J.E. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A preliminary report. Rev. Bras. Psiquiatr., 2015, 37(1), 13-20. doi: 10.1590/1516-4446-2014-1496
  627. Ona, G.; Kohek, M.; Massaguer, T.; Gomariz, A.; Jiménez, D.F.; Dos Santos, R.G.; Hallak, J.E.C.; Alcázar-Córcoles, M.Á.; Bouso, J.C. Ayahuasca and public health: Health status, psychosocial well-being, lifestyle, and coping strategies in a large sample of ritual ayahuasca users. J. Psychoactive Drugs, 2019, 51(2), 135-145. doi: 10.1080/02791072.2019.1567961
  628. Santos, R.G.; Landeira-Fernandez, J.; Strassman, R.J.; Motta, V.; Cruz, A.P.M. Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members. J. Ethnopharmacol., 2007, 112(3), 507-513. doi: 10.1016/j.jep.2007.04.012
  629. Li, L.; Vlisides, P.E. Ketamine: 50 years of modulating the mind. Front. Hum. Neurosci., 2016, 10, 612. doi: 10.3389/fnhum.2016.00612
  630. Domino, E.F.; Chodoff, P.; Corssen, G. Pharmacologic effects of CI-581, a new dissociative anesthetic, in man. Clin. Pharmacol. Ther., 1965, 6(3), 279-291. doi: 10.1002/cpt196563279
  631. Mion, G.; Villevieille, T. Ketamine pharmacology: An Update (Pharmacodynamics and Molecular Aspects, Recent Findings). CNS Neurosci. Ther., 2013, 19(6), 370-380. doi: 10.1111/cns.12099
  632. Wei, Y.; Chang, L.; Hashimoto, K. A historical review of antidepressant effects of ketamine and its enantiomers. Pharmacol. Biochem. Behav., 2020, 190, 172870. doi: 10.1016/j.pbb.2020.172870
  633. Kohtala, S. Ketamine—50 years in use: From anesthesia to rapid antidepressant effects and neurobiological mechanisms. Pharmacol. Rep., 2021, 73(2), 323-345. doi: 10.1007/s43440-021-00232-4
  634. U.S. Department of Justice. Administration USDE. Schedules of controlled substances: Placement of ketamine into schedule III. rules and regulations. Fed. Regist., 1999, 64(133), 37663-37831.
  635. Carboni, E.; Carta, A.R.; Carboni, E.; Novelli, A. Repurposing ketamine in depression and related disorders: Can this enigmatic drug achieve success? Front. Neurosci., 2021, 15, 657714. doi: 10.3389/fnins.2021.657714
  636. Liu, Y.; Lin, D.; Wu, B.; Zhou, W. Ketamine abuse potential and use disorder. Brain Res. Bull., 2016, 126, 68-73. doi: 10.1016/j.brainresbull.2016.05.016
  637. Walsh, Z.; Mollaahmetoglu, O.M.; Rootman, J.; Golsof, S.; Keeler, J.; Marsh, B.; Nutt, D.J.; Morgan, C.J.A. Ketamine for the treatment of mental health and substance use disorders: Comprehensive systematic review. BJPsych Open, 2022, 8(1), e19. doi: 10.1192/bjo.2021.1061
  638. Yensen, R. Ed.; Group Psychotherapy with a Variety of Hallucinogens; Association for Humanistic Psychology: Montreal, Quebec, Canada, 1973.
  639. Zarate, C.A., Jr; Singh, J.B.; Carlson, P.J.; Brutsche, N.E.; Ameli, R.; Luckenbaugh, D.A.; Charney, D.S.; Manji, H.K. A randomized trial of an n-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry, 2006, 63(8), 856-864. doi: 10.1001/archpsyc.63.8.856
  640. Wilkinson, S.T.; Ballard, E.D.; Bloch, M.H.; Mathew, S.J.; Murrough, J.W.; Feder, A.; Sos, P.; Wang, G.; Zarate, C.A., Jr; Sanacora, G. The effect of a single dose of intravenous ketamine on suicidal ideation: A systematic review and individual participant data meta-analysis. Am. J. Psychiatry, 2018, 175(2), 150-158. doi: 10.1176/appi.ajp.2017.17040472
  641. Grunebaum, M.F.; Ellis, S.P.; Keilp, J.G.; Moitra, V.K.; Cooper, T.B.; Marver, J.E.; Burke, A.K.; Milak, M.S.; Sublette, M.E.; Oquendo, M.A.; Mann, J.J. Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolam-controlled randomized clinical trial. Bipolar Disord., 2017, 19(3), 176-183. doi: 10.1111/bdi.12487
  642. Feder, A.; Parides, M.K.; Murrough, J.W.; Perez, A.M.; Morgan, J.E.; Saxena, S.; Kirkwood, K. aan het Rot, M.; Lapidus, K.A.B.; Wan, L-B.; Iosifescu, D.; Charney, D.S. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder. JAMA Psychiatry, 2014, 71(6), 681-688. doi: 10.1001/jamapsychiatry.2014.62
  643. Stein, M.B.; Simon, N.M. Ketamine for PTSD: Well, Isn’t That Special. Am. J. Psychiatry, 2021, 178(2), 116-118. doi: 10.1176/appi.ajp.2020.20121677
  644. Mathai, D.S.; Mora, V.; Garcia-Romeu, A. Toward synergies of ketamine and psychotherapy. Front. Psychol., 2022, 13, 868103. doi: 10.3389/fpsyg.2022.868103
  645. Drozdz, S.J.; Goel, A.; McGarr, M.W.; Katz, J.; Ritvo, P.; Mattina, G.; Bhat, V.; Diep, C.; Ladha, K.S. Ketamine assisted psychotherapy: A systematic narrative review of the literature. J. Pain Res., 2022, 15, 1691-1706. doi: 10.2147/JPR.S360733
  646. McIntyre, R.S.; Rosenblat, J.D.; Nemeroff, C.B.; Sanacora, G.; Murrough, J.W.; Berk, M.; Brietzke, E.; Dodd, S.; Gorwood, P.; Ho, R.; Iosifescu, D.V.; Lopez Jaramillo, C.; Kasper, S.; Kratiuk, K.; Lee, J.G.; Lee, Y.; Lui, L.M.W.; Mansur, R.B.; Papakostas, G.I.; Subramaniapillai, M.; Thase, M.; Vieta, E.; Young, A.H.; Zarate, C.A., Jr; Stahl, S. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and implementation. Am. J. Psychiatry, 2021, 178(5), 383-399. doi: 10.1176/appi.ajp.2020.20081251
  647. Stirling, J.; McCoy, L. Quantifying the psychological effects of ketamine: From euphoria to the k-hole. Subst. Use Misuse, 2010, 45(14), 2428-2443. doi: 10.3109/10826081003793912
  648. Ballard, E.D.; Zarate, C.A., Jr The role of dissociation in ketamine’s antidepressant effects. Nat. Commun., 2020, 11(1), 6431. doi: 10.1038/s41467-020-20190-4
  649. Dore, J.; Turnipseed, B.; Dwyer, S.; Turnipseed, A.; Andries, J.; Ascani, G.; Monnette, C.; Huidekoper, A.; Strauss, N.; Wolfson, P. Ketamine assisted psychotherapy (KAP): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. J. Psychoactive Drugs, 2019, 51(2), 189-198. doi: 10.1080/02791072.2019.1587556
  650. Krystal, J.H.; Karper, L.P.; Seibyl, J.P. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch. Gen. Psychiatry, 1994, 51(3), 199-214. doi: 10.1001/archpsyc.1994.03950030035004
  651. Morgan, C.J.A.; Mofeez, A.; Brandner, B.; Bromley, L.; Curran, H.V. Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology, 2004, 29(1), 208-218. doi: 10.1038/sj.npp.1300342
  652. Zanos, P.; Moaddel, R.; Morris, P.J.; Riggs, L.M.; Highland, J.N.; Georgiou, P.; Pereira, E.F.R.; Albuquerque, E.X.; Thomas, C.J.; Zarate, C.A., Jr; Gould, T.D. Ketamine and ketamine metabolite pharmacology: Insights into therapeutic mechanisms. Pharmacol. Rev., 2018, 70(3), 621-660. doi: 10.1124/pr.117.015198
  653. Nikayin, S.; Murphy, E.; Krystal, J.H.; Wilkinson, S.T. Long-term safety of ketamine and esketamine in treatment of depression. Expert Opin. Drug Saf., 2022, 21(6), 777-787. doi: 10.1080/14740338.2022.2066651
  654. Sanacora, G.; Frye, M.A.; McDonald, W.; Mathew, S.J.; Turner, M.S.; Schatzberg, A.F.; Summergrad, P.; Nemeroff, C.B. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry, 2017, 74(4), 399-405. doi: 10.1001/jamapsychiatry.2017.0080
  655. Matveychuk, D.; Thomas, R.K.; Swainson, J.; Khullar, A.; MacKay, M-A.; Baker, G.B.; Dursun, S.M. Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers Ther. Adv. Psychopharmacol., 2020, 10 ecollection 2020. doi: 10.1177/2045125320916657
  656. Bonaventura, J.; Lam, S.; Carlton, M.; Boehm, M.A.; Gomez, J.L.; Solís, O.; Sánchez-Soto, M.; Morris, P.J.; Fredriksson, I.; Thomas, C.J.; Sibley, D.R.; Shaham, Y.; Zarate, C.A., Jr; Michaelides, M. Pharmacological and behavioral divergence of ketamine enantiomers: Implications for abuse liability. Mol. Psychiatry, 2021, 26(11), 6704-6722. doi: 10.1038/s41380-021-01093-2
  657. Andrade, C. Ketamine for depression, 3: Does chirality matter? J. Clin. Psychiatry, 2017, 78(6), e674-e677. doi: 10.4088/JCP.17f11681
  658. Dinis-Oliveira, R.J. Metabolism and metabolomics of ketamine: A toxicological approach. Forensic Sci. Res., 2017, 2(1), 2-10. doi: 10.1080/20961790.2017.1285219
  659. Ahuja, S.; Brendle, M.; Smart, L.; Moore, C.; Thielking, P.; Robison, R. Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: A retrospective descriptive cohort study. BMC Psychiatry, 2022, 22(1), 634. doi: 10.1186/s12888-022-04268-5
  660. Andrade, C. 1: Pharmacologic considerations and clinical evidence. J. Clin. Psychiatry, 2019, 80(2), 19f12820.
  661. Zanos, P.; Gould, T.D. Mechanisms of ketamine action as an antidepressant. Mol. Psychiatry, 2018, 23(4), 801-811. doi: 10.1038/mp.2017.255
  662. Zorumski, C.F.; Izumi, Y.; Mennerick, S. Ketamine: NMDA receptors and beyond. J. Neurosci., 2016, 36(44), 11158-11164. doi: 10.1523/JNEUROSCI.1547-16.2016
  663. Asim, M.; Wang, B.; Hao, B.; Wang, X. Ketamine for post-traumatic stress disorders and it’s possible therapeutic mechanism. Neurochem. Int., 2021, 146, 105044. doi: 10.1016/j.neuint.2021.105044
  664. Witt, K.; Potts, J.; Hubers, A.; Grunebaum, M.F.; Murrough, J.W.; Loo, C.; Cipriani, A.; Hawton, K. Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials. Aust. N. Z. J. Psychiatry, 2020, 54(1), 29-45. doi: 10.1177/0004867419883341
  665. Chilukuri, H.; Reddy, N.P.; Pathapati, R.M.; Manu, A.N.; Jollu, S.; Shaik, A.B. Acute antidepressant effects of intramuscular versus intravenous ketamine. Indian J. Psychol. Med., 2014, 36(1), 71-76. doi: 10.4103/0253-7176.127258
  666. Lapidus, K.A.B.; Levitch, C.F.; Perez, A.M.; Brallier, J.W.; Parides, M.K.; Soleimani, L.; Feder, A.; Iosifescu, D.V.; Charney, D.S.; Murrough, J.W. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol. Psychiatry, 2014, 76(12), 970-976. doi: 10.1016/j.biopsych.2014.03.026
  667. Abdallah, C.G.; Sanacora, G.; Duman, R.S.; Krystal, J.H. Ketamine and rapid-acting antidepressants: A window into a new neurobiology for mood disorder therapeutics. Annu. Rev. Med., 2015, 66(1), 509-523. doi: 10.1146/annurev-med-053013-062946
  668. Kojic, M.; Saelens, J.; Kadriu, B.; Zarate, C.A., Jr; Kraus, C. Ketamine for depression: Advances in clinical treatment, rapid antidepressant mechanisms of action, and a contrast with serotonergic psychedelics. Curr. Top. Behav. Neurosci., 2022, 56, 141-167. doi: 10.1007/7854_2022_313
  669. Kadriu, B.; Musazzi, L.; Henter, I.D.; Graves, M.; Popoli, M.; Zarate, C.A., Jr Glutamatergic neurotransmission: Pathway to developing novel rapid-acting antidepressant treatments. Int. J. Neuropsychopharmacol., 2019, 22(2), 119-135. doi: 10.1093/ijnp/pyy094
  670. Deakin, J.F.W.; Lees, J.; McKie, S.; Hallak, J.E.C.; Williams, S.R.; Dursun, S.M. Glutamate and the neural basis of the subjective effects of ketamine: A pharmaco-magnetic resonance imaging study. Arch. Gen. Psychiatry, 2008, 65(2), 154-164. doi: 10.1001/archgenpsychiatry.2007.37
  671. Höflich, A.; Hahn, A.; Küblböck, M.; Kranz, G.S.; Vanicek, T.; Ganger, S.; Spies, M.; Windischberger, C.; Kasper, S.; Winkler, D.; Lanzenberger, R. Ketamine-dependent neuronal activation in healthy volunteers. Brain Struct. Funct., 2017, 222(3), 1533-1542. doi: 10.1007/s00429-016-1291-0
  672. Mueller, F.; Musso, F.; London, M.; de Boer, P.; Zacharias, N.; Winterer, G. Pharmacological fMRI: Effects of subanesthetic ketamine on resting-state functional connectivity in the default mode network, salience network, dorsal attention network and executive control network. Neuroimage Clin., 2018, 19, 745-757. doi: 10.1016/j.nicl.2018.05.037
  673. Zacharias, N.; Musso, F.; Müller, F.; Lammers, F.; Saleh, A.; London, M.; de Boer, P.; Winterer, G. Ketamine effects on default mode network activity and vigilance: A randomized, placebo-controlled crossover simultaneous fMRI/EEG study. Hum. Brain Mapp., 2020, 41(1), 107-119. doi: 10.1002/hbm.24791
  674. Morris, L.S.; Costi, S.; Tan, A.; Stern, E.R.; Charney, D.S.; Murrough, J.W. Ketamine normalizes subgenual cingulate cortex hyper-activity in depression. Neuropsychopharmacology, 2020, 45(6), 975-981. doi: 10.1038/s41386-019-0591-5
  675. Alexander, L.; Gaskin, P.L.R.; Sawiak, S.J.; Fryer, T.D.; Hong, Y.T.; Cockcroft, G.J.; Clarke, H.F.; Roberts, A.C. Fractionating blunted reward processing characteristic of anhedonia by over-activating primate subgenual anterior cingulate cortex. Neuron, 2019, 101(2), 307-320.e6. doi: 10.1016/j.neuron.2018.11.021
  676. Zanos, P.; Moaddel, R.; Morris, P.J.; Georgiou, P.; Fischell, J.; Elmer, G.I.; Alkondon, M.; Yuan, P.; Pribut, H.J.; Singh, N.S.; Dossou, K.S.S.; Fang, Y.; Huang, X-P.; Mayo, C.L.; Wainer, I.W.; Albuquerque, E.X.; Thompson, S.M.; Thomas, C.J.; Zarate, C.A., Jr; Gould, T.D. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature, 2016, 533(7604), 481-486. doi: 10.1038/nature17998
  677. Klein, M.E.; Chandra, J.; Sheriff, S.; Malinow, R. Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents. Proc. Natl. Acad. Sci., 2020, 117(5), 2656-2662. doi: 10.1073/pnas.1916570117
  678. Williams, N.R.; Heifets, B.D.; Blasey, C.; Sudheimer, K.; Pannu, J.; Pankow, H.; Hawkins, J.; Birnbaum, J.; Lyons, D.M.; Rodriguez, C.I.; Schatzberg, A.F. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am. J. Psychiatry, 2018, 175(12), 1205-1215. doi: 10.1176/appi.ajp.2018.18020138
  679. Yoon, G.; Petrakis, I.L.; Krystal, J.H. Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder. JAMA Psychiatry, 2019, 76(3), 337-338. doi: 10.1001/jamapsychiatry.2018.3990
  680. Hess, E.M.; Riggs, L.M.; Michaelides, M.; Gould, T.D. Mechanisms of ketamine and its metabolites as antidepressants. Biochem. Pharmacol., 2022, 197, 114892. doi: 10.1016/j.bcp.2021.114892
  681. Chen, C.H.; Lee, M.H.; Chen, Y.C.; Lin, M.F. Ketamine-snorting associated cystitis. J. Formos. Med. Assoc., 2011, 110(12), 787-791. doi: 10.1016/j.jfma.2011.11.010
  682. Luby, E.D. Study of a new schizophrenomimetic drug—sernyl. Arch. Neurol. Psychiatry, 1959, 81(3), 363-369. doi: 10.1001/archneurpsyc.1959.02340150095011
  683. Strous, J.F.M.; Weeland, C.J.; van der Draai, F.A.; Daams, J.G.; Denys, D.; Lok, A.; Schoevers, R.A.; Figee, M. Brain changes associated with long-term ketamine abuse, a systematic review. Front. Neuroanat., 2022, 16, 795231. doi: 10.3389/fnana.2022.795231
  684. Morgan, C.J.A.; Muetzelfeldt, L.; Curran, H.V. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: A 1-year longitudinal study. Addiction, 2010, 105(1), 121-133. doi: 10.1111/j.1360-0443.2009.02761.x
  685. Bokor, G.; Anderson, P.D. Ketamine. J. Pharm. Pract., 2014, 27(6), 582-586. doi: 10.1177/0897190014525754
  686. Wong, S.W.; Lee, K.F.; Wong, J. Dilated common bile ducts mimicking choledochal cysts in ketamine abusers. Hong Kong Med. J., 2009, 15(1), 53-56.
  687. Lo, R.S.C.; Krishnamoorthy, R.; Freeman, J.G.; Austin, A.S. Cholestasis and biliary dilatation associated with chronic ketamine abuse: A case series. Singapore Med. J., 2011, 52(3), e52-e55.
  688. Chu, P.S.K.; Ma, W.K.; Wong, S.C.W.; Chu, R.W-H.; Cheng, C-H.; Wong, S.; Tse, J.M.; Lau, F-L.; Yiu, M-K.; Man, C-W. The destruction of the lower urinary tract by ketamine abuse: A new syndrome? BJU Int., 2008, 102(11), 1616-1622. doi: 10.1111/j.1464-410X.2008.07920.x
  689. Chu, P.S.K.; Kwok, S.C.; Lam, K.M. ‘Street ketamine’-associated bladder dysfunction: A report of ten cases. Hong Kong Med. J., 2007, 13(4), 311-313.
  690. Shahani, R.; Streutker, C.; Dickson, B.; Stewart, R.J. Ketamine-associated ulcerative cystitis: A new clinical entity. Urology, 2007, 69(5), 810-812. doi: 10.1016/j.urology.2007.01.038
  691. Cheung, RYK; Chan, SSC; Lee, JHS Urinary symptoms and impaired quality of life in female ketamine users: Persistence after cessation of use. Hong Kong Med. J., 2011, 17(4), 267-273.
  692. Poon, T.L.; Wong, K.F.; Chan, M.Y.; Fung, K.W.; Chu, S.K.; Man, C.W.; Yiu, M.K.; Leung, S.K. Upper gastrointestinal problems in inhalational ketamine abusers. J. Dig. Dis., 2010, 11(2), 106-110. doi: 10.1111/j.1751-2980.2010.00424.x
  693. Ng, J.; Lui, L.M.W.; Rosenblat, J.D.; Teopiz, K.M.; Lipsitz, O.; Cha, D.S.; Xiong, J.; Nasri, F.; Lee, Y.; Kratiuk, K.; Rodrigues, N.B.; Gill, H.; Subramaniapillai, M.; Mansur, R.B.; Ho, R.; Cao, B.; McIntyre, R.S. Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment. Psychopharmacology, 2021, 238(4), 917-926. doi: 10.1007/s00213-021-05767-1
  694. Findeis, H.; Sauer, C.; Cleare, A.; Bauer, M.; Ritter, P. Urothelial toxicity of esketamine in the treatment of depression. Psychopharmacology, 2020, 237(11), 3295-3302. doi: 10.1007/s00213-020-05611-y
  695. Cotter, S.; Wong, J.; Gada, N.; Gill, R.; Jones, S.C.; Chai, G.; Foster, D.; Avigan, M.; Mundkur, M. Repeated or continuous medically supervised ketamine administration associated with hepatobiliary adverse events: A retrospective case series. Drug Saf., 2021, 44(12), 1365-1374. doi: 10.1007/s40264-021-01120-9
  696. Du, R.; Han, R.; Niu, K.; Xu, J.; Zhao, Z.; Lu, G.; Shang, Y. The multivariate effect of ketamine on PTSD: Systematic review and meta-analysis. Front. Psychiatry, 2022, 13, 813103. doi: 10.3389/fpsyt.2022.813103
  697. Krystal, J.H.; Abdallah, C.G.; Averill, L.A.; Kelmendi, B.; Harpaz-Rotem, I.; Sanacora, G.; Southwick, S.M.; Duman, R.S. Synaptic loss and the pathophysiology of PTSD: Implications for ketamine as a prototype novel therapeutic. Curr. Psychiatry Rep., 2017, 19(10), 74. doi: 10.1007/s11920-017-0829-z
  698. Norbury, A.; Rutter, S.B.; Collins, A.B.; Costi, S.; Jha, M.K.; Horn, S.R.; Kautz, M.; Corniquel, M.; Collins, K.A.; Glasgow, A.M.; Brallier, J.; Shin, L.M.; Charney, D.S.; Murrough, J.W.; Feder, A. Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: Preliminary evidence. Neuropsychopharmacology, 2021, 46(13), 2266-2277. doi: 10.1038/s41386-021-01104-4
  699. Patel, R.; Spreng, R.N.; Shin, L.M.; Girard, T.A. Neurocircuitry models of posttraumatic stress disorder and beyond: A meta-analysis of functional neuroimaging studies. Neurosci. Biobehav. Rev., 2012, 36(9), 2130-2142. doi: 10.1016/j.neubiorev.2012.06.003
  700. Wu, H.; Savalia, N.K.; Kwan, A.C. Ketamine for a boost of neural plasticity: How, but also when? Biol. Psychiatry, 2021, 89(11), 1030-1032. doi: 10.1016/j.biopsych.2021.03.014
  701. Kavalali, E.T.; Monteggia, L.M. How does ketamine elicit a rapid antidepressant response? Curr. Opin. Pharmacol., 2015, 20, 35-39. doi: 10.1016/j.coph.2014.11.005
  702. Liriano, F.; Hatten, C.; Schwartz, T.L. Ketamine as treatment for post-traumatic stress disorder: A review. Drugs Context, 2019, 8, 1-7. doi: 10.7573/dic.212305
  703. Girgenti, M.J.; Ghosal, S.; LoPresto, D.; Taylor, J.R.; Duman, R.S. Ketamine accelerates fear extinction via mTORC1 signaling. Neurobiol. Dis., 2017, 100, 1-8. doi: 10.1016/j.nbd.2016.12.026
  704. Evers, A.G.; Murrough, J.W.; Charney, D.S.; Costi, S. Ketamine as a prophylactic resilience-enhancing agent. Front. Psychiatry, 2022, 13, 833259. doi: 10.3389/fpsyt.2022.833259
  705. Brachman, R.A.; McGowan, J.C.; Perusini, J.N.; Lim, S.C.; Pham, T.H.; Faye, C.; Gardier, A.M.; Mendez-David, I.; David, D.J.; Hen, R.; Denny, C.A. Ketamine as a prophylactic against stress-induced depressive-like behavior. Biol. Psychiatry, 2016, 79(9), 776-786. doi: 10.1016/j.biopsych.2015.04.022
  706. Mastrodonato, A.; Martinez, R.; Pavlova, I.P.; LaGamma, C.T.; Brachman, R.A.; Robison, A.J.; Denny, C.A. Ventral CA3 activation mediates prophylactic ketamine efficacy against stress-induced depressive-like behavior. Biol. Psychiatry, 2018, 84(11), 846-856. doi: 10.1016/j.biopsych.2018.02.011
  707. McGowan, J.C.; LaGamma, C.T.; Lim, S.C.; Tsitsiklis, M.; Neria, Y.; Brachman, R.A.; Denny, C.A. Prophylactic ketamine attenuates learned fear. Neuropsychopharmacology, 2017, 42(8), 1577-1589. doi: 10.1038/npp.2017.19
  708. Sala, N.; Paoli, C.; Bonifacino, T.; Mingardi, J.; Schiavon, E.; La Via, L.; Milanese, M.; Tornese, P.; Datusalia, A.K.; Rosa, J.; Facchinetti, R.; Frumento, G.; Carini, G.; Salerno Scarzella, F.; Scuderi, C.; Forti, L.; Barbon, A.; Bonanno, G.; Popoli, M.; Musazzi, L. Acute ketamine facilitates fear memory extinction in a rat model of PTSD along with restoring glutamatergic alterations and dendritic atrophy in the pre-frontal cortex. Front. Pharmacol., 2022, 13, 759626. doi: 10.3389/fphar.2022.759626
  709. Lazarevic, V.; Yang, Y.; Flais, I.; Svenningsson, P. Ketamine decreases neuronally released glutamate via retrograde stimulation of pre-synaptic adenosine A1 receptors. Mol. Psychiatry, 2021, 26(12), 7425-7435. doi: 10.1038/s41380-021-01246-3
  710. Asim, M.; Hao, B.; Waris, A.; Liang, Y.M.; Wang, X.G. Ketamine attenuates the PTSD-like effect via regulation of glutamatergic signaling in the nucleus accumbens of mice. Mol. Cell. Neurosci., 2022, 120, 103723. doi: 10.1016/j.mcn.2022.103723
  711. Feder, A.; Rutter, S.B.; Schiller, D.; Charney, D.S. The emergence of ketamine as a novel treatment for posttraumatic stress disorder. Adv. Pharmacol., 2020, 89, 261-286. doi: 10.1016/bs.apha.2020.05.004
  712. Hasler, G. Toward specific ways to combine ketamine and psychotherapy in treating depression. CNS Spectr., 2020, 25(3), 445-447. doi: 10.1017/S1092852919001007
  713. Clinical Trial. NCT04889664; , 2021. Available from: https://ClinicalTrials.gov/show/NCT04889664
  714. Mollaahmetoglu, O.M.; Keeler, J.; Ashbullby, K.J.; Ketzitzidou-Argyri, E.; Grabski, M.; Morgan, C.J.A. "This is something that changed my life": A qualitative study of patients’ experiences in a clinical trial of ketamine treatment for alcohol use disorders. Front. Psychiatry, 2021, 12, 695335. doi: 10.3389/fpsyt.2021.695335
  715. Krupitsky, E.M.; Grinenko, A.Y. Ketamine psychedelic therapy (KPT): A review of the results of ten years of research. J. Psychoactive Drugs, 1997, 29(2), 165-183. doi: 10.1080/02791072.1997.10400185
  716. Rothberg, R.L.; Azhari, N.; Haug, N.A.; Dakwar, E. Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial. J. Psychopharmacol., 2021, 35(2), 150-158. doi: 10.1177/0269881120970879
  717. Dakwar, E.; Anerella, C.; Hart, C.L.; Levin, F.R.; Mathew, S.J.; Nunes, E.V. Therapeutic infusions of ketamine: Do the psychoactive effects matter? Drug Alcohol Depend., 2014, 136, 153-157. doi: 10.1016/j.drugalcdep.2013.12.019
  718. Dakwar, E.; Nunes, E.V.; Hart, C.L.; Hu, M.C.; Foltin, R.W.; Levin, F.R. A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study. Neuropharmacology, 2018, 142, 270-276. doi: 10.1016/j.neuropharm.2018.01.005
  719. Veen, C.; Jacobs, G.; Philippens, I.; Vermetten, E. Subanesthetic dose ketamine in posttraumatic stress disorder: A role for reconsolidation during trauma-focused psychotherapy?Behavioral Neurobiology of PTSD. Current Topics in Behavioral Neurosciences; Vermetten, E.; Baker, D.G.; Risbrough, V.B., Eds.; Springer International Publishing: Cham, 2018, pp. 137-162. doi: 10.1007/7854_2017_34
  720. Sumner, R.L.; Chacko, E.; McMillan, R.; Spriggs, M.J.; Anderson, C.; Chen, J.; French, A.; Jung, S.H.; Rajan, A.; Malpas, G.; Hay, J.; Ponton, R.; Muthukumaraswamy, S.D.; Sundram, F. A qualitative and quantitative account of patient’s experiences of ketamine and its antidepressant properties. J. Psychopharmacol., 2021, 35(8), 946-961. doi: 10.1177/0269881121998321
  721. Joneborg, I.; Lee, Y.; Di Vincenzo, J.D.; Ceban, F.; Meshkat, S.; Lui, L.M.W.; Fancy, F.; Rosenblat, J.D.; McIntyre, R.S. Active mechanisms of ketamine-assisted psychotherapy: A systematic review. J. Affect. Disord., 2022, 315, 105-112. doi: 10.1016/j.jad.2022.07.030
  722. Price, RB; Spotts, C; Panny, BA Novel, Brief, Fully automated intervention to extend the antidepressant effect of a single ketamine infusion: A randomized clinical trial. Am. J. Psychiat., 2022, 20220216.
  723. Feder, A.; Costi, S.; Rutter, S.B.; Collins, A.B.; Govindarajulu, U.; Jha, M.K.; Horn, S.R.; Kautz, M.; Corniquel, M.; Collins, K.A.; Bevilacqua, L.; Glasgow, A.M.; Brallier, J.; Pietrzak, R.H.; Murrough, J.W.; Charney, D.S. A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. Am. J. Psychiatry, 2021, 178(2), 193-202. doi: 10.1176/appi.ajp.2020.20050596
  724. Abdallah, C.G.; Roache, J.D.; Gueorguieva, R.; Averill, L.A.; Young-McCaughan, S.; Shiroma, P.R.; Purohit, P.; Brundige, A.; Murff, W.; Ahn, K-H.; Sherif, M.A.; Baltutis, E.J.; Ranganathan, M.; D’Souza, D.; Martini, B.; Southwick, S.M.; Petrakis, I.L.; Burson, R.R.; Guthmiller, K.B.; López-Roca, A.L.; Lautenschlager, K.A.; McCallin, J.P., III; Hoch, M.B.; Timchenko, A.; Souza, S.E.; Bryant, C.E.; Mintz, J.; Litz, B.T.; Williamson, D.E.; Keane, T.M.; Peterson, A.L.; Krystal, J.H. Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: A double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology, 2022, 47(8), 1574-1581. doi: 10.1038/s41386-022-01266-9
  725. Mischel, N.A.; Balon, R. Esketamine. J. Clin. Psychopharmacol., 2021, 41(3), 233-235. doi: 10.1097/JCP.0000000000001395
  726. Commissioner Oot. FDA approves new nasal spray medication for treatmentresistant depression: Available only at a certified doctor’s office or clinic Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medicationtreatment-resistant-depression-available-only-certified (updated Tue, 03/24/2020 - 22:210
  727. Murrough, J.W.; Iosifescu, D.V.; Chang, L.C.; Al Jurdi, R.K.; Green, C.E.; Perez, A.M.; Iqbal, S.; Pillemer, S.; Foulkes, A.; Shah, A.; Charney, D.S.; Mathew, S.J. Antidepressant efficacy of ketamine in treatmentresistant major depression: A two-site randomized controlled trial. Am. J. Psychiatry, 2013, 170(10), 1134-1142. doi: 10.1176/appi.ajp.2013.13030392
  728. Shiroma, P.R.; Thuras, P.; Wels, J.; Albott, C.S.; Erbes, C.; Tye, S.; Lim, K.O. A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression. Transl. Psychiatry, 2020, 10(1), 206. doi: 10.1038/s41398-020-00897-0
  729. Ross, C.; Jain, R.; Bonnett, C.J.; Wolfson, P. High-dose ketamine infusion for the treatment of posttraumatic stress disorder in combat veterans. Ann. Clin. Psychiatry, 2019, 31(4), 271-279.
  730. Albott, C.S.; Lim, K.O.; Forbes, M.K. Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatmentresistant depression. The J. Clin. Psych., 2018, 79(3), 17m11634.
  731. Keizer, B.M.; Roache, J.D.; Jones, J.R.; Kalpinski, R.J.; Porcerelli, J.H.; Krystal, J.H. Continuous ketamine infusion for pain as an opportunity for psychotherapy for PTSD: A case series of ketamine-enhanced psychotherapy for PTSD and Pain (KEP-P2). Psychother. Psychosom., 2020, 89(5), 326-329. doi: 10.1159/000507095
  732. Shiroma, P.R.; Johns, B.; Kuskowski, M.; Wels, J.; Thuras, P.; Albott, C.S.; Lim, K.O. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. J. Affect. Disord., 2014, 155, 123-129. doi: 10.1016/j.jad.2013.10.036
  733. Pradhan, B.; Wainer, I.; Moaddel, R.; Torjman, M.C.; Goldberg, M.; Sabia, M.; Parikh, T.; Pumariega, A.J. Trauma Interventions using Mindfulness Based Extinction and Reconsolidation (TIMBER) psychotherapy prolong the therapeutic effects of single ketamine infusion on post-traumatic stress disorder and comorbid depression: a pilot randomized, placebo-controlled, crossover clinical trial. Asia Pacif. J. Clin. Trial.Nerv. Sys. Dis., 2017, 2(3), 80. doi: 10.4103/2542-3932.211589
  734. Research VOo. ClinicalTrialsgov. NCT04560660, 2021. Available from: https://ClinicalTrials.gov/show/NCT04560660
  735. University Qs. Combined Ketamine and eCBT Intervention for PTSD. 2021. Available from: https://ClinicalTrials.gov/show/NCT04771767
  736. Kelly, J.R.; Gillan, C.M.; Prenderville, J.; Kelly, C.; Harkin, A.; Clarke, G.; O’Keane, V. Psychedelic therapy’s transdiagnostic effects: A research domain criteria (RDoC) perspective. Front. Psychiatry, 2021, 12, 800072. doi: 10.3389/fpsyt.2021.800072
  737. Baldwin, J.R.; Reuben, A.; Newbury, J.B.; Danese, A. Agreement between prospective and retrospective measures of childhood maltreatment. JAMA Psychiatry, 2019, 76(6), 584-593. doi: 10.1001/jamapsychiatry.2019.0097
  738. Collishaw, S.; Pickles, A.; Messer, J.; Rutter, M.; Shearer, C.; Maughan, B. Resilience to adult psychopathology following childhood maltreatment: Evidence from a community sample. Child Abuse Negl., 2007, 31(3), 211-229. doi: 10.1016/j.chiabu.2007.02.004
  739. Felitti, V.J.; Anda, R.F.; Nordenberg, D.; Williamson, D.F.; Spitz, A.M.; Edwards, V.; Koss, M.P.; Marks, J.S. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults. The Adverse Childhood Experiences (ACE) Study. Am. J. Prev. Med., 1998, 14(4), 245-258. doi: 10.1016/S0749-3797(98)00017-8
  740. McLaughlin, K.A.; Conron, K.J.; Koenen, K.C.; Gilman, S.E. Childhood adversity, adult stressful life events, and risk of past-year psychiatric disorder: A test of the stress sensitization hypothesis in a population-based sample of adults. Psychol. Med., 2010, 40(10), 1647-1658. doi: 10.1017/S0033291709992121
  741. (US) CfSAT. Trauma-Informed Care in Behavioral Health Services. Rockville (MD); Substance Abuse and Mental Health Services Administration: US, 2014.
  742. Carlson, E.B.; Rosser-Hogan, R. Trauma experiences, posttraumatic stress, dissociation, and depression in Cambodian refugees. Am. J. Psychiatry, 1991, 148(11), 1548-1551. doi: 10.1176/ajp.148.11.1548
  743. Grant, D.M.; Beck, J.G.; Marques, L.; Palyo, S.A.; Clapp, J.D. The structure of distress following trauma: Posttraumatic stress disorder, major depressive disorder, and generalized anxiety disorder. J. Abnorm. Psychol., 2008, 117(3), 662-672. doi: 10.1037/a0012591
  744. Gros, D.F.; Price, M.; Magruder, K.M.; Frueh, B.C. Symptom overlap in posttraumatic stress disorder and major depression. Psychiatry Res., 2012, 196(2-3), 267-270. doi: 10.1016/j.psychres.2011.10.022
  745. Levitan, R.D.; Parikh, S.V.; Lesage, A.D.; Hegadoren, K.M.; Adams, M.; Kennedy, S.H.; Goering, P.N. Major depression in individuals with a history of childhood physical or sexual abuse: relationship to neurovegetative features, mania, and gender. Am. J. Psychiatry, 1998, 155(12), 1746-1752. doi: 10.1176/ajp.155.12.1746
  746. Singer, M.I.; Anglin, T.M.; Song, L.Y.; Lunghofer, L. Adolescents’ exposure to violence and associated symptoms of psychological trauma. JAMA, 1995, 273(6), 477-482. doi: 10.1001/jama.1995.03520300051036
  747. Artin, H.; Zisook, S.; Ramanathan, D. How do serotonergic psychedelics treat depression: The potential role of neuroplasticity. World J. Psychiatry, 2021, 11(6), 201-214. doi: 10.5498/wjp.v11.i6.201
  748. Kuburi, S.; Di Passa, A.M.; Tassone, V.K.; Mahmood, R.; Lalovic, A.; Ladha, K.S.; Dunlop, K.; Rizvi, S.; Demchenko, I.; Bhat, V. Neuroimaging correlates of treatment response with psychedelics in major depressive disorder: A systematic review. Chronic Stress, 2022, 6 doi: 10.1177/24705470221115342
  749. Carhart-Harris, R.L.; Bolstridge, M.; Rucker, J.; Day, C.M.J.; Erritzoe, D.; Kaelen, M.; Bloomfield, M.; Rickard, J.A.; Forbes, B.; Feilding, A.; Taylor, D.; Pilling, S.; Curran, V.H.; Nutt, D.J. Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. Lancet Psychiatry, 2016, 3(7), 619-627. doi: 10.1016/S2215-0366(16)30065-7
  750. Carhart-Harris, R.L.; Bolstridge, M.; Day, C.M.J.; Rucker, J.; Watts, R.; Erritzoe, D.E.; Kaelen, M.; Giribaldi, B.; Bloomfield, M.; Pilling, S.; Rickard, J.A.; Forbes, B.; Feilding, A.; Taylor, D.; Curran, H.V.; Nutt, D.J. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology, 2018, 235(2), 399-408. doi: 10.1007/s00213-017-4771-x
  751. Pribish, A.; Wood, N.; Kalava, A. A review of nonanesthetic uses of ketamine. Anesthesiol. Res. Pract., 2020, 2020, 1-15. doi: 10.1155/2020/5798285
  752. Mathew, S.J.; Shah, A.; Lapidus, K.; Clark, C.; Jarun, N.; Ostermeyer, B.; Murrough, J.W. Ketamine for treatment-resistant unipolar depression: Current evidence. CNS Drugs, 2012, 26(3), 189-204. doi: 10.2165/11599770-000000000-00000
  753. Ignácio, Z.M.; Réus, G.Z.; Arent, C.O.; Abelaira, H.M.; Pitcher, M.R.; Quevedo, J. New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs. Br. J. Clin. Pharmacol., 2016, 82(5), 1280-1290. doi: 10.1111/bcp.12845
  754. Aleksandrova, L.R.; Phillips, A.G.; Wang, Y.T. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism. J. Psychiatry Neurosci., 2017, 42(4), 222-229. doi: 10.1503/jpn.160175
  755. Lara, D.R.; Bisol, L.W.; Munari, L.R. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int. J. Neuropsychopharmacol., 2013, 16(9), 2111-2117. doi: 10.1017/S1461145713000485
  756. Rasmussen, K.G.; Lineberry, T.W.; Galardy, C.W.; Kung, S.; Lapid, M.I.; Palmer, B.A.; Ritter, M.J.; Schak, K.M.; Sola, C.L.; Hanson, A.J.; Frye, M.A. Serial infusions of low-dose ketamine for major depression. J. Psychopharmacol., 2013, 27(5), 444-450. doi: 10.1177/0269881113478283
  757. Xu, Y.; Hackett, M.; Carter, G.; Loo, C.; Gálvez, V.; Glozier, N.; Glue, P.; Lapidus, K.; McGirr, A.; Somogyi, A.A.; Mitchell, P.B.; Rodgers, A. Effects of low-dose and very low-dose ketamine among patients with major depression: A systematic review and meta-analysis. Int. J. Neuropsychopharmacol., 2016, 19(4), pyv124. doi: 10.1093/ijnp/pyv124
  758. Khoury, L.; Tang, Y.L.; Bradley, B.; Cubells, J.F.; Ressler, K.J. Substance use, childhood traumatic experience, and Posttraumatic Stress Disorder in an urban civilian population. Depress. Anxiety, 2010, 27(12), 1077-1086. doi: 10.1002/da.20751
  759. Sacks, J.Y.; McKendrick, K.; Banks, S. The impact of early trauma and abuse on residential substance abuse treatment outcomes for women. J. Subst. Abuse Treat., 2008, 34(1), 90-100. doi: 10.1016/j.jsat.2007.01.010
  760. Khantzian, E.J. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence; Springer, 1987.
  761. DiVito, A.J.; Leger, R.F. Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review. Mol. Biol. Rep., 2020, 47(12), 9791-9799. doi: 10.1007/s11033-020-06009-x
  762. Bogenschutz, M.P.; Johnson, M.W. Classic hallucinogens in the treatment of addictions. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2016, 64, 250-258. doi: 10.1016/j.pnpbp.2015.03.002
  763. Bogenschutz, M.P.; Forcehimes, A.A.; Pommy, J.A.; Wilcox, C.E.; Barbosa, P.C.R.; Strassman, R.J. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J. Psychopharmacol., 2015, 29(3), 289-299. doi: 10.1177/0269881114565144
  764. Rodrigues, L.S.; Rossi, G.N.; Rocha, J.M.; L Osório, F.; Bouso, J.C.; Hallak, J.E.C.; dos Santos, R.G. Effects of ayahuasca and its alkaloids on substance use disorders: An updated (2016-2020) systematic review of preclinical and human studies. Eur. Arch. Psychiatry Clin. Neurosci., 2022, 272(4), 541-556. doi: 10.1007/s00406-021-01267-7
  765. Fábregas, J.M.; González, D.; Fondevila, S.; Cutchet, M.; Fernández, X.; Barbosa, P.C.R.; Alcázar-Córcoles, M.Á.; Barbanoj, M.J.; Riba, J.; Bouso, J.C. Assessment of addiction severity among ritual users of ayahuasca. Drug Alcohol Depend., 2010, 111(3), 257-261. doi: 10.1016/j.drugalcdep.2010.03.024
  766. Thomas, G.; Lucas, P.; Capler, N.; Tupper, K.; Martin, G. Ayahuasca-assisted therapy for addiction: Results from a preliminary observational study in Canada. Curr. Drug Abuse Rev., 2013, 6(1), 30-42. doi: 10.2174/15733998113099990003
  767. Doering-Silveira, E.; Grob, C.S.; de Rios, M.D.; Lopez, E.; Alonso, L.K.; Tacla, C.; Da Silveira, D.X. Report on psychoactive drug use among adolescents using ayahuasca within a religious context. J. Psychoactive Drugs, 2005, 37(2), 141-144. doi: 10.1080/02791072.2005.10399794
  768. Bouso, J.C.; Riba, J. Ayahuasca and the treatment of drug addiction. The Therapeutic use of Ayahuasca., 2014, 95-104. doi: 10.1007/978-3-642-40426-9_6
  769. Loizaga-Velder, A.; Verres, R. Therapeutic effects of ritual ayahuasca use in the treatment of substance dependence—qualitative results. J. Psychoactive Drugs, 2014, 46(1), 63-72. doi: 10.1080/02791072.2013.873157
  770. Sessa, B.; Higbed, L.; Nutt, D. A review of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy. Front. Psychiatry, 2019, 10, 138. doi: 10.3389/fpsyt.2019.00138
  771. Grabski, M.; McAndrew, A.; Lawn, W.; Marsh, B.; Raymen, L.; Stevens, T.; Hardy, L.; Warren, F.; Bloomfield, M.; Borissova, A.; Maschauer, E.; Broomby, R.; Price, R.; Coathup, R.; Gilhooly, D.; Palmer, E.; Gordon-Williams, R.; Hill, R.; Harris, J.; Mollaahmetoglu, O.M.; Curran, H.V.; Brandner, B.; Lingford-Hughes, A.; Morgan, C.J.A. Adjunctive ketamine with relapse prevention-based psychological therapy in the treatment of alcohol use disorder. Am. J. Psychiatry, 2022, 179(2), 152-162. doi: 10.1176/appi.ajp.2021.21030277
  772. Jovaiša, T.; Laurinėnas, G.; Vosylius, S. Effects of ketamine on precipitated opiate withdrawal. Medicina, 2006, 42(8), 625-634.
  773. Dakwar, E.; Nunes, E.V.; Hart, C.L.; Foltin, R.W.; Mathew, S.J.; Carpenter, K.M.; Choi, C.J.J.; Basaraba, C.N.; Pavlicova, M.; Levin, F.R. A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: A randomized clinical trial. Am. J. Psychiatry, 2019, 176(11), 923-930. doi: 10.1176/appi.ajp.2019.18101123
  774. Krupitsky, E.; Burakov, A.; Romanova, T.; Dunaevsky, I.; Strassman, R.; Grinenko, A. Ketamine psychotherapy for heroin addiction: Immediate effects and two-year follow-up. J. Subst. Abuse Treat., 2002, 23(4), 273-283. doi: 10.1016/S0740-5472(02)00275-1
  775. Yaden, D.B.; Nayak, S.M.; Gukasyan, N.; Anderson, B.T.; Griffiths, R.R. The potential of psychedelics for end of life and palliative care; Disruptive Psychopharmacology, 2021, pp. 169-184. doi: 10.1007/7854_2021_278
  776. Castellanos, J.P.; Woolley, C.; Bruno, K.A.; Zeidan, F.; Halberstadt, A.; Furnish, T. Chronic pain and psychedelics: A review and proposed mechanism of action. Reg. Anesth. Pain Med., 2020, 45(7), 486-494. doi: 10.1136/rapm-2020-101273
  777. Yu, C.L.; Yang, F.C.; Yang, S.N.; Tseng, P.T.; Stubbs, B.; Yeh, T.C.; Hsu, C.W.; Li, D.J.; Liang, C.S. Psilocybin for end-of-life anxiety symptoms: A systematic review and meta-analysis. Psychiatry Investig., 2021, 18(10), 958-967. doi: 10.30773/pi.2021.0209
  778. Gasser, P.; Kirchner, K.; Passie, T. LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects. J. Psychopharmacol., 2015, 29(1), 57-68. doi: 10.1177/0269881114555249
  779. Sharp, T.J.; Harvey, A.G. Chronic pain and posttraumatic stress disorder: Mutual maintenance? Clin. Psychol. Rev., 2001, 21(6), 857-877. doi: 10.1016/S0272-7358(00)00071-4
  780. Beck, J.G.; Clapp, J.D. A different kind of comorbidity: Understanding posttraumatic stress disorder and chronic pain. Psychol. Trauma, 2011, 3(2), 101-108. doi: 10.1037/a0021263
  781. Schindler, E.A.D. Psychedelics in the treatment of headache and chronic pain disorders. Disruptive Psychopharmacology. Current Topics in Behavioral Neurosciences; Barrett, F.S.; Preller, K.H., Eds.; Springer International Publishing: Cham, 2022, pp. 261-285. doi: 10.1007/7854_2022_365
  782. Christie, D.; Yazar-Klosinski, B.; Nosova, E.; Kryskow, P.; Siu, W.; Lessor, D.; Argento, E. MDMA-assisted therapy is associated with a reduction in chronic pain among people with post-traumatic stress disorder. Front. Psychiatry, 2022, 13, 939302. doi: 10.3389/fpsyt.2022.939302
  783. Edinoff, A.N.; Fort, J.M.; Singh, C.; Wagner, S.E.; Rodriguez, J.R.; Johnson, C.A.; Cornett, E.M.; Murnane, K.S.; Kaye, A.M.; Kaye, A.D. Alternative options for complex, recurrent pain states using cannabinoids, psilocybin, and ketamine: A narrative review of clinical evidence. Neurol. Int., 2022, 14(2), 423-436. doi: 10.3390/neurolint14020035
  784. Ramaekers, J.G.; Hutten, N.; Mason, N.L.; Dolder, P.; Theunissen, E.L.; Holze, F.; Liechti, M.E.; Feilding, A.; Kuypers, K.P.C. A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers. J. Psychopharmacol., 2021, 35(4), 398-405. doi: 10.1177/0269881120940937
  785. Bonnelle, V.; Smith, W.J.; Mason, N.L.; Cavarra, M.; Kryskow, P.; Kuypers, K.P.C.; Ramaekers, J.G.; Feilding, A. Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: A population survey. Br. J. Pain, 2022, 16(6), 619-631. doi: 10.1177/20494637221114962
  786. Chaparro, L.E.; Smith, S.A.; Moore, R.A.; Wiffen, P.J.; Gilron, I. Pharmacotherapy for the prevention of chronic pain after surgery in adults. Cochrane Database Syst. Rev., 2013, 2013(7), CD008307.
  787. Aveline, C.; Roux, A.L.; Hetet, H.L.; Gautier, J.F.; Vautier, P.; Cognet, F.; Bonnet, F. Pain and recovery after total knee arthroplasty: a 12-month follow-up after a prospective randomized study evaluating Nefopam and Ketamine for early rehabilitation. Clin. J. Pain, 2014, 30(9), 749-754. doi: 10.1097/AJP.0000000000000033
  788. Michelet, D.; Brasher, C.; Horlin, A.L.; Bellon, M.; Julien-Marsollier, F.; Vacher, T.; Pontone, S.; Dahmani, S. Ketamine for chronic non-cancer pain: A meta-analysis and trial sequential analysis of randomized controlled trials. Eur. J. Pain, 2018, 22(4), 632-646. doi: 10.1002/ejp.1153
  789. Orhurhu, V.; Orhurhu, M.S.; Bhatia, A.; Cohen, S.P. Ketamine infusions for chronic pain: A systematic review and meta-analysis of randomized controlled trials. Anesth. Analg., 2019, 129(1), 241-254. doi: 10.1213/ANE.0000000000004185
  790. Grande, L.; Delacruz, H.; Thompson, M.; Terman, G.; Rosenblatt, R. (417) Oral ketamine for chronic pain: A 32-subject placebo-controlled trial in patients on chronic opioids. J. Pain, 2016, 17(4), S78-S79. doi: 10.1016/j.jpain.2016.01.394
  791. Marchetti, F.; Coutaux, A.; Bellanger, A.; Magneux, C.; Bourgeois, P.; Mion, G. Efficacy and safety of oral ketamine for the relief of intractable chronic pain: A retrospective 5-year study of 51 patients. Eur. J. Pain, 2015, 19(7), 984-993. doi: 10.1002/ejp.624
  792. Niesters, M.; Martini, C.; Dahan, A. Ketamine for chronic pain: Risks and benefits. Br. J. Clin. Pharmacol., 2014, 77(2), 357-367. doi: 10.1111/bcp.12094
  793. Avanceña, A.L.V.; Kahn, J.G.; Marseille, E. The costs and health benefits of expanded access to MDMA-assisted therapy for chronic and severe PTSD in the USA: A modeling study. Clin. Drug Investig., 2022, 42(3), 243-252. doi: 10.1007/s40261-022-01122-0
  794. Marseille, E.; Kahn, J.G.; Yazar-Klosinski, B.; Doblin, R. The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD. PLoS One, 2020, 15(10), e0239997. doi: 10.1371/journal.pone.0239997
  795. Marseille, E.; Mitchell, J.M.; Kahn, J.G. Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial. PLoS One, 2022, 17(2), e0263252. doi: 10.1371/journal.pone.0263252
  796. Morland, L.A.; Wells, S.Y.; Glassman, L.H.; Greene, C.J.; Hoffman, J.E.; Rosen, C.S. Advances in PTSD treatment delivery: Review of findings and clinical considerations for the use of telehealth interventions for PTSD. Curr. Treat. Options Psychiatry, 2020, 7(3), 221-241. doi: 10.1007/s40501-020-00215-x
  797. Smith, J.R.; Workneh, A.; Yaya, S. Barriers and facilitators to help-seeking for individuals with posttraumatic stress disorder: A systematic review. J. Trauma. Stress, 2020, 33(2), 137-150. doi: 10.1002/jts.22456
  798. Vargas, M.V.; Meyer, R.; Avanes, A.A.; Rus, M.; Olson, D.E. Psychedelics and other psychoplastogens for treating mental illness. Front. Psychiatry, 2021, 12, 727117. doi: 10.3389/fpsyt.2021.727117
  799. Wilkinson, S.T.; Holtzheimer, P.E.; Gao, S.; Kirwin, D.S.; Price, R.B. Leveraging neuroplasticity to enhance adaptive learning: The potential for synergistic somatic-behavioral treatment combinations to improve clinical outcomes in depression. Biol. Psychiatry, 2019, 85(6), 454-465. doi: 10.1016/j.biopsych.2018.09.004
  800. Zanos, P.; Highland, J.N.; Liu, X.; Troppoli, T.A.; Georgiou, P.; Lovett, J.; Morris, P.J.; Stewart, B.W.; Thomas, C.J.; Thompson, S.M.; Moaddel, R.; Gould, T.D. (R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses. Br. J. Pharmacol., 2019, 176(14), 2573-2592. doi: 10.1111/bph.14683
  801. Watkins, L.E.; Sprang, K.R.; Rothbaum, B.O. Treating PTSD: A review of evidence-based psychotherapy interventions. Front. Behav. Neurosci., 2018, 12, 258. doi: 10.3389/fnbeh.2018.00258
  802. Gutner, C.A.; Gallagher, M.W.; Baker, A.S.; Sloan, D.M.; Resick, P.A. Time course of treatment dropout in cognitive-behavioral therapies for posttraumatic stress disorder. Psychol. Trauma, 2016, 8(1), 115-121. doi: 10.1037/tra0000062
  803. Hundt, N.E.; Helm, A.; Smith, T.L.; Lamkin, J.; Cully, J.A.; Stanley, M.A. Failure to engage: A qualitative study of veterans who decline evidence-based psychotherapies for PTSD. Psychol. Serv., 2018, 15(4), 536-542. doi: 10.1037/ser0000212
  804. Wells, S.Y.; Morland, L.A.; Hurst, S. Veterans’ reasons for dropping out of prolonged exposure therapy across three delivery modalities: A qualitative examination. Psychol. Serv., 2022, 20(3), 483-495.
  805. Goldstein, L.A.; Colvonen, P.J.; Sarmiento, K.F. Advancing treatment of comorbid PTSD and OSA. J. Clin. Sleep Med., 2017, 13(6), 843-844. doi: 10.5664/jcsm.6638
  806. Michaels, T.I.; Purdon, J.; Collins, A.; Williams, M.T. Inclusion of people of color in psychedelic-assisted psychotherapy: A review of the literature. BMC Psychiatry, 2018, 18(1), 245. doi: 10.1186/s12888-018-1824-6
  807. Goldstein, R.B.; Smith, S.M.; Chou, S.P.; Saha, T.D.; Jung, J.; Zhang, H.; Pickering, R.P.; Ruan, W.J.; Huang, B.; Grant, B.F. The epidemiology of DSM-5 posttraumatic stress disorder in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Soc. Psychiatry Psychiatr. Epidemiol., 2016, 51(8), 1137-1148. doi: 10.1007/s00127-016-1208-5
  808. Thrul, J.; Garcia-Romeu, A. Whitewashing psychedelics: Racial equity in the emerging field of psychedelic-assisted mental health research and treatment. Drugs Educ. Prev. Policy, 2021, 28(3), 211-214. doi: 10.1080/09687637.2021.1897331
  809. Eylem, O.; De Wit, L.; Van Straten, A. Stigma for common mental disorders in racial minorities and majorities a systematic review and meta-analysis. BMC Public Health, 2020, 20(1), 1-20.
  810. Williams, M.T.; Metzger, I.W.; Leins, C.; DeLapp, C. Assessing racial trauma within a DSM-5 framework: The UConn Racial/ Ethnic Stress & Trauma Survey. Pract. Innov., 2018, 3(4), 242-260. doi: 10.1037/pri0000076
  811. Meyer, O.L.; Zane, N. The influence of race and ethnicity in clients’ experiences of mental health treatment. J. Community Psychol., 2013, 41(7), 884-901. doi: 10.1002/jcop.21580
  812. Leary, T. Drugs, set & suggestibility Paper presentation. Annual meeting of the American Psychological Association, 1961.
  813. Ulrich, R.S.; Bogren, L.; Gardiner, S.K.; Lundin, S. Psychiatric ward design can reduce aggressive behavior. J. Environ. Psychol., 2018, 57, 53-66. doi: 10.1016/j.jenvp.2018.05.002
  814. Ulrich, R.S. Effects of interior design on wellness: Theory and recent scientific research. J. Health Care Interior. Design., 1991, 3, 97-109.
  815. Papoulias, C.; Csipke, E.; Rose, D.; McKellar, S.; Wykes, T. The psychiatric ward as a therapeutic space: Systematic review. Br. J. Psychiatry, 2014, 205(3), 171-176. doi: 10.1192/bjp.bp.114.144873
  816. Iyendo, T.O. Exploring the effect of sound and music on health in hospital settings: A narrative review. Int. J. Nurs. Stud., 2016, 63, 82-100. doi: 10.1016/j.ijnurstu.2016.08.008
  817. McCartney, A.; McGovern, H.; De Foe, A. Predictors of psychedelic experience: A thematic analysis. J. Psychoactive Drugs, 2022, 1-9.
  818. Rucker, J.J.H.; Iliff, J.; Nutt, D. J. Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology, 2018, 142, 200-218. doi: 10.1016/j.neuropharm.2017.12.040
  819. Colloca, L.; Barsky, A.J. Placebo and nocebo effects. N. Engl. J. Med., 2020, 382(6), 554-561. doi: 10.1056/NEJMra1907805
  820. Ioannidis, J.P.A. Why most published research findings are false. PLoS Med., 2005, 2(8), e124. doi: 10.1371/journal.pmed.0020124
  821. Burke, M.J.; Kaptchuk, T.J.; Pascual-Leone, A. Challenges of differential placebo effects in contemporary medicine: The example of brain stimulation. Ann. Neurol., 2019, 85(1), 12-20. doi: 10.1002/ana.25387
  822. Burke, M.J.; Blumberger, D.M. Caution at psychiatry’s psychedelic frontier. Nat. Med., 2021, 27(10), 1687-1688. doi: 10.1038/s41591-021-01524-1
  823. Goodwin, G.M.; Croal, M.; Feifel, D.; Kelly, J.R.; Marwood, L.; Mistry, S.; O'Keane, V.; Peck, S.K.; Simmons, H.; Sisa, C.; Stansfield, S.C.; Tsai, J.; Williams, S.; Malievskaia, E. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology., 2023, 48(10), 1492-1499. doi: 10.1038/s41386-023-01648-7 PMID: 37443386
  824. Walsh, Z.; Thiessen, M.S. Psychedelics and the new behaviourism: Considering the integration of third-wave behaviour therapies with psychedelic-assisted therapy. Int. Rev. Psychiatry, 2018, 30(4), 343-349. doi: 10.1080/09540261.2018.1474088
  825. Maples-Keller, J.; Watkins, L.E.; Nylocks, K.M.; Yasinski, C.; Coghlan, C.; Black, K.; Jovanovic, T.; Rauch, S.A.M.; Rothbaum, B.O.; Norrholm, S.D. Acquisition, extinction, and return of fear in veterans in intensive outpatient prolonged exposure therapy: A fear-potentiated startle study. Behav. Res. Ther., 2022, 154, 104124. doi: 10.1016/j.brat.2022.104124
  826. Boyd, J.E.; Lanius, R.A.; McKinnon, M.C. Mindfulness-based treatments for posttraumatic stress disorder: A review of the treatment literature and neurobiological evidence. J. Psychiatry Neurosci., 2018, 43(1), 7-25. doi: 10.1503/jpn.170021
  827. Monson, C.M.; Fredman, S.J. Cognitive-behavioral conjoint therapy for PTSD: Harnessing the healing power of relationships; Guilford Press, 2012.
  828. Johnson, M.W.; Griffiths, R.R. Potential therapeutic effects of psilocybin. Neurotherapeutics, 2017, 14(3), 734-740. doi: 10.1007/s13311-017-0542-y
  829. Trope, A.; Anderson, B.T.; Hooker, A.R.; Glick, G.; Stauffer, C.; Woolley, J.D. Psychedelic-assisted group therapy: A systematic review. J. Psychoactive Drugs, 2019, 51(2), 174-188. doi: 10.1080/02791072.2019.1593559
  830. Blake, D.D.; Weathers, F.W.; Nagy, L.M.; Kaloupek, D.G.; Gusman, F.D.; Charney, D.S.; Keane, T.M. The development of a clinician-administered PTSD scale. J. Trauma. Stress, 1995, 8(1), 75-90. doi: 10.1002/jts.2490080106
  831. Weathers, F.W.; Bovin, M.J.; Lee, D.J.; Sloan, D.M.; Schnurr, P.P.; Kaloupek, D.G.; Keane, T.M.; Marx, B.P. The clinician-administered PTSD scale for DSM-5 (CAPS-5): Development and initial psychometric evaluation in military veterans. Psychol. Assess., 2018, 30(3), 383-395. doi: 10.1037/pas0000486
  832. Galatzer-Levy, I.R.; Bryant, R.A. 636,120 ways to have posttraumatic stress disorder. Perspect. Psychol. Sci., 2013, 8(6), 651-662. doi: 10.1177/1745691613504115
  833. Kraemer, H.C. DSM categories and dimensions in clinical and research contexts. Int. J. Methods Psychiatr. Res., 2007, 16(S1), S8-S15. doi: 10.1002/mpr.211
  834. McFarlane, A.C.; Lawrence-Wood, E.; Van Hooff, M.; Malhi, G.S.; Yehuda, R. The need to take a staging approach to the biological mechanisms of PTSD and its treatment. Curr. Psychiatry Rep., 2017, 19(2), 10. doi: 10.1007/s11920-017-0761-2
  835. Rasmusson, A.M.; Pineles, S.L. Neurotransmitter, peptide, and steroid hormone abnormalities in PTSD: biological endophenotypes relevant to treatment. Curr. Psychiatry Rep., 2018, 20(7), 52. doi: 10.1007/s11920-018-0908-9
  836. Held, P.; Smith, D.L.; Bagley, J.M.; Kovacevic, M.; Steigerwald, V.L.; Van Horn, R.; Karnik, N.S. Treatment response trajectories in a three-week CPT-Based intensive treatment for veterans with PTSD. J. Psychiatr. Res., 2021, 141, 226-232. doi: 10.1016/j.jpsychires.2021.07.004
  837. Korte, K.J.; Allan, N.P.; Gros, D.F.; Acierno, R. Differential treatment response trajectories in individuals with subclinical and clinical PTSD. J. Anxiety Disord., 2016, 38, 95-101. doi: 10.1016/j.janxdis.2016.01.006
  838. Insel, T.; Cuthbert, B.; Garvey, M. Research domain criteria (RDoC): Toward a new classification framework for research on mental disorders. In: Am. Psychiatric Assoc., 2010, 748-751.
  839. Kotov, R.; Krueger, R.F.; Watson, D.; Achenbach, T.M.; Althoff, R.R.; Bagby, R.M.; Brown, T.A.; Carpenter, W.T.; Caspi, A.; Clark, L.A.; Eaton, N.R.; Forbes, M.K.; Forbush, K.T.; Goldberg, D.; Hasin, D.; Hyman, S.E.; Ivanova, M.Y.; Lynam, D.R.; Markon, K.; Miller, J.D.; Moffitt, T.E.; Morey, L.C.; Mullins-Sweatt, S.N.; Ormel, J.; Patrick, C.J.; Regier, D.A.; Rescorla, L.; Ruggero, C.J.; Samuel, D.B.; Sellbom, M.; Simms, L.J.; Skodol, A.E.; Slade, T.; South, S.C.; Tackett, J.L.; Waldman, I.D.; Waszczuk, M.A.; Widiger, T.A.; Wright, A.G.C.; Zimmerman, M. The hierarchical taxonomy of psychopathology (HiTOP): A dimensional alternative to traditional nosologies. J. Abnorm. Psychol., 2017, 126(4), 454-477. doi: 10.1037/abn0000258
  840. Kotov, R.; Krueger, R.F.; Watson, D.; Cicero, D.C.; Conway, C.C.; DeYoung, C.G.; Eaton, N.R.; Forbes, M.K.; Hallquist, M.N.; Latzman, R.D.; Mullins-Sweatt, S.N.; Ruggero, C.J.; Simms, L.J.; Waldman, I.D.; Waszczuk, M.A.; Wright, A.G.C. The hierarchical taxonomy of psychopathology (HiTOP): A quantitative nosology based on consensus of evidence. Annu. Rev. Clin. Psychol., 2021, 17(1), 83-108. doi: 10.1146/annurev-clinpsy-081219-093304
  841. Lingiardi, V.; McWilliams, N.; Bornstein, R.F.; Gazzillo, F.; Gordon, R.M. The psychodynamic diagnostic manual version 2 (PDM-2): Assessing patients for improved clinical practice and research. Psychoanal. Psychol., 2015, 32(1), 94-115. doi: 10.1037/a0038546
  842. Passos, I.C.; Ballester, P.; Rabelo-da-Ponte, F.D.; Kapczinski, F. Precision psychiatry: The future is now. Can. J. Psychiatry, 2022, 67(1), 21-25. doi: 10.1177/0706743721998044
  843. Rezaii, N.; Wolff, P.; Price, B.H. Natural language processing in psychiatry: The promises and perils of a transformative approach. Br. J. Psychiatry, 2022, 220(5), 251-253. doi: 10.1192/bjp.2021.188
  844. Schultebraucks, K.; Yadav, V.; Shalev, A.Y.; Bonanno, G.A.; Galatzer-Levy, I.R. Deep learning-based classification of posttraumatic stress disorder and depression following trauma utilizing visual and auditory markers of arousal and mood. Psychol. Med., 2022, 52(5), 957-967. doi: 10.1017/S0033291720002718
  845. Hsin, H.; Fromer, M.; Peterson, B.; Walter, C.; Fleck, M.; Campbell, A.; Varghese, P.; Califf, R. Transforming psychiatry into data-driven medicine with digital measurement tools. NPJ Digit. Med., 2018, 1(1), 37. doi: 10.1038/s41746-018-0046-0
  846. Yetisen, A.K.; Martinez-Hurtado, J.L.; Ünal, B.; Khademhosseini, A.; Butt, H. Wearables in medicine. Adv. Mater., 2018, 30(33), 1706910. doi: 10.1002/adma.201706910
  847. Insel, T.R. Digital phenotyping. JAMA, 2017, 318(13), 1215-1216. doi: 10.1001/jama.2017.11295
  848. Moskowitz, D.S.; Young, S.N. Ecological momentary assessment: What it is and why it is a method of the future in clinical psychopharmacology. J. Psychiatry Neurosci., 2006, 31(1), 13-20.
  849. Yue, L.; Tian, D.; Chen, W.; Han, X.; Yin, M. Deep learning for heterogeneous medical data analysis. World Wide Web, 2020, 23(5), 2715-2737. doi: 10.1007/s11280-019-00764-z
  850. Appelt, A.L.; Elhaminia, B.; Gooya, A.; Gilbert, A.; Nix, M. Deep learning for radiotherapy outcome prediction using dose data: A review. Clin. Oncol., 2022, 34(2), e87-e96. doi: 10.1016/j.clon.2021.12.002
  851. Bera, K.; Braman, N.; Gupta, A.; Velcheti, V.; Madabhushi, A. Predicting cancer outcomes with radiomics and artificial intelligence in radiology. Nat. Rev. Clin. Oncol., 2022, 19(2), 132-146. doi: 10.1038/s41571-021-00560-7
  852. Capobianco, E. High-dimensional role of AI and machine learning in cancer research. Br. J. Cancer, 2022, 126(4), 523-532. doi: 10.1038/s41416-021-01689-z
  853. Tuppad, A.; Patil, S.D. Machine learning for diabetes clinical decision support: A review. Adv.Comput. Intell., 2022, 2(2), 22. doi: 10.1007/s43674-022-00034-y
  854. Chekroud, A.M.; Bondar, J.; Delgadillo, J.; Doherty, G.; Wasil, A.; Fokkema, M.; Cohen, Z.; Belgrave, D.; DeRubeis, R.; Iniesta, R.; Dwyer, D.; Choi, K. The promise of machine learning in predicting treatment outcomes in psychiatry. World Psychiatry, 2021, 20(2), 154-170. doi: 10.1002/wps.20882
  855. Gao, S.; Calhoun, V.D.; Sui, J. Machine learning in major depression: From classification to treatment outcome prediction. CNS Neurosci. Ther., 2018, 24(11), 1037-1052. doi: 10.1111/cns.13048
  856. Rost, N.; Binder, E.B.; Brückl, T.M. Predicting treatment outcome in depression: An introduction into current concepts and challenges. Eur. Arch. Psychiatry Clin. Neurosci., 2023, 273(1), 113-127. doi: 10.1007/s00406-022-01418-4
  857. Chekroud, A.M.; Zotti, R.J.; Shehzad, Z.; Gueorguieva, R.; Johnson, M.K.; Trivedi, M.H.; Cannon, T.D.; Krystal, J.H.; Corlett, P.R. Cross-trial prediction of treatment outcome in depression: A machine learning approach. Lancet Psychiatry, 2016, 3(3), 243-250. doi: 10.1016/S2215-0366(15)00471-X
  858. Aday, J.S.; Davis, A.K.; Mitzkovitz, C.M.; Bloesch, E.K.; Davoli, C.C. Predicting reactions to psychedelic drugs: A systematic review of states and traits related to acute drug effects. ACS Pharmacol. Transl. Sci., 2021, 4(2), 424-435. doi: 10.1021/acsptsci.1c00014
  859. Neria, Y.; Lazarov, A.; Zhu, X. Identifying neurobiological markers of posttraumatic stress disorder using resting-state functional magnetic resonance imaging data: The promise of data-driven computational approaches. Biol. Psychiatry Cogn. Neurosci. Neuroimaging, 2022, 7(2), 121-123. doi: 10.1016/j.bpsc.2021.11.002
  860. Romeo, B.; Hermand, M.; Pétillion, A.; Karila, L.; Benyamina, A. Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review. J. Psychiatr. Res., 2021, 137, 273-282. doi: 10.1016/j.jpsychires.2021.03.002
  861. Cavanna, F.; Pallavicini, C.; Milano, V.; Cuiule, J.; Di Tella, R.; González, P.; Tagliazucchi, E. Lifetime use of psychedelics is associated with better mental health indicators during the COVID-19 pandemic. J. Psychedelic Stud., 2021, 5(2), 83-93. doi: 10.1556/2054.2021.00172
  862. Mans, K.; Kettner, H.; Erritzoe, D.; Haijen, E.C.H.M.; Kaelen, M.; Carhart-Harris, R.L. Sustained, multifaceted improvements in mental well-being following psychedelic experiences in a prospective opportunity sample. Front. Psychiatry, 2021, 12, 647909. doi: 10.3389/fpsyt.2021.647909
  863. Gandy, S.; Bonnelle, V.; Jacobs, E.; Luke, D. Psychedelics as potential catalysts of scientific creativity and insight. Drug Sci. Policy Law, 2022, 8. doi: 10.1177/20503245221097649
  864. Horn, S.R.; Charney, D.S.; Feder, A. Understanding resilience: New approaches for preventing and treating PTSD. Exp. Neurol., 2016, 284, 119-132. doi: 10.1016/j.expneurol.2016.07.002
  865. McCulloch, D.E.W.; Grzywacz, M.Z.; Madsen, M.K.; Jensen, P.S.; Ozenne, B.; Armand, S.; Knudsen, G.M.; Fisher, P.M.D.; Stenbæk, D.S. Psilocybin-induced mystical-type experiences are related to persisting positive effects: A quantitative and qualitative report. Front. Pharmacol., 2022, 13, 841648. doi: 10.3389/fphar.2022.841648
  866. Ona, G.; Révész, D.; Kohek, M.; Rossi, G.N.; Rocha, J.M.; dos Santos, R.G.; Hallak, J.E.C.; Alcázar-Córcoles, M.Á.; Bouso, J.C. Tripping to Cope: Coping strategies and use of hallucinogens during the COVID-19 pandemic in three cultural contexts. Psychoactives, 2022, 1(1), 16-30. doi: 10.3390/psychoactives1010003
  867. Roseman, L.; Ron, Y.; Saca, A.; Ginsberg, N.; Luan, L.; Karkabi, N.; Doblin, R.; Carhart-Harris, R. Relational processes in ayahuasca groups of Palestinians and Israelis. Front. Pharmacol., 2021, 12, 607529. doi: 10.3389/fphar.2021.607529
  868. Byock, I. Taking psychedelics seriously. J. Palliat. Med., 2018, 21(4), 417-421. doi: 10.1089/jpm.2017.0684
  869. Davis, A.K.; Xin, Y.; Sepeda, N.D.; Garcia-Romeu, A.; Williams, M.T. Increases in psychological flexibility mediate relationship between acute psychedelic effects and decreases in racial trauma symptoms among people of color. Chronic Stress, 2021, 5 ecollection 2021 doi: 10.1177/24705470211035607
  870. Ching, T.H.W.; Williams, M.T.; Wang, J.B.; Jerome, L.; Yazar-Klosinski, B.; Emerson, A.; Doblin, R. MDMA-assisted therapy for post-traumatic stress disorder: A pooled analysis of ethnoracial differences in efficacy and safety from two Phase 2 open-label lead-in trials and a Phase 3 randomized, blinded placebo-controlled trial. J. Psychopharmacol., 2022, 36(8), 974-986. doi: 10.1177/02698811221104052
  871. Hutten, N.R.P.W.; Mason, N.L.; Dolder, P.C.; Kuypers, K.P.C. Self-rated effectiveness of microdosing with psychedelics for mental and physical health problems among microdosers. Front. Psychiatry, 2019, 10, 672. doi: 10.3389/fpsyt.2019.00672
  872. Hendricks, P.S.; Thorne, C.B.; Clark, C.B.; Coombs, D.W.; Johnson, M.W. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J. Psychopharmacol., 2015, 29(3), 280-288. doi: 10.1177/0269881114565653
  873. Ot’alora, G. M.; Grigsby, J.; Poulter, B.; Van Derveer, J.W., III; Giron, S.G.; Jerome, L.; Feduccia, A.A.; Hamilton, S.; Yazar-Klosinski, B.; Emerson, A.; Mithoefer, M.C.; Doblin, R. 3,4-methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic post-traumatic stress disorder: A randomized phase 2 controlled trial. J. Psychopharmacol., 2018, 32(12), 1295-1307. doi: 10.1177/0269881118806297
  874. Oehen, P.; Traber, R.; Widmer, V.; Schnyder, U. A randomized, controlled pilot study of MDMA (±3,4-methylenedioxy-methamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J. Psychopharmacol., 2013, 27(1), 40-52. doi: 10.1177/0269881112464827
  875. Dadabayev, A.R.; Joshi, S.A.; Reda, M.H.; Lake, T.; Hausman, M.S.; Domino, E.; Liberzon, I. Low dose ketamine infusion for comorbid posttraumatic stress disorder and chronic pain: A randomized double-blind clinical trial. Chronic Stress, 2020, 4 ecollection 2020 doi: 10.1177/2470547020981670
  876. Grof, S.; Goodman, L.E.; Richards, W.A.; Kurland, A.A. LSD-assisted psychotherapy in patients with terminal cancer. Int. Pharmacopsychiatry, 1973, 8(3), 129-144. doi: 10.1159/000467984
  877. Wilkinson, S.T.; Toprak, M.; Turner, M.S.; Levine, S.P.; Katz, R.B.; Sanacora, G. A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders. Am. J. Psychiatry, 2017, 174(7), 695-696. doi: 10.1176/appi.ajp.2017.17020239
  878. Berlowitz, I.; Walt, H.; Ghasarian, C.; Mendive, F.; Martin-Soelch, C. Short-term treatment effects of a substance use disorder therapy involving traditional Amazonian medicine. J. Psychoactive Drugs, 2019, 51(4), 323-334. doi: 10.1080/02791072.2019.1607956
  879. Barbosa, P.C.R.; Tófoli, L.F.; Bogenschutz, M.P.; Hoy, R.; Berro, L.F.; Marinho, E.A.V.; Areco, K.N.; Winkelman, M.J. Assessment of alcohol and tobacco use disorders among religious users of ayahuasca. Front. Psychiatry, 2018, 9, 136. doi: 10.3389/fpsyt.2018.00136
  880. Dakwar, E.; Levin, F.; Hart, C.L.; Basaraba, C.; Choi, J.; Pavlicova, M.; Nunes, E.V. A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: A randomized midazolam-controlled pilot trial. Am. J. Psychiatry, 2020, 177(2), 125-133. doi: 10.1176/appi.ajp.2019.19070684
  881. Krupitsky, E.M.; Burakov, A.M.; Dunaevsky, I.V.; Romanova, T.N.; Slavina, T.Y.; Grinenko, A.Y. Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J. Psychoactive Drugs, 2007, 39(1), 13-19. doi: 10.1080/02791072.2007.10399860
  882. Danforth, A.L.; Grob, C.S.; Struble, C.; Feduccia, A.A.; Walker, N.; Jerome, L.; Yazar-Klosinski, B.; Emerson, A. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: A randomized, double-blind, placebo-controlled pilot study. Psychopharmacology, 2018, 235(11), 3137-3148. doi: 10.1007/s00213-018-5010-9
  883. Holze, F.; Gasser, P.; Müller, F.; Dolder, P.C.; Liechti, M.E. Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: A randomized, double-blind, placebo-controlled phase II study. Biol. Psychiatry, 2023, 93(3), 215-223. doi: 10.1016/j.biopsych.2022.08.025
  884. Wilkinson, S.T.; Rhee, T.G.; Joormann, J.; Webler, R.; Ortiz Lopez, M.; Kitay, B.; Fasula, M.; Elder, C.; Fenton, L.; Sanacora, G. Cognitive behavioral therapy to sustain the antidepressant effects of ketamine in treatment-resistant depression: A randomized clinical trial. Psychother. Psychosom., 2021, 90(5), 318-327. doi: 10.1159/000517074

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Bentham Science Publishers, 2024